mTBICPGFullCPG50821816 PDF

VA/DoD CLINICAL PRACTICE GUIDELINE FOR
THE MANAGEMENT OF CONCUSSION-MILD

TRAUMATIC BRAIN INJURY
Department of Veterans Affairs
Department of Defense
QUALIFYING STATEMENTS
The Department of Veterans Affairs and the Department of Defense guidelines are based upon the best
information available at the time of publication. They are designed to provide information and assist
decision making. They are not intended to define a standard of care and should not be construed as one.
Neither should they be interpreted as prescribing an exclusive course of management.
This Clinical Practice Guideline is based on a systematic review of both clinical and epidemiological
evidence. Developed by a panel of multidisciplinary experts, it provides a clear explanation of the logical
relationships between various care options and health outcomes while rating both the quality of the
evidence and the strength of the recommendation.
Variations in practice will inevitably and appropriately occur when clinicians take into account the needs
of individual patients, available resources, and limitations unique to an institution or type of practice.
Every healthcare professional making use of these guidelines is responsible for evaluating the
appropriateness of applying them in the setting of any particular clinical situation.
These guidelines are not intended to represent TRICARE policy. Further, inclusion of recommendations
for specific testing and/or therapeutic interventions within these guidelines does not guarantee
coverage of civilian sector care. Additional information on current TRICARE benefits may be found at
www.tricare.mil or by contacting your regional TRICARE Managed Care Support Contractor.
Version 2.0 – 2016

VA/DoD Clinical Practice Guideline for the Management of Concussion-mild Traumatic Brain Injury
Prepared by:
The Management of Concussion-mild Traumatic Brain Injury

Working Group
With support from:
The Office of Quality, Safety and Value, VA, Washington, DC

&
Office of Evidence Based Practice, U.S. Army Medical Command
Version 2.0 – 2016
Based on evidence reviewed through March 2015
February 2016 Page 2 of 133

Table of Contents
I. Introduction .............................................................................................................................5
II. Background ..............................................................................................................................6

A. Terminology Conventions within this CPG ................................................................................. 7
B. Additional Educational Materials and Resources ....................................................................... 7
III. About this Clinical Practice Guideline ........................................................................................9

A. Methods...................................................................................................................................... 9
B. Conflict of Interest .................................................................................................................... 12
C. Scope of this CPG ...................................................................................................................... 12
D. Highlighted Features of this CPG .............................................................................................. 12
E. Patient-centered Care .............................................................................................................. 13
F. Implementation ........................................................................................................................ 14
IV. Guideline Working Group ....................................................................................................... 15
V. Algorithms ............................................................................................................................. 16
A. Module A: Initial Presentation (>7 Days Post-injury) ............................................................... 17
B. Module B: Management of Symptoms Persisting >7 days ....................................................... 18
VI. Recommendations ................................................................................................................. 19

A. Diagnosis and Assessment ........................................................................................................ 22
B. Co-occurring Conditions ........................................................................................................... 27
C. Treatment ................................................................................................................................. 27
D. Setting of Care .......................................................................................................................... 39
VII. Knowledge Gaps and Recommended Research ....................................................................... 43

A. Diagnosis and Assessment ........................................................................................................ 43
B. Treatment ................................................................................................................................. 43
C. Care Delivery............................................................................................................................. 43
Appendix A: Guideline Development Methodology........................................................................... 44

A. Developing the Scope and Key Questions ................................................................................ 44
B. Conducting the Systematic Review .......................................................................................... 45
C. Convening the Face-to-face Meeting ....................................................................................... 72
D. Grading Recommendations ...................................................................................................... 72

E. Recommendation Categorization ............................................................................................. 75

F. Drafting and Submitting the Final CPG ..................................................................................... 77
Appendix B: Clinical Symptom Management ..................................................................................... 79

A. Appendix Contents ................................................................................................................... 79
B. Introduction .............................................................................................................................. 79
C. Co-occurring Conditions ........................................................................................................... 80
D. Headache .................................................................................................................................. 81
E. Dizziness and Disequilibrium .................................................................................................... 90
F. Visual Symptoms....................................................................................................................... 93
G. Fatigue ...................................................................................................................................... 94
H. Sleep Disturbance ..................................................................................................................... 94
I. Cognitive Symptoms ................................................................................................................. 97
J. Persistent Pain .......................................................................................................................... 98
K. Hearing Difficulties ................................................................................................................... 98
L. Smell (Olfactory Deficits) .......................................................................................................... 99
M. Nausea ...................................................................................................................................... 99
N. Changes in Appetite .................................................................................................................. 99
O. Numbness ............................................................................................................................... 100
Appendix C: Mechanism of Injury ................................................................................................... 101
Appendix D: Evidence Table ........................................................................................................... 104
Appendix E: 2009 Recommendation Categorization ........................................................................ 108
Appendix F: Participants List .......................................................................................................... 122
Appendix G: Acronym List .............................................................................................................. 124
References..................................................................................................................................... 127

I. Introduction
The Department of Veterans Affairs (VA) and Department of Defense (DoD) Evidence-Based Practice
Working Group (EBPWG) was established and first chartered in 2004, with a mission to advise the
“…Health Executive Council on the use of clinical and epidemiological evidence to improve the health of
the population across the Veterans Health Administration (VHA) and Military Health System,” by
facilitating the development of clinical practice guidelines (CPG) for the VA and DoD populations.[1] This
CPG is intended to provide primary care providers/patient aligned care teams (PACT) and other
healthcare providers with a framework by which to evaluate, treat, and manage the individual needs
and preferences of patients with a history of mild traumatic brain injury (mTBI).
In 2009, the VA and DoD published a CPG for the Management of Concussion-mild Traumatic Brain
Injury (2009 mTBI CPG), which was based on evidence reviewed through 2008. Since the release of that
guideline, research has expanded the general knowledge and understanding of mTBI. Recognition of the
complex nature of this condition has led to the adoption of new strategies to manage and treat
individuals with a history of mTBI.
Consequently, the process to update the 2009 mTBI CPG was initiated in 2014. The updated CPG
includes evidence-based information on the management of patients with a history of mTBI. The CPG is
primarily intended to assist primary care providers in the management of all aspects of patient care,
including, but not limited to, diagnosis, assessment, treatment and follow-up. However, this CPG may be
used by all healthcare providers. The system-wide goal of evidence-based guidelines is to improve the
patient’s health and well-being. This CPG guides providers in the care of patients with a history of mTBI
along the management pathways that are supported by evidence. The expected outcomes of successful
implementation of this guideline are to:
• Assess the patient’s condition and determine the best treatment method
• Optimize the clinical management to improve symptoms and functioning, adherence to
treatment, recovery, well-being, and quality of life outcomes
• Minimize preventable complications and morbidity
• Emphasize the use of patient-centered care

II. Background
A traumatic brain injury (TBI) is defined as a traumatically induced structural injury and/or physiological
disruption of brain function as a result of an external force and is indicated by new onset or worsening
of at least one of the following clinical signs immediately following the event:[2,3]
• Any period of loss of or a decreased level of consciousness
• Any loss of memory for events immediately before or after the injury (posttraumatic amnesia)
• Any alteration in mental state at the time of the injury (e.g., confusion, disorientation, slowed
thinking, alteration of consciousness/mental state)
• Neurological deficits (e.g., weakness, loss of balance, change in vision, praxis, paresis/plegia,
sensory loss, aphasia) that may or may not be transient
• Intracranial lesion
External forces may include any of the following events: the head being struck by an object, the head
striking an object, the brain undergoing an acceleration/deceleration movement without direct external
trauma to the head, a foreign body penetrating the brain, forces generated from events such as a blast
or explosion, or other forces.
The above criteria define the event of a TBI. Not all individuals exposed to an external force will sustain a
TBI, but any person who has a history of such an event with immediate manifestation of any of the
above signs and symptoms can be said to have had a TBI. For more details about mechanisms of brain
injury, see Appendix C: Mechanism of Injury.
The Centers for Disease Control and Prevention (CDC) estimate that approximately 2.2 million
emergency department visits and 50,000 deaths occur annually due to TBI.[2] In the 2014 CDC Report to
Congress “Traumatic Brain Injury In the United States: Epidemiology and Rehabilitation,” according to
data from the DoD, 235,046 Service Members (or 4.2% of the 5,603,720 who served in the Army, Air
Force, Navy, and Marine Corps) were diagnosed with a TBI between 2000 and 2011.[2] Similarly, the
Defense and Veterans Brain Injury Center (DVBIC) estimates that over 1.7 million people sustain a TBI
every year in the United States.[4] Of these injuries, approximately 84% are classified as mTBI.
To determine the TBI severity, clinicians should use the criteria displayed in Table 1 below.

Table 1. Classification of TBI Severity [3]

(If a patient meets criteria in more than one category of severity, the higher severity level is assigned)
Criteria Mild Moderate Severe
Structural imaging Normal Normal or abnormal Normal or abnormal
>30 min and
Loss of Consciousness (LOC) 0-30 min >24 hours
<24 hours
Alteration of consciousness/ mental state
up to 24 hours >24 hours; severity based on other criteria
(AOC)*
Posttraumatic amnesia (PTA) 0-1 day >1 and <7 days >7 days
Glasgow Coma Scale (GCS) (best available
13-15 9-12 <9
score in first 24 hours)**
*Alteration of mental status must be immediately related to the trauma to the head. Typical symptoms would be looking and
feeling dazed and uncertain of what is happening, confusion, and difficulty thinking clearly or responding appropriately to
mental status questions, and being unable to describe events immediately before or after the trauma event.
**In April 2015, the DoD released a memorandum recommending against the use of GCS scores to diagnose TBI. See the
memorandum for additional information.[3]
A. Terminology Conventions within this CPG

This CPG focuses only on mild TBI (mTBI or concussion). Within this CPG, the terms “mTBI” and
“concussion” are used interchangeably. Patients are also referred to as “patients with a history of mTBI”
denoting patients that have been diagnosed with a TBI of mild severity. The use of the phrase “patients
with mTBI,” although widely used in clinical practice, is discouraged in this document because the
accepted clinical case definition of mTBI refers only to those symptoms and signs that occur in the
immediate injury period, and thus should never be used in present tense to refer to ongoing symptoms
that persist and are attributed to the TBI injury event after the immediate period.
The Work Group acknowledges that there is not standard terminology regarding the periods following
mTBI; however, the following construct of terms is used within this CPG and was arrived at by Work Group
consensus. The terms used within this CPG to delineate post-injury periods following mTBI are outlined
below:
• Immediate period refers to 0-7 days post-injury
• Acute period refers to 1-6 weeks post-injury
• Post-acute period refers to 7-12 weeks post-injury
• Chronic refers to >12 weeks post-injury
B. Additional Educational Materials and Resources

For additional information on mTBI, there are several topic-specific resources published and offered by
the Defense Centers of Excellence (DCoE), Office of the Surgeon General (OTSG), and DVBIC that pertain
to the content described in this CPG. These resources may offer additional information about numerous
topics in the care and management of patients with a history of mTBI. See the OTSG Army Toolkit 1 and
1 See the OTSG Army Toolkit here: http://www.cs.amedd.army.mil/borden/Portlet.aspx?ID=065de2f7-81c4-4f9d-9c85-

75fe59dbae13

the DVBIC educational materials and publications list 2 for more details. The Work Group has not
reviewed the scientific content or quality of any of those materials, and is not in a position to endorse
them.
2 See the DVBIC patient and provider educational materials here: http://dvbic.dcoe.mil/resources, and the DVBIC publications
list here: http://dvbic.dcoe.mil/research/browse/dvbic-publications

III. About this Clinical Practice Guideline

This guideline represents a significant step toward improving the treatment and management of patients
with a history of mTBI, who present for care in the VA and DoD. As with other CPGs, challenges remain,
including the need to develop effective strategies for guideline implementation and to evaluate the effect
of guideline adherence on clinical outcomes. This guideline is intended for VA and DoD healthcare
providers including physicians, nurse practitioners, physician assistants, psychologists, social workers,
nurses, speech-language pathologists, occupational therapists, physical therapists, and others involved in
the primary care of Service Members or Veterans who have a history of suspected or diagnosed mTBI.
This CPG is not intended to serve as a standard of care. Standards of care are determined on the basis of
all clinical data available for a patient and are subject to change as scientific knowledge and technology
advances and patterns evolve. This CPG is based on evidence reviewed through March 2015, and is
intended to provide a general guide to best practices. The guideline can assist care providers, but the
use of a CPG must always be considered as a recommendation, within the context of a provider’s clinical
judgment, for the care of an individual.
A. Methods
The current document is an update to the 2009 mTBI CPG. The methodology used in developing the
2016 CPG follows the Guideline for Guidelines,[1] an internal document of the VA and DoD EBPWG. The
Guideline for Guidelines can be downloaded from http://www.healthquality.va.gov/policy/index.asp.
This document provides information regarding the process of developing guidelines, including the
identification and assembly of the Guideline Champions (Champions) and other subject matter experts
from within the VA and DoD, known as the Work Group, and ultimately, the development and
publication of an updated mTBI CPG.
The Champions and Work Group for this CPG were charged with developing evidence-based clinical
practice recommendations, as well as writing and publishing a guideline document to be used by
providers within the VA/DoD healthcare system. Specifically, the Champions and the Work Group
members for this guideline were responsible for identifying the key questions (KQs) of the greatest
clinical relevance, importance, and interest for the management of patients with a history of mTBI. The
amount of new scientific evidence that had accumulated since the previous version of the CPG was also
taken into consideration in the identification of the KQs. The Champions and the Work Group also
provide direction on inclusion and exclusion criteria for the evidence review and assessed the level of
quality of the evidence. In addition, the Champions assisted in:
• Identifying appropriate disciplines of individuals to be included as part of the Work Group
• Directing and coordinating the Work Group
• Participating throughout the guideline development and review processes
The VA Office of Quality, Safety and Value, in collaboration with the Office of Evidence Based Practice,
U.S. Army Medical Command, the proponent for CPGs for the DoD, identified three clinical leaders, Dr.
David X. Cifu from the VA and Colonel Geoffrey G. Grammer, MD and Colonel Lisa A. Teegarden, PsyD
from the DoD, as Champions for the 2016 CPG.

The Lewin Team (Team), including The Lewin Group, Duty First Consulting, ECRI Institute, and Sigma
Health Consulting, LLC, was contracted by the VA and DoD to support the development of this CPG and
conduct the evidence review. The team held the first conference call in December 2014, with
participation from the contracting officer’s representative (COR), leaders from the VA Office of Quality,
Safety and Value and the DoD Office of Evidence Based Practice, and the Champions. During this call, the
project team discussed the scope of the guideline initiative, the roles and responsibilities of the
Champions, the project timeline, and the approach for developing and prioritizing specific research
questions on which to base a systematic review about the management of mTBI. The group also
identified a list of clinical specialties and areas of expertise that are important and relevant to the
management of mTBI, from which Work Group members were recruited. The specialties and clinical
areas of interest included: blind rehabilitation, family medicine, occupational therapy (OT), language
neurology, nursing, pharmacy, physical medicine and rehabilitation (PM&R), physical therapy (PT),
polytrauma care, primary care, psychiatry, psychology, and speech-language pathology.
The guideline development process for the 2016 CPG update consisted of the following steps:
1. Formulating and prioritizing KQs for the systematic review
2. Conducting the systematic review
3. Convening a face-to-face meeting with the CPG Champions and Work Group members
4. Drafting and submitting a final CPG about the management of mTBI to the VA/DoD EBPWG
Appendix A: Guideline Development Methodology provides a detailed description of each of these tasks.
a. Reconciling 2009 CPG Recommendations

Evidence-based CPGs should be current, which typically requires revisions based on new evidence or as
scheduled subject to time-based expirations. For example, the U.S. Preventive Services Task Force
(USPSTF) has a process for refining or otherwise updating its recommendations pertaining to preventive
services.[5] Further, the inclusion criteria for the National Guideline Clearinghouse specify that a
guideline must have been developed, reviewed, or revised within the past five years.
The mTBI Guideline Work Group focused largely on developing new and updated recommendations
based on the evidence review conducted for the priority areas addressed by the KQs. In addition to
those new and updated recommendations, the Guideline Work Group considered the current
applicability of other recommendations that were included in the previous 2009 mTBI CPG, subject to
evolving practice in today’s environment.
A set of recommendation categories was adapted from those used by the National Institute for Health
and Care Excellence (NICE, UK).[6,7] These categories, along with their corresponding definitions, were
used to account for the various ways in which recommendations could have been updated. In brief, the
categories took into account whether or not the evidence that related to a recommendation was
systematically reviewed as part of the update, the degree to which the recommendation was modified,
and the degree to which a recommendation is relevant in the current patient care environment and
inside the scope of the CPG. Additional information regarding these categories and their definitions can
be found in Appendix A: Guideline Development Methodology. The categories for the recommendations

included in the 2016 version of the guideline are noted in the Recommendations. The categories for the
recommendations from the 2009 mTBI CPG are noted in Appendix E: 2009 Recommendation
Categorization.
Because the 2009 mTBI CPG was developed using an evidence-rating method (USPSTF method) differing
from the methodology currently used (GRADE method), the CPG Work Group recognized the need to
accommodate the transition in evidence rating systems from the 2009 mTBI CPG to the current CPG. In
order to report the strength of all recommendations using a consistent format (i.e., the GRADE system)
the CPG Work Group converted the USPSTF strengths of the recommendation accompanying the
carryover recommendations from the 2009 guideline to the GRADE system. As such, the CPG Work
Group considered the strength of the evidence cited for each recommendation in the 2009 mTBI CPG as
well as harms and benefits, values and preferences, and other implications, where appropriate. The CPG
Work Group referred to the available evidence as summarized in the body of the 2009 mTBI CPG and did
not assess the evidence review systematically that was conducted for the 2009 mTBI CPG. In some
instances, selected peer-reviewed literature published since the 2009 mTBI CPG was considered along
with the evidence base used for that CPG. When newer literature was considered in converting the
strength of the recommendation from the USPSTF to GRADE system, it is referenced in the discussion of
the corresponding recommendation, as well as in Appendix D: Evidence Table.
The CPG Work Group recognizes that, while there are practical reasons for incorporating findings from a
previous systematic review, previous recommendations, or recent peer-reviewed publications into an
updated CPG, doing so does not involve an original, comprehensive systematic review and, therefore,
may introduce bias.[8] In contrast, the recommendations labeled as “Reviewed” were based on a new or
an updated systematic review of the literature.
b. Peer Review Process

The CPG was developed through an iterative process in which the Work Group produced multiple drafts
of the CPG. The process for developing the initial draft is described in more detail in Drafting and
Submitting the Final Clinical Practice Guideline.
Once a near-final draft of the guideline was agreed upon by the Champions and Work Group members,
the draft was sent out for peer review and comment. The draft was posted on a wiki website for a
period of 14 business days. The peer reviewers comprised individuals working within the VA and DoD
health systems as well as experts from relevant outside organizations designated by the Work Group
members. The VA and DoD Leadership reached out to both the internal and external peer reviewers to
solicit their feedback on the CPG. Organizations designated by the Work Group who were contacted to
participate in the peer review included the following:
• Defense and Veterans Brain Injury Center

• IHC Family Practice Center
• National Center for Medical Rehabilitation Research
• University of North Carolina, Department of Rehabilitation Research
• University of Utah, Rehabilitation and Wellness Clinic

Reviewers were provided a hyperlink to the wiki website where the draft CPG was posted. All reviewer
feedback was posted in tabular form on the wiki site, along with the name of the reviewer, for
transparency. All feedback from the peer reviewers was discussed and considered by the Work Group.
Modifications made throughout the CPG development process were made in accordance with the
evidence.
B. Conflict of Interest
At the start of this guideline development process and at other key points throughout, the project team
was required to submit disclosure statements to reveal any areas of potential conflict of interest in the
past two years, including verbal affirmations of no conflict of interest at regular meetings. The project
team was also subject to random web-based surveillance (e.g., ProPublica). If there was a positive (yes)
conflict of interest response (actual or potential), then action was taken by the co-chairs and evidence-
based practice program office, based on the level and extent of involvement, to mitigate the conflict of
interest. Actions ranged from restricting participation and/or voting on sections related to a conflict, to
removal from the Work Group. Recusal was determined by the individual, co-chairs, and the Office of
Evidence Based Practice.
Noted conflict of interest disclosures:

• COL Sidney Hinds II, MD, has previously served on the National Football League (NFL) Head
Trauma Advisory Board; however, over 12 months has elapsed since this engagement.
• Scott McDonald, PhD, is involved in TBI research that is funded by the VA and by General
Dynamics.
The above disclosures were brought forward by the individuals and evaluated by VA/DoD leadership.
Given the nature of the disclosures, the Work Group members were authorized to continue work on the
CPG in an unrestricted capacity.
C. Scope of this CPG

This CPG is designed to assist providers in managing or co-managing patients with a history of mTBI.
Moreover, the patient population of interest for this CPG is adults who are eligible for care in the VHA
and DoD healthcare delivery systems. It includes Veterans as well as deployed and non-deployed active
duty Service Members, and National Guard and Reserve components. This CPG does not address the
following populations:
• Individuals in the immediate period (within seven days) following mTBI
• Individuals with moderate or severe TBI
• Children or adolescents
D. Highlighted Features of this CPG

The 2016 edition of the VA/DoD CPG for the Management of Concussion-mTBI is the first update to the
original CPG. It provides best practice recommendations for the care of patients with a history of mTBI.
While screening for and addressing co-occurring mental disorders is considered good clinical practice,
specific guidance on management of co-occurring mental health conditions is beyond the scope of this

CPG. Interested readers are referred to related VA/DoD CPGs (e.g., Posttraumatic Stress Disorder
[PTSD] 3, Major Depressive Disorder [MDD] 4 , Bipolar Disorder 5, Suicide Risk 6). A particular strength of
this CPG is the multidisciplinary stakeholder involvement from its inception, ensuring representation
from the broad spectrum of clinicians engaged in the management of patients with a history of mTBI.
The literature review encompassed studies published between 2008 and March 2015, was systematic,
based on specific inclusion/exclusion criteria (see Appendix A: Guideline Development Methodology),
and targeted 10 KQs focusing on the means by which the delivery of healthcare could be optimized for
patients with a history of mTBI. The selected KQs were prioritized from many possible KQs. Due to
resource constraints, a review of the evidence in all aspects of care for patients with a history of mTBI
was not feasible for the update to this CPG.
The framework for recommendations used in this CPG considered factors beyond the strength of the
evidence, including balancing desired outcomes with potential harms of treatment, equity of resource
availability, and the potential for variation in provider and patient values and preferences. Applicability
of the evidence to VA/DoD populations was also taken into consideration.
Additionally, several components of this CPG offer further guidance for providers on the clinical
management of patients with a history of mTBI. The evidence synthesis for this CPG found a lack of
randomized clinical trials (RCTs) for treatment of symptoms in patients with a history of mTBI. As such,
Appendix B: Clinical Symptom Management offers symptom-based clinical guidance and best practices
that have been reviewed by the experts assembled to produce this CPG. However, this material is set
apart from the body of the CPG, as it is based on expert consensus and common clinical practice. A set
of algorithms also accompanies the guideline to provide an overview of the recommendations in the
context of the flow of clinician decision making and to assist with training providers. The algorithm may
be used to help facilitate translation of guideline recommendations into effective practice.
E. Patient-centered Care
Guidelines encourage providers to use a patient-centered approach. Regardless of setting or availability
of professional expertise, any patient in the healthcare system may be offered the interventions
recommended in this guideline and found to be appropriate to the patient’s specific condition according
to the clinician’s clinical judgment and patient values and preferences.
Treatment and care should take into account a patient’s needs and preferences. Good communication
between healthcare professionals and the patient is essential. Information provided to patients by
health professionals should be supported by evidence and be tailored to the patient’s needs. The
information that patients are given about treatment and care should be culturally appropriate (including
3 See the VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Reaction.
Available at: http://www.healthquality.va.gov/guidelines/mh/ptsd/index.asp
4 See the VA/DoD Clinical Practice Guideline for Management of Major Depressive Disorder. Available at:
http://www.healthquality.va.gov/guidelines/mh/mdd/index.asp
5 See the VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder in Adults. Available at:
http://www.healthquality.va.gov/guidelines/mh/bd/index.asp
6 See the VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide. Available at:
http://www.healthquality.va.gov/guidelines/mh/srb/index.asp

care in a military setting) and available to people who do not speak or read English or who have limited
literacy skills. Information should also be accessible to people with additional needs such as physical,
sensory or learning disabilities.
Care of Veterans and Service Members in transition between facilities, services, or from the DoD
healthcare system to the VA healthcare system should have a transition plan and be managed according
to best practice with emphasis on continuity of care. Healthcare teams should work jointly to provide
assessment and services to patients within this transitioning population. Management should be
reviewed throughout the transition process, and there should be clarity between providers to ensure
continuity of care. Providers can use programs and mechanisms put in place within VA/DoD to assist
with transitions such as DVBIC’s Recovery Support Specialist (RSS) program, or the Lead Coordinator
Initiative for those who require a care plan and/or case manager. Rehabilitation therapists with
expertise in mTBI should also be competent in military/Veteran culture and should understand the
important role of developing a therapeutic alliance with the patient.
F. Implementation
This CPG and associated algorithms were designed to be adapted by individual healthcare providers with
consideration of local needs and resources. The algorithms serve as tools to prompt providers to
consider key decision points in the course of an episode of care. Within the body of the CPG, the
recommendations offer evidence-based guidance for the care of patients with a history of mTBI.
Appendix B: Clinical Symptom Management also offers users of the CPG a symptom-based clinical guide
to best practices that have been reviewed by the Work Group. It should be noted that this material is set
apart from the body of the CPG because it is based on expert consensus and common clinical practice. In
addition, a clinician summary, clinician pocket card, and patient guide were developed to accompany
this CPG to facilitate use of the content.
This CPG represents current clinical practice as of the date of publication. It is important to note,
however, that scientific evidence often evolves and may result in the need to update this guideline. New
technology and more research will improve patient care in the future. The CPG can assist in identifying
priority areas for research and to inform optimal allocation of resources. Future studies examining the
results of CPG implementation may lead to the development of new evidence particularly relevant to
clinical practice.

IV. Guideline Working Group

Guideline Working Group*
Department of Veterans Affairs Department of Defense
David X. Cifu, MD (Co-Chair) COL Geoffrey G. Grammer, MD (Co-Chair)
Jennifer Burton, DPT COL Lisa Teegarden, PsyD (Co-Chair)
Mary Dameron, MSN, RN, CRRN, CCM, CBIS Amy O. Bowles, MD
Blessen C. Eapen, MD Megan Chilson, PharmD
Robin A. Hurley, MD, FANPA Thomas J. DeGraba, MD
Scott D. McDonald, PhD CDR Josh L. Duckworth, MD
Linda M. Picon, MCD, CCC-SLP CDR Jeffrey Feinberg, MD, MPH, FAAFP
Ronald G. Riechers, II, MD Louis M. French, PsyD
Kathryn Tortorice, PharmD, BCPS COL Sidney R. Hinds II, MD
Linda Van Horn, MSN, BSN, CFNP Charles W. Hoge, MD
Deborah Voydetich, OTR/L, SCLV Timothy Lacy, MD
James Sall, PhD, FNP-BC
Major Derrick F. Varner, PhD, DFAAPA
Office of Quality, Safety and Value Office of Evidence Based Practice
Veterans Health Administration U.S. Army Medical Command
Ernest Degenhardt, COL USA (Ret.) RN, MSN, ANP/FNP,
Eric Rodgers, PhD, FNP, BC BC
Rene Sutton, BS, HCA Corinne K. B. Devlin, MSN, RN, FNP-BC
James Sall, PhD, FNP-BC
Lewin Group ECRI Institute
Cliff Goodman, PhD
James Reston, PhD
Christine Jones, MS, MPH
Kristen D’Anci, PhD
Erin Gardner, BS
Amy Tsou, MD
Nicolas Stettler, MD, MSCE
Sigma Health Consulting, LLC Duty First Consulting
Fran Murphy, MD, MPH Anita Ramanathan, BA
*Additional contributor contact information is available in Appendix F: Participants List.

V. Algorithms
This CPG includes an algorithm that is designed to facilitate clinical decision making for the management
of mTBI. The use of the algorithm format as a way to represent patient management was chosen based
on the understanding that such a format can allow for efficient diagnostic and therapeutic decision
making, and has the potential to change patterns of resource use. The algorithm format allows the
provider to follow a linear approach in assessing the critical information needed at the major decision
points in the clinical process, and includes:
• An ordered sequence of steps of care
• Recommended observations and examinations
• Decisions to be considered
• Actions to be taken
A clinical algorithm diagrams a guideline into a step-by-step decision tree. Standardized symbols are
used to display each step in the algorithm, and arrows connect the numbered boxes indicating the order
in which the steps should be followed.[9]
Rounded rectangles represent a clinical state or condition.
Hexagons represent a decision point in the guideline, formulated as a question

that can be answered Yes or No.
Rectangles represent an action in the process of care.

A. Module A: Initial Presentation (>7 Days Post-injury)

B. Module B: Management of Symptoms Persisting >7 days

VI. Recommendations
Recommendation Strength* Category†
A. Diagnosis and Assessment
1. We suggest using the terms “history of mild traumatic brain injury (mTBI)” or Weak for Not Reviewed,
“concussion” and to refrain from using the terms “brain damage” or Amended
“patients with mTBI” in communication with patients and the public.
2. We recommend evaluating individuals who present with symptoms or Strong for Not Reviewed,
complaints potentially related to brain injury at initial presentation. Amended
3. Excluding patients with indicators for immediate referral, for patients Weak Reviewed,
identified by post-deployment screening or who present to care with against New-replaced
symptoms or complaints potentially related to brain injury, we suggest
against using the following tests to establish the diagnosis of mTBI or direct
the care of patients with a history of mTBI:
a. Neuroimaging
b. Serum biomarkers, including S100 calcium-binding protein B (S100-B),
glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal esterase
L1 (UCH-L1), neuron specific enolase (NSE), and α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR) peptide
c. Electroencephalogram (EEG)
4. We recommend against performing comprehensive neuropsychological/ Strong Not Reviewed,
cognitive testing during the first 30 days following mTBI. For patients with against Amended
symptoms persisting after 30 days, see Recommendation 17.
5. For patients identified by post-deployment screening or who present to care Strong Reviewed,
with symptoms or complaints potentially related to brain injury, we against New-replaced
recommend against using the following tests in routine diagnosis and care of
patients with symptoms attributed to mTBI:
a. Comprehensive and focused neuropsychological testing, including
Automated Neuropsychological Assessment Metrics (ANAM), Neuro-
Cognitive Assessment Tool (NCAT), or Immediate Post-Concussion
Assessment and Cognitive Testing (ImPACT)
6. For patients with new symptoms that develop more than 30 days after mTBI, Weak for Not Reviewed,
we suggest a focused diagnostic work-up specific to those symptoms only. Amended
B. Co-occurring Conditions
7. We recommend assessing patients with symptoms attributed to mTBI for Strong for Not Reviewed,
psychiatric symptoms and comorbid psychiatric disorders including major Amended
depressive disorder (MDD), posttraumatic stress disorder (PTSD), substance
use disorders (SUD) and suicidality. Consult appropriate VA/DoD clinical
practice guidelines.
C. Treatment
8. We suggest considering, and offering as appropriate, a primary care, Weak for Not Reviewed,
symptom-driven approach in the evaluation and management of patients Amended
with a history of mTBI and persistent symptoms.
a. Effect of mTBI Etiology on Treatment Options and Outcomes
9. We recommend not adjusting treatment strategy based on mechanism of Strong Reviewed,
injury. against New-added
10. We recommend not adjusting outcome prognosis based on mechanism of Strong Reviewed,
injury. against New-added


b. Headache
11. We suggest that the treatment of headaches should be individualized and Weak for Reviewed,
tailored to the clinical features and patient preferences. The treatment may New-replaced
include:
a. Headache education including topics such as stimulus control, use of
caffeine/tobacco/alcohol and other stimulants
b. Non-pharmacologic interventions such as sleep hygiene education, dietary
modification, physical therapy (PT), relaxation and modification of the
environment (for specific components for each symptom, see Appendix B:
Clinical Symptom Management)
c. Pharmacologic interventions as appropriate both for acute pain and
prevention of headache attacks
c. Dizziness and Disequilibrium
12. In individuals with a history of mTBI who present with functional Weak for Reviewed,
impairments due to dizziness, disequilibrium, and spatial disorientation Amended
symptoms, we suggest that clinicians offer a short-term trial of specific
vestibular, visual, and proprioceptive therapeutic exercise to assess the
individual’s responsiveness to treatment. Refer to occupational therapy (OT),
physical therapy (PT) or other vestibular trained care provider as appropriate.
A prolonged course of therapy in the absence of patient improvement is
strongly discouraged.
d. Tinnitus
13. There is no evidence to suggest for or against the use of any particular N/A Reviewed,
modality for the treatment of tinnitus after mTBI. New-added
e. Visual Symptoms
14. There is no evidence to suggest for or against the use of any particular N/A Reviewed,
modality for the treatment of visual symptoms such as diplopia, New-added
accommodation or convergence disorder, visual tracking deficits and/or
photophobia after mTBI.
f. Sleep Disturbance
15. We suggest that treatment of sleep disturbance be individualized and Weak for Reviewed,
tailored to the clinical features and patient preferences, including the Amended
assessment of sleep patterns, sleep hygiene, diet, physical activities and
sleep environment. The treatment may include, in order of preference:
a. Sleep education including education about sleep hygiene, stimulus
control, use of caffeine/tobacco/alcohol and other stimulants
b. Non-pharmacologic interventions such as cognitive behavioral therapy
specific for insomnia (CBTi), dietary modification, physical activity,
relaxation and modification of the sleep environment (for specific
components for each symptoms see Appendix B: Clinical Symptom
Management)
c. Pharmacologic interventions as appropriate to aid in sleep initiation and
sleep maintenance
g. Behavioral Symptoms
16. We recommend that the presence of psychological or behavioral symptoms Strong for Reviewed,
following mTBI should be evaluated and managed according to existing Amended
evidence-based clinical practice guidelines, and based upon individual factors
and the nature and severity of symptoms.


h. Cognitive Symptoms
17. We suggest that patients with a history of mTBI who report cognitive symptoms Weak for Not Reviewed,
that do not resolve within 30-90 days and have been refractory to treatment for Amended
associated symptoms (e.g., sleep disturbance, headache) be referred as
appropriate for a structured cognitive assessment or neuropsychological
assessment to determine functional limitations and guide treatment.
18. We suggest that individuals with a history of mTBI who present with Weak for Reviewed,
symptoms related to memory, attention or executive function problems that New-replaced
do not resolve within 30-90 days and have been refractory to treatment for
associated symptoms should be referred as appropriate to cognitive
rehabilitation therapists with expertise in TBI rehabilitation. We suggest
considering a short-term trial of cognitive rehabilitation treatment to assess
the individual patient responsiveness to strategy training, including
instruction and practice on use of memory aids, such as cognitive assistive
technologies (AT). A prolonged course of therapy in the absence of patient
improvement is strongly discouraged.
19. We suggest against offering medications, supplements, nutraceuticals or Weak Not Reviewed,
herbal medicines for ameliorating the neurocognitive effects attributed to against Amended
mTBI.
D. Setting of Care
20. We suggest against routine referral to specialty care in the majority of Weak Reviewed,
patients with a history of mTBI. against Amended
21. If the patient’s symptoms do not resolve within 30-90 days and are refractory Weak for Reviewed,
to initial treatment in primary care and significantly impact activities of daily Amended
living (ADLs), we suggest consultation and collaboration with a locally
designated TBI or other applicable specialist.
22. For patients with persistent symptoms that have been refractory to initial Weak for Reviewed,
psychoeducation and treatment, we suggest referral to case managers within Amended
the primary care setting to provide additional psychoeducation, case
coordination and support.
23. There is insufficient evidence to recommend for or against the use of N/A Reviewed,
interdisciplinary/multidisciplinary teams in the management of patients with New-replaced
chronic symptoms attributed to mTBI.
*For additional information, please refer to Grading Recommendations.
†For additional information, please refer to Recommendation Categorization and Appendix E: 2009 Recommendation
Categorization.


Recommendation
1. We suggest using the terms “history of mild traumatic brain injury (mTBI)” or “concussion” and
to refrain from using the terms “brain damage” or “patients with mTBI” in communication with
patients and the public.
(Weak For| Not Reviewed, Amended)
Discussion
Within this guideline, the terms concussion and mTBI are used interchangeably. The use of the term
concussion or history of mild TBI may be preferred when communicating with the patient, indicating a
transient condition, avoiding the use of the terms "brain damage" or "brain injury" that may
inadvertently reinforce misattribution of symptoms or insecurities about recovery. The patient who is
told he or she has "brain damage" based on vague symptoms or complaints and no clear indication of
significant head trauma may develop a long-term perception of disability that may be difficult to
reverse.[10] The terms “concussion” and “mTBI” will be used throughout this document as a
convention. Also, patients should not be referred to as “mTBI patients” or “patients with mTBI” as this
implies that the mTBI (the injury itself, clinically defined only by immediate symptoms/signs at the time
of injury) is continuing currently.
Recommendation
2. We recommend evaluating individuals who present with symptoms or complaints potentially
related to brain injury at initial presentation.
(Strong For| Not Reviewed, Amended)
Discussion
A thorough history and physical examination are the basis of any clinical diagnosis. Currently, the diagnosis
of mTBI is based on clinical criteria obtained during a history and physical exam (see Algorithms for
definition). Symptoms associated with mTBI are identified while conducting the history of present illness.
The signs and symptoms associated with mTBI are evaluated through physical examination and history and
are treated in accordance with this guideline. This recommendation was not reviewed in the recent
literature review; however, the strength of this recommendation is strong. The content of the 2009 mTBI
CPG was reviewed and generally accepted as current best practice. The Work Group recognized primary
care providers should consider, as appropriate during each encounter, the following physical findings, signs
and symptoms (“red flags”) that may indicate a neurologic condition that requires urgent specialty
consultation (e.g., consultation with neurology, neuro-surgical):
• Progressively declining level of • Double vision
consciousness • Worsening headache
• Progressively declining neurological exam • Cannot recognize people or disoriented to
• Pupillary asymmetry place
• Seizures • Slurred speech
• Repeated vomiting • Unusual behavior
• Neurological deficit: motor or sensory

Evaluating individuals in military operational settings who are exposed to potentially concussive events (e.g.,
blast, motor vehicle accidents, blow to the head) while in theater is strongly encouraged as soon as possible
after exposure.
Detecting mTBI close to the time of injury is best for providing optimal care and potentially preventing persisting
symptoms. DoDI 6490.11 mandates that all Service Members exposed to a potentially concussive event be
screened for TBI using the Military Acute Concussion Evaluation (MACE), and be required to rest for 24 hours
regardless of results.[11] The MACE assesses neurological status and history to help the evaluation after an
mTBI, queries for symptoms, and briefly assesses cognitive functioning. However, studies have shown
inconclusive results with regard to the validity of the MACE as a clinical evaluation tool to assess for cognitive
function acutely following concussion in military settings,[12] with particularly low sensitivity and specificity
when administered more than 12 hours after injury.[13] Since implementation of the DoDI 6490.11
requirements, there has been an increase in the number of mTBIs identified and the number of patients who
received early treatment.[11] TBI evaluation is also included in post-deployment screening efforts upon return
from deployment to combat zones to facilitate identification of those individuals exposed to concussive events
who were not evaluated in theater at the time of the event.
The Post-Deployment Health Assessment (PDHA) uses two questions to screen for TBI regarding exposure to an
injury event and experiencing an associated alteration of consciousness. However, screening months to years
following an injury event for mTBI can result in adverse effects including misdiagnosis, inflated symptom
reporting and symptom misattribution; in addition, there is no evidence base to support this practice.[14,15]
Recommendation
3. Excluding patients with indicators for immediate referral, for patients identified by post-deployment
screening or who present to care with symptoms or complaints potentially related to brain injury, we
suggest against using the following tests to establish the diagnosis of mTBI or direct the care of patients
with a history of mTBI:
a. Neuroimaging
b. Serum biomarkers, including S100 calcium-binding protein B (S100-B), glial fibrillary acidic protein
(GFAP), ubiquitin carboxyl-terminal esterase L1 (UCH-L1), neuron specific enolase (NSE), and α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) peptide
(Weak Against | Reviewed, New-replaced)
Discussion
The diagnosis of mTBI is a clinical diagnosis which, in many cases, relies on history alone. Conceptually, a
confirmatory objective test that could provide a definitive diagnosis of mTBI that could be used to direct
treatment and/or predict outcomes would be desirable. Unfortunately, at this time, evidence does not support
the use of any laboratory, imaging, or physiological test for these purposes.
There are several studies that evaluate the use of computerized tomography (CT) scan or magnetic resonance
imaging (MRI) within the first week after the concussive incident.[16,17] These studies fall beyond the scope of
this CPG, which is focused on patients seen in primary care with symptoms persisting a week after the
concussive incident. Of note, however, the study by Kim et al. found that subjects with mTBI and abnormal MRIs

within the first week were more likely to have a symptom duration of greater than two weeks.[16]
Consequently, the evidence does not support obtaining an MRI beyond the first week, but if one was completed
during the first week and was abnormal, a longer duration of symptoms might be anticipated.
While many advanced neuroimaging techniques show promise in the diagnosis of mTBI, there is no evidence to
support routine use in this population later than seven days after the event. A meta-analysis of MRI diffusion
tensor imaging (DTI) in the post-concussion population (time since injury of three days to eight years) showed
fractional anisotropy (FA) reduction in several brain regions that have been associated with brain injury.[18]
However, many of the studies had significant methodological problems, particularly problems with selection of
control groups that adequately control for potential confounders. In a military cross-sectional study with the
same FA findings (and the same methodological problems with control selection), only 40% of post-concussion
patients had abnormalities on DTI, making sensitivity inadequate for routine use at this time.[19] In addition,
these studies have not linked DTI findings with clinical presentation or outcomes.
There is emerging literature about serum biomarkers, and much of the investigation has surrounded the acute
phase with a number of good candidate proteins. In the post-acute period (greater than seven days), however,
there is little information. In a single pilot study, serum levels of the AMPAR peptide were found to be
significantly different between non-concussed controls and concussed athletes one to two weeks following
concussion.[20] While there was some correlation between AMPAR levels and baseline cognitive testing
performance, there is inadequate data at this time to suggest that the use of this proposed biomarker would
affect clinical management or outcomes.
There are no studies to support the use of EEG in routine post-concussion care.
In conclusion, the current evidence does not support the routine use of laboratory, imaging or physiologic
testing in the management of a patient more than seven days following concussion. There does not appear to be
any benefits from these tests at the present time and clinicians should consider weighing the risk of unnecessary
testing in terms of communication considerations, management of patient expectations, and utilization of
resources. Future research should include long-term outcomes with a particular focus on how these test results
can help clinical decision making.
Recommendation
4. We recommend against performing comprehensive neuropsychological/cognitive testing during the
first 30 days following mTBI. For patients with symptoms persisting after 30 days, see Recommendation
17.
(Strong Against | Not Reviewed, New-replaced)
Discussion
The Work Group reviewed, and strongly agreed with, the 2009 mTBI CPG recommendation against the use of
comprehensive cognitive testing, including neuropsychological testing, in the first 30 days after concussion/mTBI
and strongly. The supporting literature was not addressed in the updated systematic review; however, the existing
literature from the 2009 CPG (all of which was from pre-2002) was reviewed. The literature utilized in the 2009
mTBI CPG was from a systematic review from 2005 [21] and three meta-analyses [22-24] that included research
articles published prior to 2002. This literature stated that cognitive deficits after mTBI usually only persist for a
few hours or days (rarely up to 30 days or beyond). These deficits were noted to be in the domains of memory,

complex attention or working memory, and speed of mental and motor processing; however, these deficits usually
resolved rapidly. Beyond the initial week to 30 days after concussion, there is no clear correlation between an
individual’s self-report of cognitive-related symptoms and findings from formal testing.
The recommendation is made “strong against” based on a high confidence in the existing literature and clinical
consensus, the harms from early formal testing (e.g., limits ability to formally test again for six or more months,
reinforces the impaired status of the individual when rapid and full cognitive recovery is likely), the relatively
high use of resources involved in formal neuropsychological testing, and the significant variability in preferences
(for both individuals with a history of mTBI and clinical providers) for the use and specific type of formal
neuropsychological testing.
Recommendation
5. For patients identified by post-deployment screening or who present to care with symptoms or
complaints potentially related to brain injury, we recommend against using the following tests in
routine diagnosis and care of patients with symptoms attributed to mTBI:
a. Comprehensive and focused neuropsychological testing, including Automated Neuropsychological
Assessment Metrics (ANAM), Neuro-Cognitive Assessment Tool (NCAT), or Immediate Post-
Concussion Assessment and Cognitive Testing (ImPACT).
(Strong Against | Reviewed, Amended)
Discussion
Following the immediate period (more than seven days post-concussive incident), there is insufficient evidence
for recommending routine (i.e., performed for all patients) cognitive or neuropsychological testing for the
diagnosis of mTBI compared to diagnosis based on history and physical only. Although there are consistent
findings of cognitive deficits especially in the first 48 hours after injury, well-controlled, long-term natural history
studies after concussion injuries are lacking, and the diagnostic utility of information on cognitive functioning in
the post-acute period is not clear.[25] Pape et al. performed a systematic review of 13 diagnostic accuracy
studies of neurocognitive and psychological tests in the diagnosis of mTBI.[26] Across studies, encompassing
both acute and post-acute concussion/mTBI, sensitivity ranged from 13-92%, specificity ranged from 72-99%,
and correct classification (which is influenced by base rate of mTBI) ranged from 3-96%.[26] However, the
research methods employed by the majority of the 13 studies reviewed were likely to provide biased, under- or
overestimates of true diagnostic accuracy. Similarly, although there may be some clinical utility in comparing
baseline neuropsychological functioning to post-injury functioning, a review of the literature indicated that there
is insufficient evidence for this strategy as an aid to diagnose concussion/mTBI in the post-acute period.[27]
In the post-acute period after mTBI, there is insufficient evidence for recommending routine (i.e., performed for
all patients) cognitive or neuropsychological testing to guide treatment decisions and to improve outcomes
compared to routine primary care. Individuals presenting for care with complaints potentially related to mTBI
may or may not present with cognitive symptoms. As discussed in more detail in other areas of this CPG (see
section on Cognitive Symptoms), cognitive and neuropsychological testing may be indicated for symptomatic
patients in specific situations, such as baseline assessment in preparation for cognitive rehabilitation [28] and
identifying emotional or motivational factors that could impact treatment planning.[29,30]

The Work Group has high confidence in this recommendation, which is based principally on a lack of evidence
for the routine use of comprehensive and focused neuropsychological testing in the diagnosis and care of
patients with symptoms attributed to mTBI. In addition, the Work Group felt the potential harms of routine
testing outweigh the potential benefits in the post-acute period. Potential harms include unnecessary
appointments for the patient, promotion of negative illness expectations, and increased utilization of clinical
resources that could be applied elsewhere. No literature was reviewed concerning patient values and
preferences; however, the Work Group considered that some patients would prefer to receive testing in order
to validate their symptoms (or receive reassurance as to their overall well-being) whereas others would prefer
to minimize the number of appointments and procedures received. In addition to the aforementioned
implications on resource management and acceptability, the Work Group identified the potential for stigma and
the availability of testing infrastructure as a potentially limiting factor.
Future research to improve the diagnostic accuracy of tests for mTBI in the post-acute period is needed.
Identification of interactions between cognitive, behavioral, and emotional factors as well as clinical and
demographic factors may improve diagnostic and prognostic models. In addition, Pape et al. emphasized that
the clinical utility of prior research on the diagnostic accuracy of cognitive and neuropsychological tests for
concussion/mTBI has been limited by the lack of a standardized and well-defined case definition of mTBI.[26]
Future studies will have to be designed in a way that acknowledges the lack of validation of existing case
definitions.
Recommendation
6. For patients with new symptoms that develop more than 30 days after mTBI, we suggest a focused
diagnostic work-up specific to those symptoms only.
(Weak For | Not Reviewed, Amended)
Discussion
It is important to recognize that the majority of individuals who sustain a single concussion recover within hours
to days without residual deficits. Post-concussion symptoms are nonspecific (e.g., headache, nausea, dizziness,
fatigue, irritability, concentration problems), which makes it very difficult to definitively attribute symptoms to
the concussive injury, particularly as the time since the event lengthens. In addition, there is little evidence to
suggest that treatment interventions should be different when symptoms are attributed to concussion versus a
different etiology.[31] Consequently, symptom-focused evaluation and treatment is recommended, particularly
when the time since injury is greater than 30 days.
The vast majority of patients who develop symptoms after concussion will do so immediately. In some cases,
analogous to the acute trauma setting where initial events (e.g., life-threatening injury) may take precedence
over other injuries (e.g., ankle sprain), patients may not notice some symptoms until later. However, with
patients that are initially asymptomatic and develop new symptoms 30 days or more following concussion,
these symptoms are unlikely to be the result of the concussion and the work-up and management should not
focus on the initial concussion.[31]

B. Co-occurring Conditions
Recommendation
7. We recommend assessing patients with symptoms attributed to mTBI for psychiatric symptoms and
comorbid psychiatric disorders including major depressive disorder (MDD), posttraumatic stress
disorder (PTSD), substance use disorders (SUD) and suicidality. Consult appropriate VA/DoD clinical
practice guidelines.
(Strong For | Not Reviewed, Amended)
Discussion
Depression, anxiety and irritability are common co-occurring behavioral symptoms of mTBI. When behavioral
symptoms are reported, they should be treated in accordance with treatment/management recommendations
within this guideline (see Appendix B: Clinical Symptom Management) or other VA/DoD CPGs. The relationship
between mTBI and comorbid psychiatric conditions, most notably PTSD, MDD and SUD is controversial and
complex.[15,32-39] There is evidence, however, that suggests comorbid depression or other mental disorders
are associated with higher rates of persistent post-concussive symptoms and poorer outcomes following
concussion. For these reasons, it is prudent to assess for comorbid psychiatric conditions and treat in
accordance with existing VA/DoD CPGs for the Management of PTSD, 7 MDD, 8 SUD, 9 and patients at risk for
suicide. 10
The overall quality of the evidence for this recommendation is high, and the Work Group felt strongly that it is
important to recommend assessment and specific treatment for comorbid psychiatric conditions in accordance
with existing VA/DoD CPGs. The benefit of early diagnosis and treatment of behavioral health symptoms or
disorders clearly outweighs the harms; it increases the likelihood symptoms will respond favorably to treatment
thereby alleviating the distress of the patient. In addition, given the demand on behavioral health resources
within the VA and DoD, initiating treatment for behavioral symptoms within a primary care setting helps to
ensure access to care standards for behavioral health services. Assessment in primary care is also an important
component of management of chronic multisymptom conditions, of which persistent post-concussion symptoms
meet the definition. (See the VA/DoD CPG for the Management of Chronic Multisymptom Illness [CMI] 11)
For additional clinical guidance, please see Appendix B: Co-occurring Conditions.
C. Treatment
In both the military and civilian populations, over 80% of diagnosed TBIs are categorized as mild and have been
associated with multiple clinical signs and symptoms.[40,41] In conjunction with a spectrum of possible clinical
7 See the VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Reaction. Available at:
http://www.healthquality.va.gov/guidelines/mh/ptsd/index.asp
8 See the VA/DoD Clinical Practice Guideline for Management of Major Depressive Disorder. Available at:
9 See the VA/DoD Clinical Practice Guideline for Management of Substance Use Disorder. Available at:
http://www.healthquality.va.gov/guidelines/mh/sud/index.asp
10 See the VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide. Available at:
11 See the VA/DoD Clinical Practice Guideline for Management of Chronic Multisymptom Illness. Available at:
http://www.healthquality.va.gov/guidelines/mr/cmi/index.asp

presentations, a variety of clinical outcomes have also been observed in patients following a concussive
event.[42]
Recommendation
8. We suggest considering, and offering as appropriate, a primary care, symptom-driven approach in the
evaluation and management of patients with a history of mTBI and persistent symptoms.
Discussion
Individuals who have had a concussive event at some point in the past may continue to have persistent and
potentially chronic symptoms, although it is often difficult to determine the exact etiology of these symptoms.
Persistent post-concussive symptoms often involve multiple physiological domains (e.g., psychological
symptoms, neurological symptoms, neuroendocrine symptoms). There is currently insufficient evidence
regarding the long-term sequelae of concussive events. Some of a patient’s experiences may possibly be the
result of neurological injury that is not well detected by the tools available at this time. Therefore, it may be
difficult to determine which symptoms are the result of the original event and which are not.
Some presenting symptoms may be attributed to the mTBI event by both providers and patients, even though
the contribution of the original event to current symptoms is uncertain. This can place the patient into a
category in which all of his or her symptoms are considered “mTBI symptoms.” This attribution, and potential
misattribution, of symptoms to mTBI can potentially place the patient at risk. When such a patient becomes “a
TBI patient,” providers may continue to view all of his or her symptoms through that prism. Unfortunately, some
of the very programs that are intended to help patients with a history of mTBI may have the unintended
consequence of reinforcing the concept that all of his or her symptoms are mTBI-related.[43,44] When this
happens, the patient may consider himself/herself as a “lifelong” mTBI patient. Patients may subsequently be
subjected to (or request) repeated evaluations that are unlikely to be helpful and are potentially harmful (e.g.,
needless exposure to radiation). Furthermore, attributing all symptoms to mTBI may bias providers who could
miss important chronic or acute symptoms that may be more accurately associated with other conditions.
These patients are best managed within the primary care system. Rather than reinforce mTBI as the “cause” of
the patient’s problems, the primary care provider should use an approach to care that is consistent with the
treatment of chronic, multisymptom conditions. The provider should use a collaborative step-care approach that
builds on the principles of treatment for other chronic conditions, including CMI (see the VA/DoD CPG for the
Management of CMI 12) in the development of a comprehensive and personalized treatment plan. Building a
solid therapeutic patient-provider alliance is essential to the proper management of patients with a history of
mTBI. Symptoms should be acknowledged, not labeled as psychogenic, with an emphasis on reinforcing
normalcy and wellness rather than impairment and self-labeling. Regularly scheduled appointments in primary
care, rather than as-needed appointments, are recommended. Primary care providers should protect patients
from unnecessary tests or consultations that could potentially put them at risk (e.g., from medication
interactions prescribed from different providers) or lead to more negative illness expectations. Specialty
consultation should be used if clinically indicated, but the use of specialty referrals should be conducted in a

prudent and judicious fashion. This symptom-driven approach based in primary care validates the patient’s
experience, minimizes misattribution and labeling, maintains vigilance regarding new symptoms that may arise,
helps avoid needless evaluations, and reduces the use of expensive and labor intensive specialty consultation
and evaluations.
a. Effect of mTBI Etiology on Treatment Options and Outcomes

The leading causes of concussion include falls, motor vehicle accidents, being struck by or against an object,
sports injury, and assaults. Blast exposure is another mechanism of mTBI injury, though it is uncertain to what
extent the injury effects are due to primary blast exposure versus secondary or tertiary injuries from flying
debris or being thrown into a hard object. Typically, TBI resulting from blast exposure represents a threat to
military personnel only.
Recommendations
9. We recommend not adjusting treatment strategy based on mechanism of injury.
(Strong Against | Reviewed, New-added)
10. We recommend not adjusting outcome prognosis based on mechanism of injury.

(Strong Against | Reviewed, New-added)
Discussion
At the higher energy states associated with moderate and severe TBI, primary blast injury has been identified as
a distinct, complex, and dynamic process, which results in unique tissue-level pathology.[45,46] However,
unique effects associated with blast or other mechanisms of injury at lower energy states, consistent with
concussive injury, are unknown. In the absence of an identified mechanism of injury and associated
pathophysiology, treatment and prognosis are based on clinical assessment at this time. To date, assessments of
mTBI symptoms as well as other health outcomes have demonstrated no significant clinical variance based on
mechanism of injury.
In the systematic evidence review for the current mTBI CPG, none of the studies identified were specifically
designed to evaluate mechanisms of injury or effectiveness of treatment as related to mechanism of injury.
Given the limited evidence base and lack of evidence to suggest a difference in mTBI symptoms, therapy should
not be modified based on mechanism of injury at this time. An increased proportion of patients with a history of
mTBI associated with acceleration/deceleration brain injury may have anosmia, and an increased percentage of
those with blast-associated mTBI may have hearing loss, which suggests a benefit for selective screening in these
populations. Also, screening for psychological reaction and need for support may be warranted in those patients
for whom assault is the underlying etiology.
Future research may investigate mechanism-specific physiologic response and may examine pathophysiology for
which specific treatment and predictive outcome measures may be of value. Additional research is needed to
improve diagnostic criteria and develop neuroprotective therapies before specific treatment recommendations
or prognostic models can be developed based on individual mechanisms of injury.
See Appendix C: Mechanism of Injury for additional information.

b. Headache
Recommendation
11. We suggest that the treatment of headaches should be individualized and tailored to the clinical
features and patient preferences. The treatment may include:
a. Headache education including topics such as stimulus control, use of caffeine/tobacco/alcohol and
other stimulants
b. Non-pharmacologic interventions such as sleep hygiene education, dietary modification, physical
therapy (PT), relaxation and modification of the environment (for specific components for each
symptom, see Appendix B: Clinical Symptom Management)
c. Pharmacologic interventions as appropriate both for acute pain and prevention of headache attacks
(Weak For| Reviewed, Replaced)
Discussion
Headaches are common physical symptoms after mTBI occurring in 30-90% of individuals following TBI (mild,
moderate, or severe).[47,48] The International Classification of Headache Disorders- 2nd edition defines
posttraumatic headaches as secondary headache disorders that start within seven days after head trauma.[49]
Posttraumatic headaches are commonly classified as migraine headaches, tension-type headaches, mixed
tension/migraine headaches or cervicogenic headaches. The normal recovery of posttraumatic headaches
following concussion is usually rapid (hours to days) with most headaches resolving within three months.
However, in some cases, headaches may last longer and are referred to as persistent posttraumatic
headaches.[50]
The overall evidence for the treatment of posttraumatic headaches neither supports nor refutes the
effectiveness of current management strategies and the clinician must use best clinical judgment in treating
headaches while weighing benefits and possible risks.
Clinical consideration for the management of posttraumatic headaches should begin with a detailed headache
history, including headache location, severity, intensity, frequency, and associated symptoms (e.g., nausea,
vomiting, photophobia) and physical examination with a focused neurological and musculoskeletal (including
cervical spine) examination. Headache phenotype (e.g., migraines, tension type, cervicogenic headache, mixed
headache) should be diagnosed and a treatment plan should be initiated. Headache management should take a
patient-centered approach with the treatment program individualized and tailored to meet the needs and
clinical presentation of the patient. Comorbid symptoms (e.g., dizziness, vision impairment, cognitive
impairment, tinnitus) and conditions (e.g., PTSD, depression) should also be assessed and considered prior to
initiation of the treatment program. Treatment considerations may include both non-pharmacologic and
pharmacologic management options. Non-pharmacologic management may include education on lifestyle
modifications, PT, integrative medicine techniques (e.g., acupuncture, relaxation therapy, mindfulness training),
biofeedback and cognitive behavioral therapy (CBT).
Pharmacologic management for acute headache may include nonsteroidal anti-inflammatory drugs (NSAIDs),
aspirin or acetaminophen. The use of the triptan class of medication (e.g., sumatriptan) for migraine-type
headaches may be efficacious. For chronic daily headaches the use of prophylactic medications (e.g.,
topiramate) may be considered. (See Appendix B: Clinical Symptom Management for pharmacologic
management options.) In the acute phase of management of posttraumatic headaches, narcotic analgesics

should be avoided, if possible. Also, special consideration is recommended for the assessment of medication-
overuse headaches. Patients with posttraumatic headaches that are refractory to treatment should be referred
to a physical medicine and rehabilitation physician, neurologist or brain injury specialist for further assessment.
Further research is needed to address headache management after mTBI.
For additional clinical guidance, please see Appendix B: Headache.
c. Dizziness and Disequilibrium

Dizziness and disequilibrium are common symptoms/signs of many diagnoses, including mTBI. Dizziness was
reported in one study as occurring in 26% of soldiers immediately after a deployment-related concussion, but
only in 5% of all soldiers after returning from deployment. It is not clear to what degree this symptom was
directly due to the previous mTBI in these soldiers. Dizziness is one of the most common symptoms in primary
care.[51,52]
Recommendation
12. In individuals with a history of mTBI who present with functional impairments due to dizziness,
disequilibrium, and spatial disorientation symptoms, we suggest that clinicians offer a short-term trial of
specific vestibular, visual, and proprioceptive therapeutic exercise to assess the individual’s
responsiveness to treatment. Refer to occupational therapy (OT), physical therapy (PT) or other
vestibular trained care provider as appropriate. A prolonged course of therapy in the absence of patient
(Weak For| Reviewed, New-added)
Discussion
In the acute stage, mTBI may cause dizziness.[53-55] Subjective reports of dizziness correlate with objective
testing only during the first week after the concussion/mTBI.[56] Mild TBI may cause coordination deficits of the
lower extremities (imbalance) and/or upper extremities (dysmetria).[57-59] Cognitive distractions or
performance of dual tasks are sensitive provocative tests for detection of imbalance and coordination deficits in
the acute stage of mTBI.[57,59] Adjusting for age, gender, educational and employment status, patients with a
history of mTBI who had a skull fracture, dizziness, and/or headache were at increased risk of developing
persistent symptoms at one month.[60]
Although there is efficacy of vestibular and balance rehabilitation programs in patients with vestibular disorders
in general, such as following acoustic neuroma resection or unexplained dizziness treated in primary care
settings, there is no evidence that any specific program improves post-mTBI related symptoms.[61-63] One
uncontrolled case series reported that preliminary vestibular rehabilitation or graded exercise improved
posttraumatic dizziness symptoms in some patients.[54] In one randomized trial, Naguib and Madian found that
a group of individuals with a history of TBI (all levels of severity) participating in a vestibular rehabilitation
program immediately after the head trauma demonstrated significantly shorter recovery time than patients
receiving a medication (betahistine) alone, with faster recovery in those with milder brain injury.[64]
Given the lack of evidence specific to vestibular rehabilitation in the mTBI population, it is unknown if the
benefits of implementing a specific vestibular program, guided by a qualified vestibular rehabilitation therapist,
could outweigh potential harms in certain patients (harms could include loss of patient’s time and resources to
attend a course of therapy without significant improvement or heightening negative perceptions of one’s health

status). The purpose of such a trial would be to assess whether a particular patient benefits from vestibular
rehabilitation techniques, as suggested. From case observations, one to two sessions can be sufficient for some
patients, while others may benefit from more sessions. To minimize the potential negative effects of protracted,
ineffective treatment, we suggest goal-based, functional re-assessment to determine treatment responsiveness.
A prolonged course of therapy in the absence of patient improvement is strongly discouraged. Consideration
should be given to patient preferences. Options should be presented clearly, such as whether participation will
be primarily in a clinical setting with an adjunct home exercise program, or primarily focus on a home exercise
program with infrequent follow-ups to manage and direct patient progress. While a brief trial of vestibular
therapy may be considered, a symptom-based approach per other guidelines may be also considered. See
related VA/DoD CPGs (e.g., PTSD13, MDD14 , Bipolar Disorder15, Patients at Risk for Suicide16, CMI17). Future
controlled research is recommended on vestibular rehabilitation exercises in patients with a history of mTBI.
Rigorous research should be conducted to define the types of dizziness in this patient population that will
respond positively to specific vestibular rehabilitation.
For additional clinical guidance, please see Appendix B: Dizziness and Disequilibrium.
d. Tinnitus
Tinnitus is a common problem among the Operation Iraqi Freedom (OIF), Operation Enduring Freedom (OEF)
and Operation New Dawn (OND) Veterans and Service Members who have sustained an mTBI.[65] A
retrospective study published in 2012 reported that 75.7% of the Veterans with a history of mTBI reported
tinnitus.[66] Tinnitus can occur as a direct consequence of mTBI, but can also occur from other causes such as a
side effect from medications used to treat other common symptoms associated with mTBI.[67]
Recommendation
13. There is no evidence to suggest for or against the use of any particular modality for the treatment of
tinnitus after mTBI.
(N/A | Reviewed, New-added)
Discussion
As a guide to treatment, there is no evidence to support or refute differentiating tinnitus after mTBI from
tinnitus from other etiologies. However, in a patient with functionally limiting symptoms, the Work Group
suggests considering a short-term trial of tinnitus management (e.g., white noise generator, biofeedback,
hypnosis, relaxation therapy) to assess the individual’s responsiveness to treatment. Refer to an audiologist as
appropriate. A prolonged course of therapy in the absence of patient improvement is strongly discouraged.
13See the VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Reaction. Available at:
14See the VA/DoD Clinical Practice Guideline for Management of Major Depressive Disorder. Available at:
15See the VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder in Adults. Available at:
16See the VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide. Available at:

The literature search identified one prospective study of tinnitus after TBI conducted by Henry et al. that found
no significant improvement in tinnitus after six sessions of telephone counseling over six months.[68]
Confidence in the quality of the study is very low. The benefits and harms or burden are balanced with some
variation of patient values and preferences. The purpose of such a trial would be to assess whether a particular
patient benefits from tinnitus management techniques, as suggested. From case observations, one to two
sessions can be sufficient for some patients, while others may benefit from more sessions. To minimize the
potential negative effects of protracted, ineffective treatment, we suggest goal-based, functional re-assessment
to determine treatment responsiveness.
Acute audiologic symptoms, including altered acuity, tinnitus and sensitivity to noise, occur in up to three-
quarters of all individuals who sustain a concussion. The vast majority of those symptoms resolve within a
month, unless there is significant or permanent injury to the eardrum. Audiologic symptoms may be related to
concurrent injury to ear structure or other related medical conditions; assessment should be done to rule out
these causes. The guideline panel advises performing an otologic examination, reviewing medications for
ototoxicity and referring to audiology for hearing assessment if no other apparent cause if found. The Work
Group acknowledges a paucity of literature on the difference between tinnitus from mTBI versus tinnitus from
any other etiology and urges that head-to-head comparison trials be conducted.
e. Visual Symptoms
Recommendation
14. There is no evidence to suggest for or against the use of any particular modality for the treatment of
visual symptoms such as diplopia, accommodation or convergence disorder, visual tracking deficits
and/or photophobia after mTBI.
(N/A | Reviewed, New-added)
Discussion
Visual dysfunction is a common complaint following mTBI,[69-71] manifested by problems with near visual
acuity, an accommodation dysfunction, eye movement and ocular alignment disorders, and photophobia/glare
sensitivity. Non-resolving vision disorders have a significant impact on functional performance and quality of life.
Common vision complaints may include problems with reading print and electronic media, as well as changes to
visual habits such as using a cell phone/texting, driving, visual gaming and participating in sports.
Limited evidence exists to demonstrate that vision rehabilitation reduces or eliminates functionally-limiting
vision symptoms following mTBI. However, in a patient with functionally limiting symptoms, we suggest
considering a short-term trial of specific visual rehabilitation to assess the individual’s responsiveness to
treatment. Consider a referral to optometry, ophthalmology, neuro-ophthalmology, neurology, and/or a vision
rehabilitation team. A prolonged course of therapy in the absence of patient improvement is strongly
discouraged. Only one study among patients with a history of mTBI (with data reported in three separate
publications) met inclusion criteria for the systematic review update for this CPG.[72-74] Although results of this
study concluded that oculomotor training improved reading rate and reading grade level efficiency, the overall
quality rating for the evidence was very low due to serious study design limitations (non-randomized, patients-
blinded, crossover study), a small number of patients (n=12), and a short length of follow-up (treatment effects
measured at seven weeks). Despite the lack of evidence to support vision rehabilitation care in patients with a
history of mTBI, clinicians may consider a brief trial of an individualized vision therapy program while taking into

consideration potential harms (e.g., utilizing patient’s time and resources to attend therapy with the possibility
of completing the intervention without significant improvement, fostering negative illness expectations). The
purpose of such a trial would be to assess whether a particular patient benefits from visual rehabilitation
techniques, as suggested. From case observations, one to two sessions can be sufficient for some patients, while
others may benefit from more sessions. To minimize the potential negative effects of protracted, ineffective
treatment, we suggest goal-based, functional re-assessment to determine treatment responsiveness. Further
research is needed to provide evidence on effective treatment interventions for visual dysfunction following
mTBI.
For additional clinical guidance, please see Appendix B: Visual Symptoms.
f. Sleep Disturbance
Sleep disturbances can occur in approximately 30% of patients following mTBI.[75] These disturbances can
include the following: (1) Persistent difficulty falling asleep or staying asleep despite the opportunity, (2) Delayed
sleep phase syndrome, and (3) Irregular sleep-wake pattern. Sleep apnea, depression, pain, and other conditions
may contribute to the overall poor quality of sleep. Pharmacologic treatment of sleep disturbance following
mTBI may be complex. For all pharmacologic interventions, providers should weigh the risk-benefit profiles,
including toxicity and abuse potential.
Recommendation
15. We suggest that treatment of sleep disturbance be individualized and tailored to the clinical features
and patient preferences, including the assessment of sleep patterns, sleep hygiene, diet, physical
activities and sleep environment. The treatment may include, in order of preference:
a. Sleep education including education about sleep hygiene, stimulus control, use of caffeine/tobacco/
alcohol and other stimulants
b. Non-pharmacologic interventions such as cognitive behavioral therapy specific for insomnia (CBTi),
dietary modification, physical activity, relaxation and modification of the sleep environment (for
specific components for each symptoms see Appendix B: Clinical Symptom Management)
c. Pharmacologic interventions as appropriate to aid in sleep initiation and sleep maintenance
(Weak For| Reviewed, Amended)
Discussion
There is no available literature demonstrating that sleep dysfunction after mTBI should be treated any
differently than sleep dysfunction from other causes. A small study of 24 patients evaluated the use of
acupuncture or a control intervention in the management of insomnia after mTBI.[76] Insomnia, as measured by
the Insomnia Severity Index (ISI), and sleep time did not clinically improve.
Treatment of sleep disorders among patients with a history of mTBI can include both non-pharmacologic and
pharmacologic therapy. The aim of sleep management is to establish a regular, normalized sleep-wake pattern.
Non-pharmacologic therapies such as CBT and sleep hygiene may be employed. Tools used with CBT may
include sleep education, stimulus control, sleep restriction, as well as methods to deal with stress, all with a goal
of empowering the patient to manage his or her sleep dysfunction, especially in relation to comorbid conditions
(e.g., circadian rhythm shift, restless leg syndrome, periodic limb movement disorder, rapid eye movement
[REM] sleep behavior disorder).[77] CBT has proven efficacious in the treatment of sleep disorders as

demonstrated in a meta-analysis of behavioral therapies for insomnia that reported CBT improved subjective
sleep quality and decreased subjective wake time during the night.[78]
Pharmacologic therapy for sleep dysfunction may include either prescription or over-the-counter (OTC)
medications. The aim of therapy should be to use medications that will not produce dependency and have
minimal adverse effects for patients with a history of mTBI. Medications should be used on a short-term basis
only and may include trazodone, mirtazapine, and tricyclic antidepressants (e.g., amitriptyline). The use of
benzodiazepines should be avoided in patients with a history of mTBI due to potential development of
dependency and worsening of other persistent symptoms such as cognitive changes and decision making ability,
as well as a high likelihood to worsen comorbid health conditions if present (particularly depression or PTSD).
For additional clinical guidance, please see Appendix B: Sleep Disturbance.
g. Behavioral Symptoms
Although the rates, intensity, and types of psychiatric symptoms following mTBI remain unclear, some evidence
exists for the association of mental disorders, such as MDD or PTSD, with reduced recovery after concussion
injury. Behavioral symptoms can also emerge following trauma due to direct or indirect effects of trauma.
Commonly reported diagnostic groups include mood, anxiety, substance misuse, and trauma- and stress-related
disorders, such as PTSD.[79-82]
Recommendation
16. We recommend that the presence of psychological or behavioral symptoms following mTBI should be
evaluated and managed according to existing evidence-based clinical practice guidelines, and based
upon individual factors and the nature and severity of symptoms.
(Strong For | Reviewed, Amended)
Discussion
The emergence of psychiatric symptoms after mTBI can depend on many factors, including pre-injury
psychosocial function and/or pre-existing mental illness, genetic predisposition to psychiatric illness, injury
factors, and post-injury psychosocial factors. The nature and severity of symptoms (including any presence of
suicidal ideation or threats to others), as ascertained in a thorough medical history, is necessary to choose
appropriate treatments. Given the association of depression, PTSD, and other mental health problems with a
history of mTBI and other injuries, it is recommended to assess for these conditions and consult related VA/DoD
CPGs (e.g., PTSD 18, MDD 19 , Bipolar Disorder 20, Patients at Risk for Suicide 21, CMI 22).
18See the VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Reaction. Available at:
19See the VA/DoD Clinical Practice Guideline for Management of Major Depressive Disorder. Available at:
20See the VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder in Adults. Available at:
21See the VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide. Available at:

The standard of care for psychological and behavioral symptoms following mTBI includes both
psychotherapeutic and pharmacologic treatment modalities. In the 2009 mTBI CPG, there was stronger evidence
for psychotherapies.[83-85] There has been some evidence demonstrating the effectiveness of CBT for
treatment of PTSD, decreased cognitive skills, and depression in this population. However, there is no strong
evidence for any specific therapy for irritability and other behavioral symptoms (such as impulsivity) following
mTBI. To date, there are no medications specifically approved by the U.S. Food and Drug Administration (FDA)
for treatment of post-mTBI psychiatric/behavioral symptoms. Since the 2009 mTBI CPG, there have been two
randomized double-blind controlled clinical trials of medications specifically targeting behavioral symptoms
after brain injuries. However, both studies included patients with moderate and severe brain injuries as well as
mild and may only be marginally relevant to the patient population of interest.[86,87] Thus, although there are
few studies involving specific populations with a history of mTBI, there is a broader body of evidence supporting
the use of psychotherapy or pharmacologic interventions for mental disorders. Clinicians are encouraged to
consult relevant CPGs for these conditions, taking into consideration the underlying diagnoses, patient
preferences, comorbidities, and available treatment modalities.
h. Cognitive Symptoms
Recommendation
17. We suggest that patients with a history of mTBI who report cognitive symptoms that do not resolve within
30-90 days and have been refractory to treatment for associated symptoms (e.g., sleep disturbance,
headache) be referred as appropriate for a structured cognitive assessment or neuropsychological
assessment to determine functional limitations and guide treatment.
Discussion
After 30 days post-injury, the use of formal neuropsychological testing should be reserved for specific diagnostic
or management questions (e.g., What factors are contributing to the cognitive symptoms reported?, Are there
behavioral deficits that are causing cognitive limitations or preventing clinical response to interventions?).
Testing should be tailored to the specific questions being asked, the characteristics of the individual with the
history of concussion, and to the skills, training and preferences of the neuropsychologist providing the
assessment. Individuals who present with persistent complaints of cognitive-related symptoms (e.g., subjective
memory deficits), despite normal cognitive skills on neuropsychological and functional assessments, should be
provided psychoeducation and managed by primary care with a focus on health management (e.g., diet,
exercise, mindfulness, general medical care), preventing and/or managing conditions that may affect cognition
(e.g., depression, PTSD, insomnia, substance use), and use strategies for the long-term management of
individuals with non-specific symptoms that persist for a number of months (e.g., VA/DoD CPG for the
Management of CMI 23).[22,88]

Recommendation
18. We suggest that individuals with a history of mTBI who present with symptoms related to memory,
attention or executive function problems that do not resolve within 30-90 days and have been
refractory to treatment for associated symptoms should be referred as appropriate to cognitive
rehabilitation therapists with expertise in TBI rehabilitation. We suggest considering a short-term trial of
cognitive rehabilitation treatment to assess the individual patient responsiveness to strategy training,
including instruction and practice on use of memory aids, such as cognitive assistive technologies (AT). A
prolonged course of therapy in the absence of patient improvement is strongly discouraged.
(Weak For| Reviewed, New-replaced)
Discussion
Although initial complaints of impaired memory, attention and executive function are common immediately
following mTBI, the vast majority of individuals recover within a few hours to days.[22-24] However, a small
number report new, persistent or worsening cognitive symptoms weeks, months or sometimes years post-
injury.[22,88-90] This subgroup often presents with pre-morbid or comorbid conditions, such as depression,
anxiety, poor health, chronic pain, negative self-beliefs and expectations, poor psychosocial support or other
limited coping resources, or are involved in litigation or disability processes.[22,88,90] When considering referral
to cognitive rehabilitation therapists with expertise in TBI rehabilitation (e.g., speech-language pathology,
neuropsychology, OT) for a trial of cognitive rehabilitation treatment, coexisting factors that may decrease
cognitive functioning (e.g., sleep difficulties, mental health concerns) must be considered. Conditions that have
not been treated should be addressed by primary care providers or referred to the appropriate specialist for
intervention when initiating cognitive treatment.
Cognitive-related difficulties can be treated symptomatically in some cases, regardless of the etiology of the
symptom. Early in the treatment process, it is recommended to provide individuals with psychoeducation,
supportive stress management and/or cognitive behavioral interventions to enhance recovery, in concert with
optimizing the individual’s overall health condition (e.g., sleep hygiene, pain management, dizziness
management) and comorbid conditions (e.g., PTSD, MDD, anxiety disorder, SUD). If cognitive testing is done, it
should emphasize focused assessment of functional limitations to guide interventions, and should be based on
the skills, training and preferences of the treating clinician (e.g., psychologist, occupational therapist, speech-
language pathologist). A comprehensive, holistic approach that integrates cognitive, emotional and
interpersonal skills, focuses on metacognitive strategy training (thinking about thinking), and compensatory aids
to improve planning, organization and participation in daily activities, such as work, school and household
management tasks, are some strategies that have been used.
While evidence for the effectiveness of targeted cognitive rehabilitation in the moderate-to-severe TBI
population has been well established,[91] there is limited evidence supporting a specific cognitive practice and
dosage standard for mTBI. One systematic review [92] and three RCTs [93-95] were published since the last
review of the literature and met inclusion criteria for the systematic review that informed this CPG. The overall
quality rating for the current evidence was low for reported neuropsychologic or functional outcomes.
Upcoming publications may provide additional information on this topic.
In the absence of strong scientific evidence and given that the potential harms (e.g., excessive resource use,
over-emphasis on illness and disability) are probably no greater than the benefits; a weak recommendation was

made to consider a trial of cognitive rehabilitation focused on time-limited, measurable goals related to
reducing activity limitations and improving activity participation. The purpose of such a trial would be to assess
whether a particular patient benefits from strategy training and memory compensation techniques, as
suggested. From case observations, one to two sessions can be sufficient for some patients, while others may
benefit from more sessions. To minimize the potential negative effects of protracted, ineffective treatment, we
suggest goal-based, functional re-assessment to determine treatment responsiveness. A prolonged course of
therapy in the absence of patient improvement is strongly discouraged. If used, selection of the components
and goals of the cognitive rehabilitation trial should be based on the integration of best available current
evidence with clinical expertise and judgment, and should aim to reflect patient/family preferences, values,
needs, abilities and interests.[96]
For additional clinical guidance, please see Appendix B: Cognitive Symptoms.
Recommendation
19. We suggest against offering medications, supplements, nutraceuticals or herbal medicines for
ameliorating the neurocognitive effects attributed to mTBI.
(Weak Against| Not Reviewed, Amended)
Discussion
Psychotropic medications have been used in treating cognitive issues related to other conditions, such as
attention deficit hyperactivity disorder (ADHD) and dementia. For individuals with cognitive dysfunction after
mTBI, atomoxetine, a non-stimulant ADHD medication,[97] and bromocriptine [98] have not been shown to be
effective. Cholinergic agonists have been used for Alzheimer’s patients to improve cognition and have been
studied in TBI. Both rivastigmine [99] and donepezil [100,101] have been shown to be minimally effective in
moderate to severe TBI, but are not recommended for mTBI. Lisdexamfetamine, a stimulant medication used for
ADHD, was studied in a small group of only moderate to severe TBI patients with only mild improvement
reported.[102] All of these studies have been small and some have significant methodological flaws.
Additionally, the literature utilized in the 2009 mTBI CPG was from studies that were either small and poorly
controlled or had mixed samples of injury severity. While some of these studies did include patients with a
history of mTBI, the majority of subjects were diagnosed with moderate to severe TBI and those diagnosed with
mTBI did not undergo a subgroup analysis. No medication has received approval from the FDA for the treatment
of any mTBI-related cognitive dysfunction. Predominately with the stimulant class of medications, both
substance abuse and diversion are potential concerns, with rates in the adult ADHD population ranging between
5-35%.[103]
Supplements, nutraceuticals and herbal treatments have not been studied in any controlled studies in patients
with a history of mTBI.
The recommendation has a strength of “weak against” based on a low confidence in the existing literature and
the risk of the harms from medication (e.g., side effects, medication interactions, polypharmacy) and
supplements, nutraceuticals or herbal usage (e.g., side effects, interactions with medications, non-regulated
products, variable strength and purity). There is also a relatively high use of resources associated with these
agents and significant variability in preferences (for both patients and clinical providers) for both the use and
specific type of agents recommended.

D. Setting of Care
Recommendation
20. We suggest against routine referral to specialty care in the majority of patients with a history of mTBI.
(Weak Against | Reviewed, Amended)
Discussion
The diagnosis of mTBI is a clinical diagnosis, relying predominantly on patient history. Primary care providers
can–and should–take a careful history, evaluate potential mTBI-related symptoms, and treat as appropriate.
However, providers should also be cognizant of the risks of assuming that symptoms that present months or
years after mTBI are directly attributable to the mTBI. Primary care providers are encouraged to utilize all
techniques applicable to other chronic conditions (see the VA/DoD CPG for the Management of CMI 24) and only
make referrals judiciously as clinically indicated.
Confidence in the quality of the evidence for this recommendation was low.[46,92,104] The balance of positive
outcomes or benefits slightly outweighs harms/burden to the patient in the primary care setting. There is some
variation in patient values and preferences and the Work Group speculated that some patients may desire a
more comprehensive interdisciplinary intervention (e.g., physical therapist, occupational therapist, clinical
psychologist, pain medicine and rehabilitation medicine physician), evaluation and follow-up in addition to
primary care. However, if primary care providers establish an alliance, build confidence with the patient, and
also help the patient to understand potential risks of unnecessary referrals, this may not be necessary.
Recommendation
21. If the patient’s symptoms do not resolve within 30-90 days and are refractory to initial treatment in
primary care and significantly impact activities of daily living (ADLs), we suggest consultation and
collaboration with a locally designated TBI or other applicable specialist.
(Weak For | Reviewed, Amended)
Discussion
Consultation and collaboration with a TBI specialist may be considered if symptoms are refractory to treatment.
However, it is best if care remains coordinated and managed in the primary care setting.[104] Patients should be
asked about the impact of their symptoms on their daily function. Patients with a history of mTBI are typically
independent in basic ADLs (e.g., grooming, bathing, dressing, toileting, mobility). However, a small minority of
patients may present with problems performing instrumental ADLs (IADLs). These problems may impact
independent functioning in tasks such as driving, home management, childcare, financial management, and
performance at work or school.
Patients with symptoms should be asked open-ended questions to allow them to describe their difficulties and
their impact on activity participation (e.g., What changes have you noticed due to symptom[s] in your
work/school/home performance since your injury?). Presenting patients with symptom checklists is not
recommended; however, these lists may be useful in documenting symptoms and symptom intensity.

Consultation and collaboration with a TBI specialist may be considered when the patient’s persistent symptoms
significantly impact ADLs or IADLs. Confidence in the quality of evidence is very low based on a lack of current
literature indicating improved outcomes in the TBI specialty setting versus ongoing symptom management in
the primary care setting. Additional research is needed to evaluate patient symptom management outcomes in
the TBI specialty care setting.
TBI specialist services may be provided in an outpatient treatment setting based on the individual needs of the
patient. Symptom management under the direction of primary care with support of a TBI specialist may
incorporate an interdisciplinary team setting that includes several subspecialties. A treatment plan is developed
based on comprehensive evaluations and patient/family goals.
Local TBI subspecialties to consider for referral may include:

• Audiology/Vestibular – strategies for management for tinnitus, hearing loss, and vertigo
• Optometry/Ophthalmology – strategies for management for visual impairments
• Physical Therapy – strategies for management of gait/mobility impairments, vertigo, or pain
• Speech-Language Pathology – assessment of and strategies for management of cognitive deficits and
cognitive/social communication
• Occupational Therapy – assessment and strategies for management of cognitive deficits and impact on
everyday activities/IADLs
• Psychology/Neuropsychology – assessment and management of cognitive deficits of mental health or
behavioral problems
However, it is unknown if the benefits outweigh the harms or burden of involving TBI specialists in patient
symptom management or interventions to improve performance of ADLs. Increasing the number of specialists
involved in care, even if optimally coordinated, increases the likelihood of differences in clinical opinions,
conflicting patient education messages, or potential for risks such as medication interactions. Patient
preferences and values should be considered when designing treatment plans. Other implications to consider
include the lack of availability of TBI specialists and TBI programs in certain areas, as well as differences in how
healthcare systems define a “TBI specialist.” This may present issues in resource use, equity, acceptability,
feasibility, and subgroup considerations. Lessons from the VA/DoD CMI CPG are particularly pertinent to this
discussion (see the VA/DoD CPG for the Management of CMI 25).
Recommendation
22. For patients with persistent symptoms that have been refractory to initial psychoeducation and
treatment, we suggest referral to case managers within the primary care setting to provide additional
psychoeducation, case coordination and support.
(Weak For | Reviewed, Amended)

Discussion
Individuals presenting with persistent symptoms should be considered for referral to case management,
particularly in the primary care setting. Whether the individual has recently returned from deployment or
combat, or is a Veteran who has sustained non-combat related head trauma, the need for a collaborative and
coordinated approach to comprehensive care is important.
Case managers serve multiple functions:

• Complete an in-depth assessment of functional status and coordinate treatment resources
• Ensure that the patient is screened for social service needs and behavioral health problems
• Assure that referrals are coordinated and made as appropriate to the responsible discipline
• Ensure that the patient and family have received appropriate education
• Participate in setting short- and long-term goals
• Assist in the process of moving between facilities and levels of care
• Monitor patient progress
• Coordinate and collaborate with the multidisciplinary team
The recommendation for care/case coordination and incorporating psychoeducation for patients with persistent
symptoms to improve clinical outcomes is based largely on research conducted by Bell et al.,[104] which only
included relatively acute patients. Participants in the study who received active case management telephone
follow-up with psychoeducation over the course of three months immediately following injury reported fewer
symptoms at six months post-injury than those in the control group. Confidence in the quality of evidence is low
and is based on the findings of a single study, the fact that the intervention was conducted solely by phone, and
the relative acuity of the injury. The benefit of care/case management at greater than 6-12 months post-injury is
unknown. Given the low risk and relative availability of care/case management in the military and VA settings, the
benefits of care/case coordination slightly outweigh the harms or burdens. Patient values and preferences were
noted to be similar with patients generally accepting of case management services incorporated in an
interdisciplinary team approach. Effective case management services decrease the excessive use of resources
through improved symptom management. Subgroup considerations include variability of skill of case managers
and collaboration with the interdisciplinary or primary care teams.
Case managers should complete a comprehensive psychosocial assessment of the patient and the patient’s
family. It may be necessary or beneficial to meet with other members of the patient’s support system (e.g.,
family, caregiver) and/or invite the patient to ask them to accompany him or her to an appointment. Case
managers should collaborate with the treatment team, the patient, and the patient’s family to develop a
treatment plan that emphasizes the psychosocial needs of the patient. In collaboration with the treatment
team, case managers should prepare and document a detailed treatment plan in the medical record describing
follow-up care and services required.

Recommendation
23. There is insufficient evidence to recommend for or against the use of interdisciplinary/multidisciplinary
teams in the management of patients with chronic symptoms attributed to mTBI.
(N/A | Reviewed, New-replaced)
Discussion
The overall quality of evidence was very low for studies comparing multidisciplinary interventions (e.g., physical
therapist, occupational therapist, clinical psychologist, pain medicine and rehabilitation medicine physician)
versus usual care that was managed by a general practitioner. The evidence showed no significant difference in
outcomes (TBI symptoms, fuction, quality of life, community integration) when using a multidisciplinary
intervention versus usual care. However, Snell et al. found that a multidisciplinary intervention team approach
was associated with significantly fewer mood disorder symptoms reported on the general health questionnaire
(GHQ) at six months in participants with pre-injury psychiatric difficulties.[92] Additionally, Browne et al. found
that patients who received a multidisciplinary intervention reported significantly greater pain relief compared to
controls after controlling for age, gender and injury severity.[37] There is no current evidence to support that
patients who initiate treatment for symptoms attributed to a history of mTBI should receive care solely in a
primary care or multidisciplinary setting. Furthermore, no evidence examined patients with refractory
symptoms who have failed initial treatment for symptoms attributed to a history of mTBI in primary care.
While the Work Group agreed that patients with a history of mTBI and subsequent symptoms are best treated
within the primary care setting, the Work Group also recognized that primary care providers are often
overwhelmed with a high volume of patient care encounters, and that some primary care settings may not be
structured optimally to support management of chronic symptoms. This could challenge providers to assess,
diagnose and provide recommended education. In addition to scheduling more regular primary care
appointments for patients with chronic health conditions, such as persistent post-concussive symptoms,
integrated behavioral health consultants and other specialists (e.g., nurse case managers) within the primary
care setting are resources that can assist primary care providers. The Work Group recommends more research
in this area.

VII. Knowledge Gaps and Recommended Research

During the development of the 2016 version of the CPG, the Work Group identified the following areas for
conducting future research:
• Long-term outcome studies with a focus on the role of laboratory, imaging or physiologic testing in the
management of and clinical decision making with a patient more than seven days following concussion
• Research to improve the diagnostic accuracy of tests for concussion/mTBI in the post-acute period
• Studies that acknowledge the lack of validation of existing case definitions of mTBI and examine
diagnostic accuracy of cognitive and neuropsychological tests for concussion/mTBI
• Examine mechanism-specific physiologic response and associated pathophysiology for which specific
treatment and predictive outcome measures may be of value
B. Treatment
• Studies of neuroprotective therapies to produce specific treatment recommendations or prognostic
models based on individual mechanisms of injury
• Studies to address headache management specific to patients with a history of mTBI
• Controlled research to examine vestibular rehabilitation exercises in patients with a history of mTBI;
define types of dizziness in this patient population that will respond positively to specific vestibular
rehabilitation
• Head-to-head comparison trials on the difference between tinnitus from mTBI versus tinnitus from any
other etiology
• Examine effective treatment interventions for visual dysfunction following mTBI
C. Care Delivery
• The role of interdisciplinary/multidisciplinary teams in the management of patients with chronic or
persistent symptoms attributed to a history of mTBI
• The efficacy of stepped collaborative care models of treatment delivered in primary care settings

Appendix A: Guideline Development Methodology

A. Developing the Scope and Key Questions
The CPG Champions, along with the Work Group, were tasked with identifying key evidence questions to guide
the systematic review of the literature on mTBI. These questions, which were developed in consultation with the
Lewin team, addressed clinical topics of the highest priority for the VA and DoD populations. The KQs follow the
population, intervention, comparison, outcome, timing and setting (PICOTS) framework for evidence questions,
as established by the Agency for Healthcare Research and Quality (AHRQ). Table A‐1 provides a brief overview of
the PICOTS typology.
Table A-1. PICOTS [105]

A description of the patients of interest. It includes the condition(s), populations or sub-
Patients, Population,
P or Problem
populations, disease severity or stage, co-occurring conditions, and other patient
characteristics or demographics.
Intervention or Refers to the specific treatments or approaches used with the patient or population. It
I Exposure includes doses, frequency, methods of administering treatments, etc.
Describes the interventions or care that is being compared with the intervention(s) of
C Comparison interest described above. It includes alternatives such as placebo, drugs, surgery, lifestyle
changes, standard of care, etc.
Describes the specific results of interest. Outcomes can include short, intermediate, and
O Outcome long-term outcomes, or specific results such as quality of life, complications, mortality,
morbidity, etc.
Describes the duration of time that is of interest for the particular patient intervention and
(T) Timing, if applicable
outcome, benefit, or harm to occur (or not occur).
Describes the setting or context of interest. Setting can be a location (such as primary,
(S) Setting, of applicable
specialty, or inpatient care).
The Champions and evidence review team carried out several iterations of this process, each time narrowing the
scope of the CPG and the literature review by prioritizing the topics of interest. Due to resource constraints, all
developed KQs were not able to be included in the systematic evidence review. Thus, the Champions and Work
Group determined which questions were of highest priority, and those were included in the review. Table A-2
contains the final set of KQs used to guide the systematic review for this CPG.
a. Population(s)
The KQs are specific to adult patients aged 18 years or older with mTBI or a history of mTBI treated in any
VA/DoD clinical setting. However, evidence from studies of patients with this condition managed outside the VA
system were also included. The literature search did not include patients within seven days post-injury. Injury
types considered included: blast, coup, contra-coup, direct trauma, acceleration/deceleration injury (whiplash).
b. Interventions
The diagnostic measures of interest included: neuroimaging (DTI, MRI, single photon emission computed
tomography [SPECT]), electrophysiologic imaging, EEG, gait testing, balance testing, biomarkers, effort/validity
testing, focused neurologic exam, Continuous Performance Task (CPT), neuropsychologic testing, visual, hearing,
smell, eye tracking or oculomotor tests.

Interventions to treat common symptoms of mTBI included: specialized vestibular rehabilitation exercises
(including visual, proprioceptive, and balance exercises), headache rehabilitation, medications, mind-body
interventions, integrative medicine interventions, PT and other professionally-supervised exercises, sleep
hygiene interventions, cognitive rehabilitation (e.g., brain training), CBT (various delivery methods), CBTi, white
noise generator, repetitive transcranial magnetic stimulation (rTMS), visual /ocular rehabilitation.
c. Outcomes
Outcomes of interest included: presence or intensity of symptoms attributed to mTBI; functional status;
functional status predictive value for outcomes, or predictive value versus a gold standard; quality of life;
severity of dizziness as measured by the Dizziness Handicap Inventory (DHI), Balance Error Scoring System (BESS)
test, Berg Balance Scale (BBS), or other validated tests; severity of headache as measured by visual analog
scales, the Oswestry Pain Scale, or other validated tools; safety/ adverse events; functional attention,
concentration, or memory, as measured by validated tools; severity of irritability, as reported by patient or
family, using a validated tool; severity of insomnia, as measured by the Pittsburgh Sleep Quality Index, the
Epworth Sleepiness Scale, or other validated tools; severity of tinnitus, as measured by a standardized tinnitus
questionnaire; and symptoms of visual impairment, such as diplopia, visual tracking deficits, or photophobia.
B. Conducting the Systematic Review

Extensive literature searches identified 3,259 citations potentially addressing the KQs of interest to this evidence
review. Of those, 1,663 were excluded upon title review for clearly not meeting inclusion criteria (e.g., not
pertinent to the topic, not published in English, published prior to study inclusion publication date, not a full-
length article). Overall, 1,596 abstracts were reviewed with 1,308 of those being excluded for the following
reasons: not a systematic review or clinical study, did not address a KQ of interest to this review, did not enroll a
population of interest, or published prior to January 2008. A total of 288 full-length articles were reviewed. Of
those, 193 were excluded at a first pass review for the following reasons: not addressing a KQ of interest, not
enrolling the population of interest, not meeting inclusion criteria for clinical study or systematic review, not
meeting inclusion criteria for any KQ, or being a duplicate. A total of 95 full-length articles were thought to
address one or more KQs and were further reviewed. Of these, 51 were ultimately excluded for the reasons
detailed in Figure A-1.
Overall, 42 studies (in 44 publications) addressed one or more of the KQs and were considered as evidence in
the review. Table A-2 indicates the number of studies that addressed each of the questions.

Figure A-1. Study Flow Diagram
1,663 Citations Excluded at the Title Level

3,259 Citations Identified by Searches Citations excluded at this level were off-topic, not
published in English, or published prior to
inclusion date
1,308 Citations Excluded at the Abstract Level

Citations excluded at this level were not SR or
1,596 Abstracts
CS, clearly did not address a KQ, did not report
Reviewed
on an outcome of interest, or were outside cutoff
publication dates
,
193 Citations Excluded at 1st Pass Full Article
Level
Articles excluded at this level did not: address a
key question of interest, enroll the population of
288 Full-length Articles Reviewed
interest, meet inclusion criteria for clinical study or
systematic review, meet inclusion criteria for any
key question, or were a duplicate.
51 Citations Excluded at 2nd Pass Full Article

Level
16 Wrong study design or does not address a KQ
12 Wrong study population or mTBI patients not
reported separately
95 Articles 10 SR superseded by more comprehensive
Reviewed review or study covered in an included SR
4 No outcomes of interest
9 Other
42 Included Studies (in 44 publications)
mTBI: Mild traumatic brain injury

KQ: Key question
SR: Systematic review
CS: Controlled studies

Table A-2. Evidence Base for Key Questions

Number Number of
of Studies & Type
Question Question of Studies
1 a) For adults with acute mTBI, is there a single specialized diagnostic test, or set of tests, 7 systematic
that improve accuracy of diagnosis, treatment decisions, and outcomes compared with reviews and 11
routine primary care? b) Is there a single or set of specialized tests that improve the diagnostic studies
accuracy of diagnosis, treatment decisions and outcomes in post-acute period?
2 In adults with mTBI, what is the evidence that the mechanism of injury influences 6 prognostic
treatment effectiveness and outcomes? cohort studies
3 In adults with mTBI and chronic symptoms attributed to mTBI, does the setting of care or 1 systematic
model of care impact outcomes? review and 3 RCTs
4 For adults with mTBI and vestibular origin of dizziness, do specialized vestibular 1 RCT
rehabilitation exercises improve symptoms at 3 months or more after initiation of the
exercises?
5 For adults with headaches after a mTBI, what is the evidence that any intervention is 2 systematic
effective and safe for improving symptoms (measured using standardized tools) or reviews and 2
functional status (measured using standardized tools) at 3 months or more after initiation RCTs
of the intervention?
6 a) In adults with mTBI and post-concussive symptoms of impaired attention, 1 systematic
concentration and/or memory, what is the evidence that automated (computer based) review and 3 RCTs
cognitive rehabilitation has equal or superior efficacy compared to clinician-based
services in improving chronic symptoms at 3 months or more after initiation of the
intervention? b) What is the comparative effectiveness of comprehensive
neuropsychologic rehabilitation versus targeted cognitive rehabilitation in improving
chronic symptoms at 3 months or more after initiation of the intervention?
7 In adults with mTBI and behavioral dyscontrol (irritability), what is the safety and 2 RCTs
effectiveness of cognitive behavioral therapy (CBT) or pharmacotherapy as compared to
usual care in improving symptoms as measured by patient or family report, at 3 months
or more after initiation of CBT?
8 In adults with mTBI and sleep disturbance, what is the safety and effectiveness of sleep 1 RCT
hygiene interventions when compared to each other or to pharmacotherapy in improving
outcomes at 3 months or more after initiation of the intervention?
9 In adults with mTBI and persistent tinnitus, what is the comparative effectiveness and 1 prospective
safety of tinnitus interventions, such as white noise generators, medications, transcranial cohort study
magnetic stimulation (rTMS), or other interventions on reducing symptoms when
compared to stress management strategies as measured using standardized tinnitus
questionnaires, at 3 months or more after initiation of intervention?
10 In adults with mTBI and post-concussive visual symptoms such as diplopia, visual tracking 1 non-randomized
deficits and/or photophobia, does visual rehabilitation improve symptoms at 3 months or crossover study
more after initiation of rehabilitation? (in 3 publications)
Total Evidence Base 42 Studies
d. Criteria for Study Inclusion/Exclusion

i. General Criteria
 Clinical studies or systematic reviews published on or after January 1, 2008. If multiple
systematic reviews addressed a KQ, we selected the most recent and/or comprehensive review.

Clinical studies published subsequent to relevant systematic reviews were used to supplement
the evidence base.
 Studies must have been published in English.
 Publication must be a full clinical study or systematic review; abstracts alone were not included.
Similarly, letters, editorials, and other publications that are not full-length, clinical studies were
not accepted as evidence.
 Studies enrolled adults 18 years or older. In studies that mixed adults and children, at least 80%
of the enrolled patients had to be 18 years or older.
 Studies must have enrolled ≥10 patients per treatment arm.
 Study must have reported on an outcome of interest.
 Study must have enrolled a patient population in which the most prevalent diagnosis is mTBI,
with identifiable data for the population of interest (i.e., patients with a history of mTBI should
be identifiable in the dataset). Studies that did not report separate data for mTBI were included
only in the absence of other studies meeting this criterion, and only if the remaining patients in
the study had moderate or severe TBI (not stroke). However, studies including at least 80% of
patients with a history of mTBI were not required to report separate data for patients with a
history of mTBI.
ii. Key Question-Specific Criteria
 For KQ 1a, studies must have focused on use of specialized diagnostic approaches used at less
than seven days following injury (acute period). For KQ 1b, studies must have focused on use of
specialized diagnostic approaches at least seven days after the time of injury (post-acute
period). Studies must have compared specialized diagnostic approaches to no test or usual care.
For assessment of diagnostic accuracy, diagnostic cohort studies that compared a diagnostic
test(s) to a reference standard within the same patient were acceptable.
 For KQ 2, non-randomized trials, cohort studies, case-controlled studies, and other
observational studies were accepted as evidence in addition to RCTs and systematic reviews.
Assessments must have been made at least seven days after the time of injury.
 For KQ 3, study must have been a systematic review of RCTs or an RCT. If insufficient evidence
met this criterion, then controlled observational studies were considered as evidence for this
question. Assessments must have been made at least seven days after the time of injury.
 For KQs 4–10, study must have been a systematic review of RCTs or an RCT. If insufficient
evidence met this criterion, then controlled observational studies were considered as evidence
for these questions. The minimum follow-up was three months.
e. Literature Search Strategy
ECRI Institute information specialists searched the following databases for relevant information. Search terms
and strategies for the bibliographic databases appear below.

Table A-3. Resources Searched

Name Date Limits Platform/Provider
Agency for Healthcare Research and Quality
2008 – March 2015 U.S. Department of Health & Human Services
(AHRQ)
CINAHL 2008 – March 2015 EBSCO Host
Cochrane Library 2008 – March 2015 John Wiley & Sons, Ltd.
Embase (Excerpta Medica) 2008 - March 2015 Elsevier
Healthcare Standards (HCS) 2008 – March 2015 ECRI Institute
Medline 2008 – March 2015 OVID Technologies, Inc.
National Guideline Clearinghouse (NGC) 2008 – March 2015 Agency for Healthcare Research and Quality (AHRQ)
National Institute for Health and Care Excellence
2008 – March 2015 National Institute for Health and Care Excellence
(NICE)
PsycINFO 2008 – March 2015 OVID Technologies, Inc.
PubMed (In-process, Publisher, and
2008 – March 2015 National Library of Medicine (NLM)
PubMedNotMeSH records)
TRIP 2008 – March 2015 TRIP (Jon Brassey and Dr. Chris Price)
i. Key question-specific search strategies

The strategies below are presented in Embase.com and OVID syntaxes. Embase.com was used to search for
unique EMBASE (EMTREE) records. OVID was used to simultaneously search Medline (MeSH) and PsycINFO.
Similar strategies were used to search CINAHL and PubMed, as well as the ancillary databases listed above.
Specific search strings were used to capture studies based on the KQs identified by the mTBI Working Group.
Unique strategies were structured for each question and pertain to diagnostic methods, mechanisms of injury,
care settings, dizziness, headaches, impaired concentration and memory, behavioral problems, sleep
disturbance, tinnitus, and vision impairment. These search results were further refined to capture specific study
designs, publication types, date ranges, patient populations, English language studies, and to exclude out-of-
scope citations.

Table A-4. Topic-specific Search Terms

Concept Controlled Vocabulary Keywords/PubMed Concepts
Patient Population
Traumatic Brain Injury EMBASE brain
brain concussion concuss*
brain injury concussion damage
head injury post concussion syndrome head
injur*
traumatic brain injury
mtbi
MeSH post*
brain concussion postconcuss*
brain hemorrhage, traumatic brain injuries trauma*
brain stem hemorrhage, traumatic coma, post-
head injury
craniocerebral trauma
diffuse axonal injury intracranial hemorrhage,
traumatic
post-concussion syndrome subarachnoid
hemorrhage, traumatic
PsycINFO
brain concussion
brain damage
head injuries
traumatic brain injury
CINAHL
brain concussion
brain injuries
head injuries
intracranial hemorrhage
right hemisphere injuries
left hemisphere injuries
postconcussion syndrome
KQ1 EMBASE agnosia
For adults with acute mTBI agnosia anosmia
a. Is there a single specialized anosmia assess*
diagnostic test, or set of tests, balance disorder biological marker*
that improve accuracy of balance impairment biomarker*
diagnosis, treatment decisions, brain mapping brain map*
and outcomes compared with
routine primary care? biological marker calcium binding protein*
brain electrophysiology computed tomograph*
b. Is there a single or set of
specialized tests that improve brain injury assessment decision*
the accuracy of diagnosis, brain radiography diagnos*
treatment decisions and brain scintiscanning diagnostic imag*
outcomes in post-acute period? brain tomography diffuse tensor
computer assisted tomography diffusion tensor
computer assisted emission tomography effort test*
diagnostic imaging elecroenceph*
diffusion tensor imaging encephalog*
echoencephalography evaluat*
electroencephalography


electrophysiological procedures exam*
electrophysiology fmri
exercise test functional magnetic*
functional magnetic resonance imaging imag*
gait magnetic resonance
gait disorder magnetoenceph*
low resolution brain electromagnetic tomography neuroimag*
magnetoencephalography neuroradiograph*
multimodal imaging olfact*
neurologic examination PET
neuropsychological test physical
neuroradiology positron emission
nuclear magnetic resonance imaging s100
odor recognition test s100b
physical examination scinisc*
single photon emission
positron emission tomography
protein s 100 smell*
SPECT
protein s100B
SPECT-CT
radiography test*
single photon emission computed tomography
tomograph*
smelling disorder
spiral computer assisted tomography
tomography
MeSH
agnosia
biological markers
brain mapping
techniques
diagnosis, differential
diagnostic imaging
diagnostic techniques, neurological
diagnostic texts, routine
diffusion magnetic resonance imaging
diffusion tensor imaging
echoencephalography
electrophysiology
gait
gait disorders, neurologic
image processing, computer assisted
imaging, three-dimensional
magnetic resonance imaging
magnetic resonance spectroscopy
magnetoencephalography
multimodal imaging
neuroimaging
neurologic examination
neuropsychological tests
neuroradiography


olfaction disorders
physical examination
positron-emission tomography
postural balance
s100 calcium binding protein beta subunit
s100 proteins
smell
spectroscopy
tomography, emission computed, single photon
tomography, spiral computed
tomography, x-ray computed
PsycINFO
Agnosia
anosmia
behavioral assessment
biological markers
differential diagnosis
encephalography
equilibrium
functional magnetic resonance imaging
gait
neuroimaging
neuropsychological assessment
olfactory perception
positron emission
spectroscopy
positron emission tomography
stereotaxic atlas
tomography
CINAHL
agnosia
anosmia
balance, postural
biological markers
brain mapping
calcium binding proteins
diagnostic imaging
digital imaging
electrophysiology
eye movement measurements
eye movements
gait
gait disorders, neurologic
imaging, three-dimensional
magnetic resonance spectroscopy


multidetector computed tomography
neurologic examination
neuropsychological tests
neuroradiography
oculomotor muscles
oculomotor nerve
oculomotor nerve disease
olfaction disorders
smell
spectroscopy
tomography, emission computed
tomography, emission-computed, single-photon
tomography, spiral computed
tomography, x-ray computed
KQ2 EMBASE accelerat*
In adults with mTBI, what is the acceleration accident*
evidence that the mechanism of blast injury decelerat*
injury influences treatment contrecoup injury blast*
effectiveness and outcomes? deceleration bomb*
traffic accident car
whiplash injury car accident*
MeSH cause*
acceleration coup
accidents, traffic contrecoup
blast injuries decelerat*
contrecoup injury deploy*
deceleration explosi*
explosions injur*
whiplash injuries mechanism*
PsycINFO non-deploy*
military deployment nondeplo*
motor traffic accidents traffic
whiplash traffic accident*
CINAHL un-deploy*
acceleration (mechanics) undeploy*
accidents, traffic type*
blast injuries whiplash
whiplash injuries
KQ3 EMBASE ambulatory
In adults with mTBI and chronic ambulatory care care
symptoms attributed to mTBI, does case management case manag*
the setting of care or model of care case manager center*
impact outcomes? community hospital clinic
a. What is the comparative day hospital clinics
effectiveness of primary care collaborativ*
with case management versus emergency health service
consult
an interdisciplinary team model emergency ward
consultation
on symptom reduction and general hospital cooperativ*
improvements in quality of life, general practice department*
satisfaction and functional general practitioner doctor*
status following mTBI? emergency


b. What is the evidence that health care facility family
certain subpopulations of health center general
patients with mTBI benefit hospital hospital*
from integrated inpatient
multidisciplinary team outpatient care
outpatient department integrat*
approaches and what are the
criteria for referral? primary health care interdisciplin*
primary medical care location*
c. Do outcomes differ based on
multidisciplin*
setting of post-acute (i.e., private hospital
greater than seven days) nurs*
public hospital
management approaches such outpatient
rapid response team
as inpatient/outpatient patient
rehabilitation center physician*
primary/specialty?
rehabilitation hospital practice
residential care practitioner*
residential home primary
team nursing professional
teamwork refer
tertiary care center referral
MeSH residential
ambulatory care setting*
ambulatory care facilities specialist
case management specialty
team*
emergency service, hospital
tertiary
family practice
treatment*
hospitals
hospitals, veterans unit
units
inpatient
veteran*
nursing, team
ward*
outpatients
outpatient clinics, hospital
patient handoff
patient care team
primary health care
referral and consultation
residential treatment
tertiary care centers
trauma centers
PsycINFO
case management
clinics
emergency services
hospitalized patients
hospitals
interdisciplinary treatment approach
outpatient treatment
outpatients
primary health care
professional consultation
professional referral
residential care institutions
self managing work teams


walk in clinics
work teams
teams
CINAHL
ambulatory care facilities
case management
case managers
community health centers
emergency service
hospitals
hospitals, veterans
inpatients
multidisciplinary care team
nurse-managed centers
outpatients
outpatient service
physicians, family
primary health care
referral and consultation
residential care
residential facilities
rural health centers
team nursing
teamwork
KQ4 EMBASE balance
For adults with mTBI and vestibular balance disorder balance error scoring system
origin of dizziness, do specialized balance impairment berg balance scale
vestibular rehabilitation exercises dizziness canalith
improve symptoms at 3 months or kinesiotherapy continuous performance test
more after initiation of the physiotherapy dizziness handicap inventory
exercises? vertigo
vestibular disorder test
vestibular function deficit
vestibular test disorder*
vestibular testing equipment dizz*
exercise*
MeSH epley
dizziness
exercise therapy equilibrium
impair*
physical therapy modalities
labyrinth
postural balance
vertigo liberatory
loss
vestibular diseases
maneuver*
vestibular function tests
problem*
PsycINFO screen*
equilibrium semont
exercise symptom
labyrinth diseases test*
physical therapy therap*
vertigo treat*
vestibular apparatus
vertigo
CINAHL vestibular
balance, postural


balance training, physical
dizziness
physical therapy
therapeutic exercise
vertigo
vestibular diseases
vestibular functional tests
KQ5 EMBASE glasgow
For adults with headaches after a functional assessment functional status headache*
mTBI, what is the evidence that glasgow outcome scale measure*
any intervention is effective and headache index*
safe for improving symptoms measurement migraine*
(measured using standardized migraine oswestry
tools) or functional status oswestry disability index pain
(measured using standardized questionnaire questionnaire
tools) at 3 months or more after rating scale rating scale*
initiation of the intervention?? severity of illness index rivermead
scale*
MeSH
glasgow coma scale severity
severity of illness
glasgow outcome scale
headache
headache disorders
migraine disorders
pain measurement
post-traumatic headache
psychometrics
questionnaires
severity of illness index
PsycINFO
headache
migraine headache
questionnaires
rating scales
severity (disorders)
CINAHL
behavior rating scales
functional status
headache
headache, primary
headache, secondary
questionnaires
scales
severity of illness indexes
structured questionnaires
tension headache
ways of coping questionnaires


KQ6 EMBASE attention
In adults with mTBI and post- attention brief*
concussive symptoms of impaired attention deficit disorder cognitive behav*
attention, concentration and/or computer assisted therapy cognitive rehab*
memory: concentration loss cognitive therap*
a. What is the evidence that group therapy comprehensive
automated (computer based) memory computer*
cognitive rehabilitation has memory assessment concentration
equal or superior efficacy memory disorder focused
compared to clinician-based mental concentration group*
services in improving chronic cognitive rehabilitation individual*
symptoms at 3 months or more cognitive therapy
support group memories
after initiation of the memory
intervention? psychotherapy
psychiatr*
b. What is the comparative MeSH psychol*
effectiveness of comprehensive attention psychotherap*
neuropsychologic rehabilitation attention deficit disorder short*
versus targeted cognitive attention deficit disorder with hyperactivity support group*
rehabilitation in improving cognitive therapy targeted
chronic symptoms at 3 months computer user training
or more after initiation of the memory
intervention? memory disorders
psychotherapy
psychotherapy, brief
psychotherapy, group
self-help groups
therapy, computer assisted
PsycINFO
attention
attention deficit disorder
attention deficit disorder with hyperactivity
brief psychotherapy
cognitive behavior therapy
cognitive rehabilitation
concentration
computer assisted therapy
group counseling
group psychotherapy
individual psychotherapy
memory
memory disorders
psychotherapy
support groups
CINAHL
attention
attention deficit hyperactivity disorder
cognitive therapy
memory disorders
psychotherapy
rehabilitation, cognitive
support groups
therapy, computer assisted


KQ7 EMBASE irrational
In adults with mTBI and behavioral antidepressant agent irritabl*
dyscontrol (irritability), what is the anxiolytic agent medicat*
safety and effectiveness of anxiolytic agent tranquilizer neuroleptic*
cognitive behavioral therapy (CBT) behavior partner*
or pharmacotherapy as compared behavior disorder pharmacother*
to usual care in improving caregiver psychopharmacol*
symptoms as measured by patient caregiver burden psychotherap*
or family report, at 3 months or cognitive behavioral stress management sedativ*
more after initiation of CBT? cognitive therapy spouse*
cognitive rehabilitation support*
domestic violence targeted
dysfunctional therapy tranquiliz*
emotional abuse uncontrol*
emotional stress unpredictab*
extended family unsafe
family unstable
family assessment violen*
family conflict wife
family coping wives
family functioning
family interaction
family life
family stress
group therapy
hypnotic sedative agent
mental instability
neuroleptic agent
patient assessment
patient attitude
partner violence
psychopharmacology
psychotherapy
psychotrauma
sedative agent
support group
violence
MeSH
anti-anxiety agents
antidepressive agents
antipsychotic agents
behavioral control
behavioral symptoms
brief psychotherapy
cognitive therapy
dangerous behavior
drug therapy
family
family conflict
"hypnotics and sedatives"
nuclear family
patient satisfaction


psychopharmacology
psychotherapy
self-help groups
tranquilizing agents
PsycINFO
aggressive behavior
antidepressant drugs
behavior problems
brief psychotherapy
dangerousness
family
family conflict
family crises
family intervention
family members
family relations
family therapy
group counseling
group psychotherapy
'hypnotics and sedatives'
minor tranquilizers
neuroleptic drugs
psychopharmacology
sedatives
self destructive behavior
self injurious behavior
self report
tranquilizing drugs
support groups
violence
CINAHL
aggression
antianxiety agents
antidepressive agents
behavioral changes
cognitive therapy
domestic violence
dysfunctional family
family
family attitudes
family relations
'hypnotics and sedatives'
intimate partner violence
nuclear family
psychopharmacology
psychotherapy


risk taking behaviors
self-injurious behavior
social behavior disorders
support groups
tranquilizing agents
verbal abuse
violence
KQ8 EMBASE acupressure
In adults with mTBI and sleep acupressure acupuncture
disturbance, what is the safety and acupuncture alternative
effectiveness of sleep hygiene alternative medicine ambien
interventions when compared to central sleep apnea syndrome benadryl
each other or to pharmacotherapy apnea*
circadian rhythm sleep disorder
in improving outcomes at 3 circadian
months or more after initiation of cognitive rehabilitation cognitive behavior*
the intervention? cognitive therapy cognitive processing therap*
diphenhydramine cognitive rehab* cognitive
dream therap* complementary
dreaming
diphenhydramine
eszopiclone dream*
herbaceous agent
drug*
herbal medicine epworth sleepiness scale
holistic care eszopiclone
hypnotic sedative agent exercis*
insomnia holistic*
insomnia severity index hygiene
integrative medicine hypnotic*
nightmare insomnia*
parasomnia lunesta
prazosin nightmare*
reiki parasomnia*
relaxation training pittsburgh sleep quality index
rem sleep deprivation prazosin
sedative agent reiki
sleep relax*
sleep arousal disorder sedat*
sleep disorder sleep*
sleep disorder assessment yoga
sleep disordered breathing zolpidem
sleep therapy
unpleasant dream
vivid dream
yoga
zolpidem tartrate
MeSH
acupressure
acupuncture
acupuncture therapy
analgesics
complementary medicine
diphenhydramine


dreams
circadian rhythm
cognitive therapy
complementary therapies
diphenhydramine
drug therapy
holistic health
hypnotics and sedatives
medicine, chinese traditional
prazosin
prescription drugs
psychotropic drugs
relaxation therapy
rem sleep parasomnias
sleep
sleep apnea
sleep apnea, central
sleep apnea, obstructive
sleep apnea syndromes
sleep arousal disorders
sleep deprivation
sleep disorders, circadian
rhythm
sleep disorders, intrinsic
sleep initiation and maintenance disorders
sleep-wake transition disorders
sleep initiation and
maintenance disorders
therapeutic touch
PsycINFO
acupuncture
alternative medicine
diphenhydramine
dream analysis
dream content
dream recall
dreaming
drug therapy
holistic health
hypnotic drugs
insomnia
lucid dreaming
medicinal herbs and
plants
nightmares
prescription drugs
relaxation therapy
rem dreams
sleep disorders
sleep onset
sleep-wake cycle


sleep treatment
sleep-wake cycle
yoga
CINAHL
alternative health facilities
alternative therapies
cognitive therapy
diphenhydramine
drugs, prescription
eszopiclone
holistic care
holistic health
holistic nursing
hypnotics and sedatives
insomnia
meditation
relaxation techniques
sleep arousal disorders
sleep disorders, circadian rhythm
sleep disorders, intrinsic
sleep-wake transition disorders
Zolpidem
KQ9 EMBASE acoustic*
In adults with mTBI and persistent alternative medicine alternative
tinnitus, what is the comparative auditory rehabilitation auditory
effectiveness and safety of tinnitus cochlea implant cochlear
interventions, such as white noise cochlear implantation cognitive behavior* cognitive
generators, medications, cognitive behavioral stress management processing therap*
transcranial magnetic stimulation cognitive rehabilitation cognitive rehab*
(rTMS), or other interventions on cognitive therapy cognitive therap* complementary
reducing symptoms when functional assessment drug*
compared to stress management functional status evoked
strategies as measured using glasgow outcome scale hearing aid*
standardized tinnitus hearing aid magnetic*
questionnaires, at 3 months or psychotropic agent measure*
more after initiation of questionnaire medicat*
intervention? rating scale meditat*
severity of illness index mindful*
transcranial magnetic stimulation noise generator
transcranial magnetic stimulation system index*
tinnitus psychotropic* questionnaire*
white noise rehab*
scale*
MeSH severity of illness
acoustic stimulation sound generator*
behavior therapy stress*
cochlear implantation tinnitus
cochlear implants transcranial
cognitive therapy white noise
complementary therapies
hearing aids
meditation
mindfulness
perceptual masking


psychotropic drugs
questionnaires
therapeutic use
severity of illness index
transcranial magnetic stimulation
stress, psychological
tinnitus
PsycINFO
acoustics
auditory evoked potentials
auditory perception
auditory stimulation
behavior therapy
cochlear implants
functional analysis
disability evaluation
hearing aids
measurement
meditation
mindfullness
questionnaires
rating scales
severity (disorders)
stress
stress management
tinnitus
transcranial magnetic stimulation
white noise
CINAHL
acoustic stimulation
auditory perception
auditory diseases, central
auditory neuropathy
behavior rating scales
evoked potentials, auditory, brainstem
cochlear implant
functional status
hearing aids
magnetic therapy
meditation
mindfulness
questionnaires
scales
severity of illness indexes
stress management
structured questionnaires
tinnitus
tinnitus retraining therapy
ways of coping questionnaires


KQ10 EMBASE blur*
In adults with mTBI and post- abnormal vision deficien*
concussive visual symptoms such diplopia deficit*
as diplopia, visual tracking deficits photosensitivity diplopia
and/or photophobia, does visual vision test disorder*
rehabilitation improve symptoms visual disorder double*
at 3 months or more after visual impairment double vision
initiation of rehabilitation? eye
MeSH
diplopia eyes
photosensitivity disorders eyesight
impair*
vision disorders
ocular
vision tests
oculo*
PsycINFO photophobia photosensitiv*
vision disorders rehab*
sensitiv*
CINAHL
therap*
diplopia
track*
photosensitivity disorders
visual perception train*
vision disorders vision
vision screening visual*
sight
vision, subnormal
vision tests
OVID Conventions:
* (within or following a term) = truncation character (wildcard)
.ab. = limit to abstract
ADJn = search terms within a specified number (n) of words from each other in any order
exp/ = “explodes” controlled vocabulary term (e.g., expands search to all more specific related terms in the vocabulary’s
hierarchy)
.mp. = combined search fields (default if no fields are specified)
.pt. = publication type
.ti. = limit to title
.ti,ab. = limit to title and abstract fields

Table A-5. Medline/PsycINFO Search Strategies Presented in OVID Syntax

Set # Concept Search Statement
1 Mild Traumatic Brain Injury exp brain concussion/ or exp brain damage/ or exp brain injuries/ or exp brain
hemorrhage, traumatic/ or exp brain stem hemorrhage, traumatic/ or exp coma,
post-head injury/ or exp craniocerebral trauma/ or exp intracranial hemorrhage,
traumatic/ or exp post-concussion syndrome/ or exp subarachnoid hemorrhage,
traumatic/ or exp traumatic brain injury/ or ((brain or head) adj1 (concuss* or
damage* or injur* or trauma*)).ti,ab. or (post* adj1 concuss*).ti,ab. or
mtbi.ti,ab. or postconcuss*.ti,ab.
2 KQ1 exp agnosia/ or exp anosmia/ or exp biological markers/ or exp brain mapping/
Diagnostic or exp diagnostic imaging/ or exp diagnostic techniques, neurological/ or exp
Assessments/Tests/Procedures diagnostic texts, routine/ or exp diffusion magnetic resonance imaging/ or exp
diffusion tensor imaging/ or exp echoencephalography/ or exp
electroencephalography/ or exp electrophysiology/ or exp encephalography/ or
exp functional magnetic resonance imaging/ or exp gait/ or exp gait disorders,
neurologic/ or exp image processing, computer assisted/ or exp imaging, three-
dimensional/ or exp magnetic resonance imaging/ or exp magnetic resonance
spectroscopy/ or exp magnetoencephalography/ or exp multimodal imaging/ or
exp neuroimaging/ or exp neurologic examination/ or exp neuropsychological
assessment/ or exp neuropsychological tests/ or exp neuroradiography/ or exp
olfaction disorders/ or exp olfactory perception/ or exp positron emission/ or
exp positron emission tomography/ or exp positron-emission tomography/ or
exp postural balance/ or exp s100 calcium binding protein beta subunit/ or exp
s100 proteins/ or exp smell/ or exp spectroscopy/ or exp stereotaxic atlas/ or
exp tomography/ or exp tomography, emission computed, single photon/ or exp
tomography, spiral computed/ or exp tomography, x-ray computed/ or (agnosia
or anosmia or biological marker* or biomarker* or brain map* or calcium
binding protein* or computed tomograph* or diagnostic imag* or diffuse tensor
or diffusion tensor or echoenceph* or effort test* or elecroenceph* or
encephalogr* or functional magnetic or fmri or magnetic resonance or
magnetoenceph* or neuroimag* or neuroradiograph* or PET or positron
emission or s100 or s100b or scinisc* or single photon emission or SPECT or
SPECT-CT or tomograph*).ti,ab. or (diagnos* adj2 decision*).ti,ab. or
((electrophysiolog* or gait or neurolog* or neuropsych* or olfact* or physical*
or smell*) adj1 (assess* or diagnos* or evaluat* or exam* or test*)).ti,ab.
3 KQ2 exp acceleration/ or exp accidents, traffic/ or exp blast injuries/ or exp
Mechanism of Injury contrecoup injury/ or exp deceleration/ or exp explosions/ or exp military
deployment/ or exp motor traffic accidents/ or exp whiplash/ or exp whiplash
injuries/ or (accelerat* or accident* or blast* or bomb* or car accident* or coup
or contrecoup or decelerat* or deploy* or explosi* or non-deploy* or
nondeploy* or traffic accident* or un-deploy* or undeplo* or whiplash).ti,ab. or
(injur* adj2 (cause* or mechanism* or type*)).ti,ab.
4 KQ3 exp ambulatory care/ or exp ambulatory care facilities/ or exp case
Care Settings management/ or exp clinics/ or exp emergency service, hospital/ or exp
emergency services/ or exp family practice/ or exp hospitalized patients/ or exp
hospitals/ or exp hospitals, veterans/ or exp inpatient/ or exp interdisciplinary
treatment approach/ or exp nursing, team/ or exp outpatient clinics, hospital/
or exp outpatient treatment/ or exp outpatients/ or exp patient care team/ or
exp patient handoff/ or exp primary health care/ or exp professional
consultation/ or exp professional referral/ or exp "referral and consultation"/ or
exp residential care institutions/ or exp residential treatment/ or exp self
managing work teams/ or exp teams/ or exp tertiary care centers/ or exp
trauma centers/ or exp walk in clinics/ or exp work teams/ or (team* adj1 (care
or collaborat* or cooperativ* or integrat* or interdisciplin* or multidisciplin* or
nurs* or treatment*)).ti,ab. or (case adj1 manag*).ti,ab. or ((treatment or care)
adj1 (location* or setting*)).ti,ab. or ((ambulatory or emergency or inpatient* or


outpatient* or primary or residential or tertiary or veteran*) adj1 (center* or
clinic or clinics or department* or hospital* or location* or setting* or unit or
units or ward*)).ti,ab. or ((patient or professional or specialist or specialty) adj1
(consult or consultation or refer or referral)).ti,ab. or ((primary or family) adj1
(care or doctor* or physician* or practitioner*)).ti,ab.
5 KQ4 ((exp dizziness/ or exp equilibrium/ or exp labyrinth diseases/ or exp postural
Dizziness/Vestibular balance/ or exp vertigo/ or exp vestibular diseases/) and (exp exercise/ or exp
Rehabilitation exercise therapy/ or exp physical therapy/ or exp physical therapy modalities/ or
exp vestibular apparatus/ or exp vestibular function tests/)) or ((balanc* or
canalith or dizz* or epley or equlibrium or labyrinth or liberatory or semont or
vertigo or vestibular) adj1 (deficit* or disorder* or exercis* or impair* or loss*
or maneuver* or problem* or screen* or symptom* or test* or therap* or
treat*)).ti,ab or (balance error scoring system or berg balance scale or
continuous performance test or dizziness handicap inventory).ti,ab.
6 KQ5 ((exp headache/ or exp headache disorders/ or exp migraine disorders/ or exp
Headache migraine headache/ or exp post-traumatic headache/) and (exp glasgow coma
scale/ or exp glasgow outcome scale/ or exp pain measurement/ or
psychometrics/ or exp questionnaires/ or exp rating scales/ or exp "severity
(disorders)"/ or exp severity of illness index/)) or ((headache* or migraine*) adj1
(glasgow or measure* or index* or oswestry or questionnaire* or rivermead or
rating scale* or scale* or severity of illness)).ti,ab.
7 KQ6 ((exp attention/ or exp attention deficit disorder/ or exp attention deficit
Attention/Concentration/ disorder with hyperactivity/ or exp concentration/ or exp memory/ or exp
Memory Impairment memory disorders/) and (exp brief psychotherapy/ or exp cognitive behavior
therapy/ or exp cognitive rehabilitation/ or exp cognitive therapy/ or exp
computer assisted therapy/ or exp computer user training/ or exp group
counseling/ or exp group psychotherapy/ or exp individual psychotherapy/ or
exp psychotherapy/ or exp psychotherapy, brief/ or exp psychotherapy, group/
or exp self-help groups/ or exp support groups/ or exp therapy, computer
assisted/)) or ((attention or concentration or memories or memory).ti,ab. and
((brief* or comprehensive or computer* or focused or group* or individual* or
short* or targeted) adj1 (cognitive behav* or cognitive therap* or cognitive
rehab* or psychol* or psychotherap* or psychiatric*))).ti,ab.
8 KQ7 ((exp aggressive behavior/ or exp behavior problems/ or exp behavioral control/
Behavioral Problems or exp behavioral symptoms/ or exp dangerous behavior/ or exp
dangerousness/ or exp self destructive behavior/ or exp self injurious behavior/
or exp self report/ or exp violence/) and (exp anti-anxiety agents/ or exp
antidepressant drugs/ or exp antidepressive agents/ or exp antipsychotic
agents/ or exp brief psychotherapy/ or exp cognitive therapy/ or exp cognitive
behavior therapy/ or exp cognitive rehabilitation/ or exp drug therapy/ or exp
family/ or exp family conflict/ or exp family crises/ or exp family intervention/ or
exp family members/ or exp family relations/ or exp family therapy/ or exp
group counseling/ or exp group psychotherapy/ or exp 'hypnotics and
sedatives'/ or exp individual psychotherapy/ or exp neuroleptic drugs/ or exp
nuclear family/ or exp psychopharmacology/ or exp psychotherapy/ or exp
psychotherapy, brief/ or exp sedatives/ or exp self-help groups/ or exp support
groups/ or exp tranquilizing agents/ or exp tranquilizing drugs)) or ((abus* or
aggress* or anger or angry or conflict* or danger* or destruct* or discontrol* or
distress* or erratic* or instability or irrational* or irrit* or uncontrol* or
unpredict* or unsafe or unstable or violen*) adj1 (antianxiety or antidepress* or
antipsychotic* or care giver or caregiver* or child* or cognitive behav* or
cognitive rehab* or cognitive therap* or domestic or drug therap* or family or
families or group therap* or husband or partner* or medicat* or neuroleptic* or
psychiatr* or psychol* or psychopharmacol* or psychotherap* or sedative* or
spouse* or support group* or tranquiliz* or wife or wives)).ti,ab


9 KQ8 ((exp circadian rhythm/ or exp insomnia/ or exp rem sleep behavior disorder/ or
Sleep Disturbance exp rem sleep parasomnias/ or exp sleep/ or exp sleep apnea/ or exp sleep apnea,
central/ or exp sleep apnea, obstructive/ or exp sleep apnea syndromes/ or exp
sleep arousal disorders/ or exp sleep deprivation/ or exp sleep disorders/ or exp
sleep disorders, circadian rhythm/ or exp sleep disorders, intrinsic/ or exp "sleep
initiation and maintenance disorders"/ or exp sleep onset/ or exp sleep wake
cycle/ or exp sleep-wake transition disorders) and (exp acupressure/ or exp
acupuncture/ or exp acupuncture therapy/ or exp alternative medicine/ or exp
analgesics/ or exp cognitive behavior therapy/ or exp cognitive rehabilitation/ or
exp cognitive therapy/ or exp complementary medicine/ or exp complementary
therapies/ or exp diphenhydramine/ or exp dream analysis/ or exp dream
content/ or exp dream recall/ or exp dreaming/ or exp dreams/ or exp drug
therapy/ or exp glasgow outcome scale/ or exp holistic health/ or exp hypnotic
drugs/ or exp "hypnotics and sedatives"/ or exp lucid dreaming/ or exp "medicinal
herbs and plants"/ or exp medicine, chinese traditional/ or exp nightmares/ or exp
prazosin/ or exp prescription drugs/ or exp relaxation therapy/ or exp rem
dreams/ or exp sleep treatment/ or exp therapeutic touch/ or exp yoga/)) or
((apnea* or circadian or insomnia* or parasomnia* or sleep*) adj3 (acupressure
or acupuncture or alternative or ambien or apnea* or benadryl or circadian or
cognitive behavior* or cognitive processing therap* or cognitive rehab* or
cognitive therap* or complementary or diphenhydramine or dream* or drug* or
eszopiclone or exercis* or holistic* or hygiene or hypnotic* or lunesta or
nightmare* or prazosin or reiki or relax* or sedat* or yoga or zolpidem)).ti,ab. or
(epworth sleepiness scale or pittsburgh sleep quality index).mp.
10 KQ9 ((exp tinnitus/) and (exp acoustic stimulation/ or exp acoustics/ or exp auditory
Tinnitus evoked potentials/ or exp auditory perception/ or exp auditory stimulation/ or
exp behavior therapy/ or exp cochlear implantation/ or exp cochlear implants/
or exp cognitive behavior therapy/ or exp cognitive rehabilitation/ or exp
cognitive therapy/ or exp complementary therapies/ or exp functional analysis/
or exp glasgow outcome scale/ or exp hearing aids/ or exp measurement/ or
exp meditation/ or exp mindfulness/ or exp perceptual masking/ or exp
psychotropic drugs/ or exp questionnaires/ or exp rating scales/ or exp "severity
(disorders)"/ or exp severity of illness index/ or exp stress management/ or exp
stress, psychological/ or exp transcranial magnetic stimulation/ or exp white
noise/)) or ((tinnitus) adj3 (acoustic* or alternative or auditory or cochlear or
cognitive behavior* or cognitive processing therap* or cognitive rehab* or
cognitive therap* complementary or drug* or evoked or hearing aid* or
magnetic* or measure* or medicat* or meditat* or mindful* or noise generator
or index* or psychotropic* or questionnaire* or rehab* or scale* or severity of
illness or sound generator* or stress* or transcranial or white noise)).ti,ab.
11 KQ10 exp diplopia/ or exp photosensitivity disorders/ or exp vision disorders/ or exp
Visual Symptoms vision tests/ or (diplopia or double vision or photophobia or
photosensitiv*).ti,ab. or ((eye or eyes or eyesight or ocular or oculo* or vision or
visual* or sight) adj3 (blur* or deficien* or deficit* or diplopia or disorder* or
double* or impair* or photosensitiv* or rehab* or sensitiv* or track* or train*
or therap*)).ti,ab.
12 Combine Key Questions 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13 Combine mTBI set and Key
1 and 12
Questions
14 Remove unwanted study 13 not ((authored book or autobiography or biography or book or case reports
designs/publication or comment or conference* or dissertation abstract edited book or editorial or
types/patient populations encyclopedia or lectures or letter or news or note or proceeding or video-audio
media or webcasts).pt. or (bibliography or chapter or column/opinion or
comment/reply or dissertation or editorial or encyclopedia entry or letter or
obituary or review-book).dt. or (adolescen* or antenatal or babies or baby or


birth or child* or infan* or kid or kids or neonat* or newborn* or paediatric* or
pediatric* or perinatal or prenatal or teen* or toddler* or young* or youth*).ti.)
15 Limit to specific study 14 and (clinical trials as topic/ or crossover studies/ or doubleblind method/ or
designs/publication meta-analysis as topic/ or random allocation/ or randomized controlled trials as
types/patient populations topic/ or single-blind method/ or (clinical trial or controlled clinical trial or meta-
analysis or randomized controlled trial or review).pt. or (ACTRN* or cross over or
crossover or ISRTCN or latin square or meta analy* or meta-analy* or metaanal*
or randomized or randomized controlled trial* or placebo* or systematic
review*).mp. or ((doubl* or singl* or trebl* or tripl*) adj2 (blind* or mask* or
sham*)).mp. or (evidence or random* or systematic*).ti. or (NCT* not NCT).mp.)
16 Limit to English language limit 15 to english language
17 Limit to humans Limit 16 to humans
18 Apply date limits Limit 17 to "2008-current"
19 Final set Remove duplicates
EMBASE Conventions:
* (within or following a term) = truncation character (wildcard)
:ab = limit to abstract
:ab,ti = limit to abstract and title
NEAR/n = search terms within a specified number (n) of words from each other in any order
/exp = “explodes” controlled vocabulary term (e.g., expands search to all more specific related terms in the vocabulary’s
hierarchy)
:it. = limit to publication type
:ti. = limit to title

Table A-6. EMBASE Search Strategies Conducted Using EMTREE Syntax

1 Mild Traumatic Brain Injury 'brain concussion'/exp OR 'brain injury'/exp OR concussion/exp OR 'head
injury'/exp OR 'post concussion syndrome'/exp OR 'traumatic brain
injury'/exp OR (brain OR head) NEAR/1 (concuss* OR damage* OR injur* OR
trauma*) OR post* NEAR/1 concuss* OR mtbi:ab,ti OR postconcuss*:ab,ti
2 KQ1 agnosia/exp OR anosmia/exp OR 'balance disorder'/exp OR 'balance
Diagnostic impairment'/exp OR 'biological marker'/exp OR 'brain electrophysiology'/exp
Assessments/Tests/Procedures OR 'brain injury assessment'/exp OR 'brain mapping'/exp OR 'brain
radiography'/exp OR 'brain scintiscanning'/exp OR 'brain tomography'/exp
OR 'computer assisted emission tomography'/exp OR 'computer assisted
tomography'/exp OR 'computer tomography'/exp OR 'diagnostic
imaging'/exp OR 'diffusion tensor imaging'/exp OR
'echoencephalography'/exp OR 'electroencephalography'/exp OR
'electrophysiological procedures'/exp OR electrophysiology/exp OR 'exercise
test'/exp OR 'eye movement'/exp OR 'functional magnetic resonance
imaging'/exp OR gait/exp OR 'gait disorder'/exp OR 'low resolution brain
electromagnetic tomography'/exp OR 'magnetoencephalography'/exp OR
'multimodal imaging'/exp OR 'neurologic examination'/exp OR
'neuropsychological test'/exp OR 'neuroradiology'/exp OR 'nuclear magnetic
resonance imaging'/exp OR 'odor recognition test'/exp OR 'physical
examination'/exp OR 'positron emission tomography'/exp OR 'protein S
100'/exp OR 'protein S100B'/exp OR 'radiography'/exp OR 'single photon
emission computer tomography'/exp OR 'smelling disorder'/exp OR 'spiral
computer assisted tomography'/exp OR 'tomography'/exp OR (agnosia OR
anosmia OR 'biological marker' OR 'biological markers' OR biomarker* OR
'brain map' OR 'brain mapping' OR 'computed tomography' OR 'diagnostic
imaging' OR 'diffuse tensor' OR 'diffusion tensor' OR echoenceph* OR
elecroenceph* OR encephalogr* OR 'functional magnetic' OR fmri OR
'magnetic resonance' OR magnetoenceph* OR neuroimag* OR
neuroradiograph* OR PET OR 'positron emission' OR scinisc* OR 'single
photon emission' or s100 OR s100b OR SPECT OR SPECT-CT OR
tomograph*):ab,ti OR (diagnos* NEAR/2 decision*):ab,ti OR ((equilibrium OR
gait OR neurolog* OR neurophysiol* OR neuropsych* OR olfact* OR
physical* OR smell*) NEAR/1 (assess* OR diagnos* OR evaluat* OR exam*
OR test*)):ab,ti OR 'calcium binding' NEAR/1 protein* OR effort NEAR/1 test*
OR symptom* NEAR/1 valid*
3 KQ2 'acceleration'/exp OR 'blast injury'/exp OR 'contrecoup injury'/exp OR
Mechanism of Injury 'deceleration'/exp OR 'traffic accident'/exp OR 'whiplash injury'/exp OR
accelerat*:ab,ti OR decelerat*:ab,ti OR blast*:ab,ti OR bomb*:ab,ti OR
coup:ab,ti OR contrecoup:ab,ti OR deploy*:ab,ti OR explosi*:ab,ti OR
nondeploy*:ab,ti OR whiplash:ab,ti OR undeploy*:ab,ti OR (car OR traffic)
NEAR/1 (injur*) OR (cause* OR mechanism* OR type*) NEAR/2 (injur*)
4 KQ3 'ambulatory care'/exp OR 'case management'/exp or 'case manager'/exp OR
Care Settings 'community hospital'/exp OR 'day hospital'/exp OR 'emergency health
service'/exp OR 'emergency ward'/exp OR 'general hospital'/exp OR 'general
practice'/exp OR 'general practitioner'/exp OR 'health care facility'/exp OR
'health center'/exp OR 'hospital'/exp OR 'outpatient care'/exp OR 'outpatient
department'/exp OR 'primary health care'/exp OR 'primary medical care'/exp
OR 'private hospital'/exp OR 'public hospital'/exp OR 'rapid response
team'/exp OR 'rehabilitation center'/exp OR 'rehabilitation hospital'/exp OR
'residential care'/exp OR 'residential home'/exp OR 'team nursing'/exp OR
teamwork/exp OR 'tertiary care center'/exp OR (team* NEAR/1 (care OR
collaborat* OR cooperativ* OR integrat* OR interdisciplin* OR multidisciplin*
OR nurs* OR treatment*)):ab,ti OR (case NEAR/1 manag*):ab,ti or
((treatment OR care) NEAR/1 (location* OR setting*)):ab,ti or ((ambulatory


OR emergency OR inpatient* OR outpatient* OR primary OR residential OR
tertiary OR veteran*) NEAR/1 (center* OR clinic OR clinics OR department*
OR hospital* OR location* OR setting* OR unit OR units OR ward*)):ab,ti or
((patient OR professional OR specialist OR specialty) NEAR/1 (consult OR
consultation OR refer OR referral)):ab,ti or ((primary OR family) NEAR/1 (care
OR doctor* OR physician* OR practitioner*)):ab,ti
5 KQ4 'balance disorder'/exp OR 'balance impairment'/exp OR dizziness/exp OR
Dizziness/Vestibular Rehabilitation kinesiotherapy/exp OR physiotherapy/exp OR vertigo/exp OR 'vestibular
disorder'/exp OR 'vestibular function'/exp OR 'vestibular test'/exp OR
'vestibular testing equipment'/exp OR ((balanc* OR canalith OR dizz* OR
epley OR equlibrium OR labyrinth OR liberatory OR semont OR vertigo OR
vestibular) NEAR/1 (deficit* or disorder* or exercis* or impair* or loss* or
maneuver* or problem* or screen* or symptom* or test* or therap* or
treat*)):ab,ti OR ('continuous performance test' or 'balance error scoring
system' or 'berg balance scale' or 'dizziness handicap inventory'):ab,ti
6 KQ5 headache/exp OR migraine/exp AND ('glasgow outcome scale'/exp OR
Headache measurement/exp OR 'oswestry disability index'/exp OR questionnaire/exp
OR 'rating scale'/exp OR 'severity of illness index'/exp) OR (headache*:ab,ti
OR migraine*:ab,ti AND (glasgow:ab,ti OR measure*:ab,ti PR index*:ab,ti OR
oswestry:ab,ti OR questionnaire*:ab,ti OR 'rating scale':ab,ti OR
rivermead:ab,ti OR scale*:ab,ti OR 'severity of illness':ab,ti))
7 KQ6 attention/exp OR 'attention deficit disorder'/exp OR 'concentration loss'/exp
Attention/Concentration/Memory OR memory/exp OR 'memory assessment'/exp OR 'memory disorder'/exp OR
Impairment 'mental concentration'/exp AND ('cognitive rehabilitation'/exp OR 'cognitive
therapy'/exp OR 'computer assisted therapy'/exp OR 'group therapy'/exp OR
psychotherapy/exp OR 'support group'/exp) OR (attention OR concentration
OR memories OR memory AND (brief* OR comprehensive OR computer* OR
focused OR group* OR individual* OR short* OR targeted) NEAR/1 ('cognitive
behavior' OR 'cognitive behaviour' OR 'cognitive behavioral' OR 'cognitive
behavioural' OR 'cognitive rehabilitation' OR 'cognitive therapy' OR psychol*
OR psychotherap* OR psychiatric*))
8 KQ7 behavior/exp OR 'behavior disorder'/exp OR 'domestic violence'/exp OR
Behavioral Problems 'emotional abuse'/exp OR 'emotional stress'/exp OR 'family conflict'/exp OR
'family stress'/exp OR 'mental instability'/exp OR 'partner violence'/exp OR
psychotrauma/exp OR violence/exp AND ('antidepressant agent'/exp OR
'anxiolytic agent'/exp OR 'anxiolytic agent tranquilizer'/exp OR caregiver/exp
OR 'caregiver burden'/exp OR 'cognitive behavioral stress management'/exp
OR 'cognitive rehabilitation'/exp OR 'cognitive therapy'/exp OR 'dysfunctional
therapy'/exp OR 'extended family'/exp OR family/exp OR 'family
assessment'/exp OR 'family coping'/exp OR 'family functioning'/exp OR
'family interaction'/exp OR 'family life'/exp OR 'group therapy'/exp OR
'hypnotic sedative agent'/exp OR 'neuroleptic agent'/exp OR 'patient
assessment'/exp OR 'patient attitude'/exp OR 'psychopharmacology'/exp OR
'psychotherapy'/exp OR 'sedative agent'/exp OR 'support group'/exp) OR
((abus* OR aggress* OR anger OR angry OR conflict* OR danger* OR
destruct* or discontrol* OR distress* OR erratic OR instability OR irrational*
OR irrit* OR uncontrol* OR unpredict* OR unsafe OR unstable OR violen*)
NEAR/1 (antianxiety OR antidepress* OR antipsychotic* OR 'care giver' OR
caregiver* OR 'cognitive behavior' OR 'cognitive behaviour' OR 'cognitive
behavioral' OR 'cognitive behavioural' OR 'cognitive therapy' OR 'cognitive
rehabilitation' OR domestic OR 'drug therapy' OR families OR family OR
medicat* OR 'group therapy' OR husband* OR neuroleptic* OR partner* OR
psychiatr* OR psycholog* OR psychopharmacol* OR psychother* OR
sedative* OR spouse* OR 'support group' OR tranquiliz* OR wife OR
wives)):ab,ti


9 KQ8 (sleep/exp OR 'circadian rhythm sleep disorder'/exp OR insomnia/exp OR 'REM
Sleep Disturbance sleep deprivation'/exp OR 'sleep disorder'/exp OR 'sleep arousal disorder'/exp
OR 'sleep disorder assessment'/exp OR 'sleep disordered breathing'/exp OR
parasomnia/exp AND (acupressure/exp OR acupuncture/exp OR 'alternative
medicine'/exp OR 'central sleep apnea syndrome'/exp OR 'cognitive
rehabilitation'/exp OR 'cognitive therapy'/exp OR diphenhydramine/exp OR
dream/exp OR dreaming/exp OR eszopiclone/exp OR 'herbaceous agent'/exp
OR 'herbal medicine'/exp OR 'holistic care'/exp OR 'hypnotic sedative
agent'/exp OR 'insomnia severity index'/exp OR 'integrative medicine'/exp OR
nightmare/exp OR prazosin/exp OR reiki/exp OR 'relaxation training'/exp OR
'sedative agent'/exp OR 'sleep disorder assessment'/exp OR 'sleep
therapy'/exp OR 'unpleasant dream'/exp OR 'vivid dream'/exp OR yoga/exp OR
'zolpidem tartrate'/exp)) OR ((apnea* OR circadian OR insomnia* OR
parasomnia* OR sleep*) NEAR/3 (acupressure OR acupuncture OR alternative
OR ambien OR benadryl OR circadian OR cognitive OR complementary OR
diphenhydramine OR dream* OR drug* OR eszopiclone OR exercis* OR
holistic* OR hygiene OR hypnotic* OR lunesta OR nightmare* OR prazosin OR
reiki OR relax* OR sedat* OR yoga OR zolpidem)):ab,ti OR epworth sleepiness
scale OR pittsburgh sleep quality index
10 KQ9 tinnitus/exp AND ('alternative medicine'/exp OR 'auditory rehabilitation'/exp
Tinnitus OR 'cochlea implant'/exp OR 'cochlear implantation'/exp OR 'cognitive
behavioral stress management'/exp OR 'cognitive rehabilitation'/exp OR
'cognitive therapy'/exp OR 'functional assessment'/exp OR 'functional
status'/exp OR 'glasgow outcome scale'/exp OR 'hearing aid'/exp OR
'psychotropic agent'/exp OR questionnaire/exp OR 'rating scale'/exp OR
'severity of illness index'/exp OR 'stress management'/exp OR 'transcranial
magnetic stimulation'/exp OR 'transcranial magnetic stimulation system'/exp
OR 'white noise'/exp) OR (tinnitus NEAR/1 (acoustic OR alternative OR
auditory OR cochlear OR cognitive OR complementary OR drug* OR evoked
OR 'hearing aid' OR magnetic OR medicat* OR meditat* OR mindful* OR
'noise generator' OR index* OR psychotropic OR questionnaire* OR rehab*
OR scale* OR 'severity of illness' OR 'sound generator' OR stress* OR
transcranial OR 'white noise')):ab,ti
11 KQ10 'abnormal vision'/exp OR diplopia/exp OR photosensitivity/exp OR 'vision
Visual Symptoms test'/exp OR 'visual disorder'/exp OR 'visual impairment'/exp OR
diplopia:ab,ti OR 'double vision':ab,ti OR photophobia:ab,ti OR
photosensitiv*:ab,ti OR ((eye OR eyes OR eyesight OR ocular OR oculo* OR
vision or visual* OR sight*) NEAR/3 (blur* OR deficien* OR deficit* OR
diplopia or disorder* OR double* OR impair* OR photosensitiv* OR rehab*
OR sensitiv* OR track* OR train* OR therap*)):ab,ti
12 Combine Key Questions #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11
13 Combine mTBI set and Key #1 AND #12
Questions
14 Apply limits #13 AND [humans]/lim AND [english]/lim AND [2008-2015]/py
(English language/humans/2008-
2015)
15 Remove unwanted study #14 NOT ('case study/exp' OR 'case report/exp' OR 'conference abstract':it
designs/publication types/patient OR 'conference paper':it OR 'conference review':it OR editorial:it OR letter:it
populations OR note:it)
16 Selected study designs/publication 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'meta
types analysis'/exp OR placebo/exp OR randomization/exp OR 'randomized
controlled trial'/exp OR 'single blind procedure'/exp OR 'systematic
review'/exp OR actrn*:ab,ti OR 'clinical trial':ab,ti OR 'controlled clinical
trial':ab,ti OR 'cross over':ab,ti OR crossover:ab,ti OR isrtcn:ab,ti OR 'latin


square':ab,ti OR metaanaly*:ab,ti OR placebo*:ab,ti OR randomized:ab,ti OR
(doubl* OR singl* OR trebl* OR tripl*) NEAR/2 (blind* OR mask* OR sham*)
OR 'randomized controlled' NEAR/1 trial* OR systematic NEAR/1 review* OR
meta* NEAR/1 analy* OR evidence:ti OR random*:ti OR systematic*:ti OR
(nct* NOT nct)
17 Combine results with selected #15 AND #16
study designs/publication types
18 Limit to Embase results #17 AND [embase]/lim
19 Omit Medline Results #18 NOT [medline]/lim
C. Convening the Face-to-face Meeting

In consultation with the Contracting Officer’s Representative (COR), the Champions, and the Work Group, the
Lewin Team convened a three and a half day face-to-face meeting of the CPG Champions and Work Group
members on June 29 – July 2, 2015. These experts were gathered to develop and draft the clinical
recommendations for an update to the 2009 mTBI CPG. Lewin presented findings from the evidence review of
KQs 1-10 in order to facilitate and inform the process.
Under the direction of the Champions, the Work Group members were charged with interpreting the results of
the evidence review, and asked to review, assess, and categorize recommendations from the 2009 mTBI CPG.
The members also developed new clinical practice recommendations not present in the 2009 mTBI CPG, based
on the 2015 evidence review. The subject matter experts were divided into three smaller subgroups at this
meeting.
As the Work Group members drafted clinical practice recommendations, they also assigned a grade for each
recommendation based on a modified GRADE and USPSTF methodology. Each recommendation was graded by
assessing the quality of the overall evidence base, the associated benefits and harms, the variation in values and
preferences, and other implications of the recommendation.
D. Grading Recommendations
This CPG uses the GRADE methodology to assess the quality of the evidence base and assign a grade for the
strength of each recommendation. The GRADE system uses the following four domains to assess the strength of
each recommendation: [106]
• Balance of desirable and undesirable outcomes
• Confidence in the quality of the evidence
• Values and preferences
• Other implications, as appropriate, include:
 Resource Use
 Equity
 Acceptability
 Feasibility

 Subgroup considerations
The following sections further describe each domain.
Balance of desirable and undesirable outcomes refers to the size of anticipated benefits (e.g., increased
longevity, reduction in morbid event, resolution of symptoms, improved quality of life [QoL], decreased resource
use) and harms (e.g., decreased longevity, immediate serious complications, adverse event, impaired quality of
life, increased resource use, inconvenience/hassle) relative to each other. This domain is based on the
understanding that the majority of clinicians will offer patients therapeutic or preventive measures as long as
the advantages of the intervention exceed the risks and adverse effects. The certainty or uncertainty of the
clinician about the risk-benefit balance will greatly influence the strength of the recommendation.
Some of the discussion questions that fall under this domain include:
• Given the best estimate of typical values and preferences, are you confident that the benefits outweigh
the harms and burden or vice versa?
• Are the desirable anticipated effects large?
• Are the undesirable anticipated effects small?
• Are the desirable effects large relative to undesirable effects?
Confidence in the quality of the evidence reflects the quality of the evidence base and the certainty in that
evidence. This second domain reflects the methodological quality of the studies for each outcome variable. In
general, the strength of recommendation follows the level of evidence, but not always, as other domains may
increase or decrease the strength. The evidence review used for the development of recommendations for
mTBI, conducted by ECRI, assessed the confidence in the quality of the evidence base and assigned a rate of
“High,” “Moderate,” “Low,” or “Very Low.”
The elements that go into the confidence in the quality of the evidence include:
• Is there high or moderate quality evidence that answers this question?
• What is the overall certainty of this evidence?
Values and preferences is an overarching term that includes patients’ perspectives, beliefs, expectations, and
goals for health and life. More precisely, it refers to the processes that individuals use in considering the
potential benefits, harms, costs, limitations, and inconvenience of the therapeutic or preventive measures in
relation to one another. For some, the term “values” has the closest connotation to these processes. For others,
the connotation of “preferences” best captures the notion of choice. In general, values and preferences increase
the strength of the recommendation when there is high concordance and decrease it when there is great
variability. In a situation in which the balance of benefits and risks are uncertain, eliciting the values and
preferences of patients and empowering them and their surrogates to make decisions consistent with their
goals of care becomes even more important. A recommendation can be described as having “similar values,”
“some variation,” or “large variation” in typical values and preferences between patients and the larger
populations of interest.

Some of the discussion questions that fall under the purview of values and preferences include:
• Are you confident about the typical values and preferences and are they similar across the target
population?
• What are the patient’s values and preferences?
• Are the assumed or identified relative values similar across the target population?
Other implications consider the practicality of the recommendation, including resources use, equity,
acceptability, feasibility and subgroup considerations. Resource use is related to the uncertainty around the
cost-effectiveness of a therapeutic or preventive measure. For example statin use in the frail elderly and others
with multiple comorbidities may not be effective and depending on the societal benchmark for willingness to
pay, may not be a good use of resources. Equity, acceptability, feasibility and subgroup considerations require
similar judgments around the practically of the recommendation.
The framework below was used by the Work Group to guide discussions on each domain.
Table A-7. Evidence to Recommendation Framework

Decision Domain Judgment
Balance of desirable and undesirable outcomes
 Given the best estimate of typical values and preferences, are you  Benefits outweigh harms/burden
confident that the benefits outweigh the harms and burden or vice versa?  Benefits slightly outweigh harms/burden
 Are the desirable anticipated effects large?  Benefits and harms/burden are balanced
 Are the undesirable anticipated effects small?  Harms/burden slightly outweigh benefits
 Are the desirable effects large relative to undesirable effects?  Harms/burden outweigh benefits
Confidence in the quality of the evidence
 Is there high or moderate quality evidence that answers this question?  High
 What is the overall certainty of this evidence?  Moderate
 Low
 Very low
Values and preferences
 Are you confident about the typical values and preferences and are they  Similar values
similar across the target population?  Some variation
 What are the patient’s values and preferences?  Large variation
 Are the assumed or identified relative values similar across the target
population?
Other implications (e.g., resource use, equity, acceptability, feasibility, subgroup considerations)
 Are the resources worth the expected net benefit from the Various considerations
recommendation?
 What are the costs per resource unit?
 Is this intervention generally available?
 Is this intervention and its effects worth withdrawing or not allocating
resources from other interventions?
 Is there lots of variability in resource requirements across settings?

The strength of a recommendation is defined as the extent to which one can be confident that the desirable
effects of an intervention outweigh its undesirable effects and is based on the framework above, which
combines the four domains.[106] GRADE methodology does not allow for recommendations to be made based
on expert opinion alone. While strong recommendations are usually based on high or moderate confidence in
the estimates of effect (quality of the evidence) there may be instances where strong recommendations are
warranted even when the quality of evidence is low.[107] In these types of instances where the balance of
desirable and undesirable outcomes and values and preferences played large roles in determining the strength
of a recommendation, this is explained in the discussion section for the recommendation.
The GRADE of a recommendation is based on the following elements:

• Four decision domains used to determine the strength and direction (described above)
• Relative strength (Strong or Weak)
• Direction (For or Against)
The relative strength of the recommendation is based on a binary scale, “Strong” or “Weak.” A strong
recommendation indicates that the Work Group is highly confident that desirable outcomes outweigh
undesirable outcomes. If the Work Group is less confident of the balance between desirable and undesirable
outcomes, they present a weak recommendation.
Similarly, a recommendation for a therapy or preventive measure indicates that the desirable consequences
outweigh the undesirable consequences. A recommendation against a therapy or preventive measure indicates
that the undesirable consequences outweigh the desirable consequences.
Using these elements, the grade of each recommendation is presented as part of a continuum:
• Strong For (or “We recommend offering this option …”)
• Weak For (or “We suggest offering this option …”)
• Weak Against (or “We suggest not offering this option …”)
• Strong Against (or “We recommend against offering this option …”)
Note that weak (For or Against) recommendations may also be termed “Conditional,” “Discretionary,” or
“Qualified.” Recommendations may be conditional based upon patient values and preferences, the resources
available, or the setting in which the intervention will be implemented. Recommendations may be at the
discretion of the patient and clinician or they may be qualified with an explanation about the issues that would
lead decisions to vary.
E. Recommendation Categorization
a. Recommendation Categories and Definitions
For use in the 2016 mTBI CPG, a set of recommendation categories was adapted from those used by the
National Institute for Health and Care Excellence (NICE, UK).[6,7] These categories, along with their
corresponding definitions, were used to account for the various ways in which recommendations could have
been updated. The categories and definitions can be found in Table A-8.

Table A-8. Recommendation Categories and Definitions

Evidence Recommendation
Reviewed* Category* Definition*
New-added New recommendation following review of the evidence
Recommendation from previous CPG that has been carried over to the updated CPG
New-replaced
and has been changed following review of the evidence
Recommendation from previous CPG that has been carried forward to the updated
Not changed
CPG where the evidence has been reviewed but the recommendation is not changed
Reviewed
Recommendation from the previous CPG that has been carried forward to the
Amended updated CPG where the evidence has been reviewed and a minor amendment has
been made
Recommendation from the previous CPG that has been removed based on review of
Deleted
the evidence
Recommendation from previous CPG that has been carried forward to the updated
Not changed
CPG, but for which the evidence has not been reviewed
Recommendation from the previous CPG that has been carried forward to the
Not
Amended updated CPG where the evidence has not been reviewed and a minor amendment
reviewed
has been made
Recommendation from the previous CPG that has been removed because it was
Deleted
deemed out of scope for the updated CPG
*Adapted from the NICE guideline manual (2012)[6] and Garcia et al. (2014)[7]
b. Categorizing Recommendations with an Updated Review of the Evidence

Recommendations were first categorized by whether or not they were based on an updated review of the
evidence. If evidence had been reviewed, recommendations were categorized as “New-added,” “New-
replaced,” “Not changed,” “Amended,” or “Deleted.”
“Reviewed, New-added” recommendations were original, new recommendations that were not in the 2009
mTBI CPG. “Reviewed, New-replaced” recommendations were in the previous version of the guideline, but were
modified to align with the updated review of the evidence. These recommendations could have also included
clinically significant changes to the previous version. Recommendations categorized as “Reviewed, Not changed”
were carried forward from the previous version of the CPG unchanged.
To maintain consistency between 2009 recommendations, which were developed using the USPSTF
methodology, and 2016 recommendations, which were developed using the GRADE methodology, it was
necessary to modify the 2009 recommendations to include verbiage to signify the strength of the
recommendation (e.g., “We recommend,” “We suggest”). Because the 2009 recommendations inherently
needed to be modified at least slightly to include this language, the “Not changed” category was not used. For
recommendations carried forward to the updated CPG with review of the evidence and slightly modified
wording, the “Reviewed, Amended” recommendation category was used. This allowed for the wording of the
recommendation to reflect GRADE methodology as well as for any other non-substantive (i.e., not clinically
meaningful) language changes deemed necessary.
Recommendations could have also been designated “Reviewed, Deleted.” These were recommendations from
the previous version of the CPG that were not brought forward to the updated guideline after review of the
evidence. This occurred if the evidence supporting the recommendations was out of date, to the extent that

there was no longer any basis to recommend a particular course of care and/or new evidence suggests a shift in
care, rendering recommendations in the previous version of the guideline obsolete.
c. Categorizing Recommendations without an Updated Review of the Evidence

There were also cases in which it was necessary to carry forward recommendations from the previous version of
the CPG without a systematic review of the evidence. Due to time and budget constraints, the update of the
mTBI CPG could not review all available evidence on management of mTBI, but instead focused its KQs on areas
of new or updated scientific research or areas that were not previously covered in the CPG.
For areas of research that have not changed, and for which recommendations made in the previous version of
the guideline were still relevant, recommendations could have been carried forward to the updated guideline
without an updated systematic review of the evidence. These recommendations were categorized as “Not
reviewed.” If evidence had not been reviewed, recommendations could have been categorized as “Not
changed,” Amended,” or “Deleted.”
“Not reviewed, Not changed” recommendations refer to recommendations from the previous version of the
mTBI CPG that were carried forward unchanged to the updated version. The category of “Not reviewed,
Amended” was used to designate recommendations which were modified from the 2009 CPG with the updated
GRADE language, as explained above.
Recommendations could also have been categorized as “Not reviewed, Deleted” if they were determined to be
out of scope. A recommendation was out of scope if it pertained to a topic (e.g., population, care setting,
treatment, condition) outside of the scope for the updated CPG as defined by the Work Group.
The categories for the recommendations included in the 2016 version of the guideline are noted in the
Recommendations. The categories for the recommendations from the 2009 mTBI CPG are noted in Appendix D.
F. Drafting and Submitting the Final CPG

Following the face-to-face meeting, the Champions and Work Group members were given writing assignments
to craft discussion sections to support each of the new recommendations and/or to update discussion sections
from the 2009 mTBI CPG to support the amended “carried forward” recommendations. The Work Group also
considered tables, appendices, and other sections from the 2009 mTBI CPG for inclusion in the update. During
this time, the Champions and Work Group also made additional revisions to the algorithms, as necessary.
After developing the initial draft of the updated CPG, an iterative review process was used to solicit feedback on
and make revisions to the CPG. Once they were developed, the first two drafts of the CPG were posted on a wiki
website for a period of 14-20 business days for internal review and comment by the Work Group. All feedback
submitted during each review period was reviewed and discussed by the Work Group and appropriate revisions
were made to the CPG.
Draft 3 of the CPG was made available for peer review and comment. This process is described in Peer Review
Process. After revisions were made based on the feedback received during the peer review and comment
period, the Champions presented the CPG to the EBPWG for their approval. Changes were made based on
feedback from the EBPWG and the guideline was finalized.

The Work Group also produced a set of guideline toolkit materials which included a provider summary,
pocketcards, and a patient summary. The final 2016 mTBI CPG was submitted to the EBPWG in January 2016.

Appendix B: Clinical Symptom Management

A. Appendix Contents
Co-occurring Conditions.................................................................................................................................... 80
Headache........................................................................................................................................................... 81
Dizziness and Disequilibrium............................................................................................................................. 90
Visual Symptoms............................................................................................................................................... 93
Fatigue............................................................................................................................................................... 94
Sleep Disturbance.............................................................................................................................................. 94
Cognitive Symptoms.......................................................................................................................................... 97
Persistent Pain................................................................................................................................................... 98
Hearing Difficulties............................................................................................................................................ 98
Smell (Olfactory Deficits)................................................................................................................................... 99
Nausea............................................................................................................................................................... 99
Changes in Appetite........................................................................................................................................... 99
Numbness.......................................................................................................................................................... 100
This appendix includes options for treatment of co-occurring conditions and a selected list of physical symptoms
that are most common in patients presenting with symptoms following a concussion/mTBI. The options were
formulated based on consensus of clinical experts. The evidence synthesis for this CPG found a lack of RCTs for
treatment of symptoms in patients with a history of mTBI. As such, the approach to symptom management is
based on common clinical practice.
B. Introduction
Emergence of neuropsychiatric post-concussive symptoms after mTBI can depend on many factors including
pre-injury psychosocial function and/or pre-existing illnesses/conditions, genetic predisposition to
neuropsychiatric disorders, injury factors, and post-injury psychosocial and health factors. The nature and
severity of symptoms, as ascertained in a thorough medical history, is necessary to choose appropriate
treatments. To date, a comprehensive treatment plan that addresses both psychosocial and pharmacologic
interventions is recommended by experts in the field, as there is a paucity of strong evidence specifically
targeting this population.
There is a complex relationship among concussion/mTBI symptoms (e.g., headache, sleep disturbances,
cognition, mood) and it is clinically reasonable to expect that alleviating/improving one symptom may lead to
improvement in other symptom clusters. The presence of comorbid psychiatric problems such as MDD, anxiety
disorders, PTSD or SUD–whether or not these are regarded as etiologically related to the mTBI–should be
treated aggressively using appropriate psychotherapeutic and pharmacologic interventions.
There are no specific FDA approved pharmaceutical agents for the treatment of any post-concussive
neurological or psychiatric symptoms emerging after mTBI. Experts in the field recommend using published
CPGs for other neuropsychiatric conditions as a reference, as well as the general guidance from the fields of
neuropsychiatry and behavioral neurology. See guidance such as:
• VA/DoD Clinical Practice Guidelines Homepage - www.healthquality.va.gov

• VA National Center for PTSD: Traumatic Brain Injury and PTSD -

http://www.ptsd.va.gov/professional/co-occurring/traumatic-brain-injury-ptsd.asp
• Defense Center of Excellence (DCoE) Resource Catalog -
http://www.dcoe.mil/PsychologicalHealth/Resources.aspx
• VA Health Services Research and Development: Evidence-based Synthesis Program -
www.hsrd.research.va.gov/publications/esp/
However, this committee did not review and cannot endorse the accuracy or clinical utility of any such guidance
that is available.
Treatments are symptom based and not based on the historical traumatic event. While there is little empirical
evidence, some experts prescribe medications for attention, irritability, sleep, agitation, anxiety, stress, mood
disturbances, headaches, and symptoms of impaired balance/dizziness. Sound clinical judgment with a thorough
clinical history, targeted physical exam, and any needed laboratory testing appropriate to the condition are always
prudent before prescribing any medication. Following recommended dosing guidelines is prudent as well.
Table B-1. General Considerations in Using Medication for Treatment of Symptoms after Brain
Injury
 Avoid medications that lower the seizure threshold (e.g., bupropion, traditional antipsychotic medications) or those
that can cause confusion (e.g., lithium, benzodiazepines, anticholinergic agents).
 Before prescribing medications, rule out social factors (e.g., abuse, neglect, caregiver conflict, environmental issues).
 Unless side effects prevail, give full therapeutic trials at maximal tolerated doses before discontinuing a medication
trial. Under-treatment is common.
 Patients with a history of TBI can be more sensitive to side effects. Watch closely for toxicity and drug-drug interactions.
Assess regularly for side effects.
 Limit quantities of medications with high risk for suicide as the suicide rate is higher in this population.
 Educate patients and family/care givers to avoid the use of alcohol with the medications.
 Minimize caffeine and avoid herbal or diet supplements such as “energy” products as some contain agents that cross-
react with the psychiatric medications and lead to a hypertensive crisis.
C. Co-occurring Conditions
a. Clinical Guidance
 Assess individuals in a primary care setting. Typical screening instruments are the Patient Health
Questionnaire (PHQ-2 or PHQ-9), the Generalized Anxiety Disorder Scale (GAD-2 or GAD-7), and
the primary care PTSD screener or PTSD Checklist (PCL). While these instruments do not
diagnose individuals with MDD, anxiety, or PTSD, they serve to identify individuals who require
further assessment.
 If a patient’s psychiatric history is too complex to clearly diagnose a comorbid psychiatric
diagnosis, consider consulting with, or referring to, a behavioral health provider. For individuals
who present with an existing psychiatric diagnosis, refer to behavioral health services for further
follow-up/treatment if indicated.
 Evaluation of patients with persistent symptoms following concussion/mTBI should include
assessment for suicidal ideation and homicidal ideation.

 Patients with persistent symptoms following concussion/mTBI should be re-evaluated for

psychiatric symptoms and comorbid psychiatric disorders.
 In patients with persistent post-concussive symptoms, which have been refractory to treatment,
consideration should be given to other factors that may be contributing, including psychiatric
disorders, lack of psychosocial support, negative illness expectations, and compensation/
litigation. However, clinicians should be very careful with any communications with patients
regarding possible attributions of physical symptoms to any of these causes, and should follow
clinical guidelines for management of persistent unexplained symptoms. (See the VA/DoD CPG
for the Management of CMI 26)
 Referral of patients with persistent behavioral symptoms to mental health specialty should be
considered.
D. Headache
a. Background
Posttraumatic headaches occur acutely in up to 90% of all individuals who sustain a concussion. Of note,
amongst Veterans who have sustained a concussion, headaches are one of the most common persisting
complaints and are often rated as moderate severity or higher.[108] Posttraumatic headaches usually develop
within seven days of head trauma and can resolve within three months (acute posttraumatic headache) or
persist for longer than three months (chronic posttraumatic headache). The inclusion of neck trauma is
important to acknowledge because the most frequent forms of civilian head trauma also cause injury to the
cervical spinal column, spinal cord and neck musculature. Individuals who sustain head and neck injury can have
headaches in which the pain originates from both the head and the neck. In addition, cervicogenic headaches
may require specific types of treatment dedicated to the cervical spine.
Although posttraumatic headaches represent a unique category of headache, they often share features of other
types of headaches. Characterization of the predominant clinical phenotype in posttraumatic headaches is
critical to establishing appropriate management as the pharmacologic and non-pharmacologic strategies parallel
those used in clinical practice to manage primary headache disorders. The three most common patterns of
posttraumatic headaches are:
1. Tension-type headaches, including cervicogenic component
2. Migraine headaches, or
3. Mixed migraine and tension-type headaches

Table B-2. Criteria for Characterizing Posttraumatic Headaches as Tension-like (Including

Cervicogenic) or Migraine-like Based upon Headache Features
Headache Type
Headache Feature Tension-like (including cervicogenic pain) Migraine-like
Pain Intensity Usually mild-moderate Often severe or debilitating
Pain Character Dull, aching, or band like pressure Throbbing or pulsatile, can also be
Sharp pain may be present, but is not predominant sharp/stabbing or electric-like
Duration Usually less than 4 hours Can last longer than 4 hours
Phono- or photo-phobia One but not both may be present One, or both usually present
Able to carry out routine Usually; of note, cervicogenic headaches Usually not, or with a decreased level of
activities/work may be triggered by work environment/posture participation, often worsened with
physical exertion
Location Bilateral frontal, retro-orbital, temporal, cervical Often unilateral and may vary in location
and occipital, or holocephalic among episodes
Nausea or malaise Not present Usually present
Palpable muscle Pericranial muscles including temporalis, masseter, Localized muscle tenderness is not typical,
tenderness or pterygoid, posterior neck muscle, muscle tenderness may be present with
contraction sternocleidomastoid, splenius or trapezius long duration headaches
Decreased cervical range of motion may also be
present in those with cervicogenic headaches
b. Assessment
i. History and Physical Examination
Acute assessment focuses on determining if an individual has intracranial pathology as a consequence of the
brain injury or an alternate cause of the headaches. Good clinical history is critical to establishing the underlying
headache type as well as identifying red flags. Historical red flags for headaches include systemic symptoms
(fever, weight loss), atypical onset (abrupt or split second onset, awakening patient from sleep due to
headache), or focal neurologic symptoms. The appropriate examination of the posttraumatic headache patient
includes musculoskeletal assessment of the head and neck and cranial nerve examination, including test of
olfaction, funduscopic evaluation, measurement of pupil size and reaction to light, and observation of eye
movements. The examination also evaluates muscle strength and tone, gait and upper and lower extremity
coordination. Warning signs of intracranial pathology that will require neurosurgical intervention include
drowsiness, impaired motor function (hemiparesis or hemi-ataxia), unsteady gait or inability to stand, vomiting
with or without head pain, headache with valsalva maneuvers such as coughing, papilledema or pupil
asymmetry of size or reactivity to light. Patients with warning signs of intracranial pathology need to have
additional assessment including intracranial imaging.
As indicated in Table B-2, focal muscle contraction can be identified in some individuals with tension-type
headaches or cervicogenic pain. A thorough neck exam including cervical range of motion should also be
performed.
ii. Medication Review

Medication review is a critical part of the assessment of patients with posttraumatic headaches. Chronic use
(particularly daily) of NSAIDs or acetaminophen (alone or combined with caffeine), may lead to medication

overuse or rebound headaches. Rebound headaches can occur with migraine or tension headaches. Headaches
associated with medication overuse are typically tension-like in character. Treatment of medication overuse
headaches requires that patients stop daily use of acute headache medication treatment. This will invariably
lead to withdrawal symptoms that could include rebound headaches, and patients can fall into a pattern of
continued medication overuse to avoid rebound headaches. When patients are caught in a pattern of
medication overuse, they are usually refractory to preventive medications. In most cases, headaches improve
after an analgesic washout period. When rebound headaches occur as a result of OTC medications, initial
management can safely begin in primary care; however, if patients have rebound headaches secondary to
prescription agents (especially opiates or butalbital containing preparations), these patients should be managed
in a specialty care setting such as neurology or pain management. Additionally, particular caution is required for
individuals who have frequent headaches and who state that headaches respond only to opioid medications.
Such individuals should be directed to a pain clinic or headache specialist.
iii. Sleep History

Sleep deprivation can cause or exacerbate headaches in addition to several other post-concussive symptoms.
Also, certain sleep disorders such as obstructive sleep apnea can cause morning headaches which have features
of tension headaches. It is important to gather a good sleep history from the patient including details of the
sleep-wake cycles, nocturnal awakenings (nightmares or parasomnias), snoring or sleep-disordered breathing.
Basic sleep hygiene counseling can be beneficial for headache patients with symptoms of sleep apnea and
specialty referral should be considered.
c. Treatment
Selection of pharmacologic and non-pharmacologic treatments for posttraumatic headaches is based upon the
character of the headaches. Patients who have mixed migraine/tension-like headaches may need treatment for
both headache types. Based upon currently available information, most individuals with mTBI will have
improvement in their headaches during the first three months of treatment. Initial pharmacologic treatment of
uncomplicated posttraumatic headaches can begin in primary care using the guidance in Table B-3 and Table B-
4. Consider referring patients who do not respond to treatments to headache specialists or pain treatment
programs. It is important to maintain a positive outlook and to encourage active patient ownership and
involvement in the care plan. It is also important to recognize comorbid conditions, especially sleep disorders,
anxiety disorders, PTSD, and depression. Treatment of these conditions may also improve headache.
i. Posttraumatic Headaches with Tension Features

Episodic tension-type headaches may or may not require specific interventions. When the pain severity is such
that the patient desires intervention, pharmacologic and non-pharmacologic interventions should be
considered. Pharmacologic therapies to consider include acetaminophen and NSAIDs which are often trialed
OTC by patients prior to being seen. Prescription options for treatment of posttraumatic headaches with tension
features include prescription-strength NSAIDs and combination medications. Combination medications typically
are comprised of aspirin, acetaminophen, caffeine and a sedative drug in a single medication. Combination
drugs may be more effective than NSAIDs or acetaminophen alone. These drugs should not be used more than
two days a week due to side effect concerns and the potential for dependency. When using any medications,
caution must be taken to avoid overuse and subsequent rebound headaches. As such, patients may achieve
better pain relief if medication treatment is coupled with non-pharmacologic modalities such as relaxation
training, biofeedback and PT. Physical therapy may provide musculoskeletal interventions to address

cervicogenic components of headache including joint/soft tissue mobilization, cervical joint proprioception
training, cervical strengthening, ergonomic/postural assessments, and functional dry needling. Regardless of the
treatment modality, pain treatment is more likely to be successful if the intervention starts at the onset of a
headache rather than waiting for the headache pain to escalate. Patients who experience more than three
tension headaches per week may benefit from prophylactic therapy designed to prevent tension headaches.
Pharmacologic considerations for prevention of tension headaches include tricyclic antidepressants,
propranolol, anticonvulsants (topiramate) or tizanidine. Poorly controlled tension headaches can also indicate
that attention should be directed to physical or psychological factors that may be triggering the headaches.
ii. Posttraumatic Headaches with Migrainous Features

Medical treatment of migraine headaches includes strategies for acute interventions and headache prevention.
Many patients with migraines can be effectively treated with various acute headache medications and non-
pharmacologic strategies. Patients need to be aware of factors that can trigger migraines and avoid those that
trigger their headaches. Headache risk factors and triggers include sleep disruption, delaying meals, stress, and,
for some people, specific foods, beverages or odors. Non-pharmacologic treatments are often adjunctive to
acute treatment. They may be effective and may eliminate the need for pharmacologic interventions, especially
when utilized early in the evolution of a migraine. Non-pharmacologic treatments commonly employed are
relaxation, biofeedback, visualization, extracranial pressure, and thermal therapies. Regular exercise and
maintaining consistent sleep and meal schedules are important parts of the overall treatment regimen but are
more effective as preventive than as abortive treatments.
Effective acute treatment requires that patients recognize their specific personal warning signs (aura) of an
impending headache. A migraine headache often begins with mild to moderate pain that may be similar to the
pain of a tension-type headache. As the migraine progresses, the headache includes the typical migraine
features such as throbbing pain, nausea and phono- or photophobia. Acute treatment is more likely to succeed if
medication is taken as soon as the patient recognizes the warning signs. Potential abortive therapies for
migraine are listed in Table B-3.
It is important that acute migraine treatment be used prudently to avoid inducing headaches due to medication
overuse or rebound and to educate patients that acute migraine medication treatment be limited to three
treatments a week or less on a regular basis. A headache diary including frequency and medication history use
may be useful in detecting medication overuse.
Interventions to reduce headache frequency should be considered when migraine headaches occur more than
once a week or any of the following criteria exist:
a. Headache attacks that are disabling despite aggressive acute interventions
b. Patient’s desire to reduce frequency of acute attacks
c. Headaches compromise work attendance, societal integration or daily life
Selection of appropriate prophylactic therapies needs to take into account the patient’s comorbidities and
attempts should be made to address multiple symptoms with one medication. Careful consideration should also
be given to potential drug-drug interactions. Potential treatment considerations for headache prophylaxis are
listed in Table B-4.

Table B-3. Abortive Migraine Pharmacotherapy*

*Medications are listed in alphabetical order, not by preference
** Periodic reevaluation of the need for and efficacy of the therapies listed is strongly encouraged
Dosing Recommendations: Abortive Migraine Medications**
Drug Category Usual Dose Range Adverse Drug Events Comments/Cautions
NSAIDs
Ibuprofen Usual Dose: 400-600 mg;  GI effects  Rebound headache may occur with
3-4 times daily  Dizziness continuous use
Maximum Dose: 3200 mg daily  Vertigo  Potential renal impairment with
 Bleeding related risks long-term use
Ketorolac injection IM: Inject 30-60 mg as a single
dose  Associated with an increased risk of
cardiovascular thrombotic events
Limit use to 5 days (stroke and MI)
Naproxen Initial Dose: 750 mg daily  Caution in patients with history of
Titration Dose: Additional 250- GI ulcers or abdominal
500 mg may be given complications
 Limit to no more than 12 days of
Maximum Dose: 1250 mg daily the month to prevent rebound
headache
Serotonin 5-HT Receptor Agonist
Rizatriptan Initial Dose: 5-10 mg at onset of  Dizziness  Use with caution in patients with
headache, may repeat in 2 hrs  Somnolence history of cardiac events
Maximum Dose: 30 mg daily  Nausea  Serious cardiac events, including MI,
have been reported (tablet and
Sumatriptan Oral  Dizziness nasal formulations)
Initial Dose: 50-100 mg at onset  Vertigo  Risk of serotonin syndrome when
of headache, may repeat in 2 hrs  Tingling used concomitantly with other
Maximum Dose: 200 mg daily  Hypertension serotonergic drugs
 Injection site  Limit to no more than 12 days of
reactions the month to prevent rebound
Intranasal
headache
Initial Dose: 10 mg spray in 1
nostril at onset of headache,
may repeat in 2 hrs
Maximum Dose: 40 mg daily
Sub-cutaneous
Initial Dose: 6 mg SubQ at onset
of headache, may repeat in 1 hr
Transdermal
Initial Dose: Apply 1 patch (6.5
mg) at onset of headache, may
repeat in 2 hrs
Maximum Dose: 2 patches daily


Zolmitriptan Oral  Unusual taste (nasal
Initial Dose: 1.25-2.5 mg at formulation)
onset of headache, may repeat  Paresthesia
in 2 hrs  Hyperesthesia
Titration Dose: 5 mg at onset of  Dizziness
headache, may repeat in 2 hrs
Intranasal
Initial Dose: 2.5-5 mg spray in 1
nostril at onset of headache,
may repeat in 2 hrs
Maximum dose: 10 mg daily
Other
Butalbital/ Usual Dose: 1-2 tablets every 4  Dizziness  These agents should only be used as
Acetaminophen/ hrs as needed  Sedation third line therapies due to
Caffeine  GI effects dependence risk, high risk of
Maximum Dose:
rebound headache and sedation
6 tablets per day  Intoxicated feeling
 Patient selection is key when using
Butalbital/Aspirin/ Usual Dose: 1-2 capsules every these agents
Caffeine 4 hrs as needed  Use when serotonin 5-HT receptor
Maximum Dose: 6 capsules agonist is contraindicated
daily  Rebound headache with overuse
 Acetaminophen may cause severe
hepatotoxicity
 Monitor total acetaminophen
consumption
 Use caution with aspirin in patients
with history of GI ulcers or
abdominal complications
Acetaminophen/ Initial Dose: 2 capsules at onset  Dizziness  Acetaminophen may cause severe
Isometheptene/ of headache hepatotoxicity
Dichloralphenazone  Monitor total acetaminophen
Titration Dose: 1 capsule every
hr until relief is obtained consumption
Maximum Dose: 5 capsules/ the month to prevent rebound
12 hrs headache


OTC
Acetaminophen Regular Strength  Liver impairment  Risk of hepatotoxicity with
 Skin rash acetaminophen containing products
Usual Dose: 650 mg every 4-6
hrs as needed  Tinnitus with aspirin containing
products
Maximum dose: 3250 mg daily  May increase maximum dose to
(for OTC use) 4000 mg per day with provider
supervision
Extra Strength
Usual Dose: 1000 mg every 6 the month to prevent rebound
hrs as needed headache
Maximum dose: 3000 mg daily
(for OTC use)
Acetaminophen/ Usual Dose: 2 tablets once daily  Liver impairment
Aspirin/ Caffeine  GI related effects
Maximum Dose: 2 tablets per
(Excedrin Extra  Bleeding related risks
day
Strength)
Aspirin Usual Dose: 325-650 mg every  GI related effects
4-6 hrs as needed  Bleeding related risks
Maximum Dose: 4000 mg daily  Renal impairment
Antiemetic agents
Prochlorperazine Usual Dose: 5-10 mg 3-4 times  Drowsiness  Use with caution in patients with
daily  Agitation severe cardiovascular disease
Maximum Dose: 40 mg daily  Constipation  Extrapyramidal effects with long-
term use
Promethazine Usual Dose: 12.5-25 mg every  Drowsiness  Extrapyramidal effects with long-
(Oral, IM, Rectal) 4-6 hrs as needed  Constipation term use
 Xerostomia  May cause photosensitivity
Note: Refer to product prescribing insert for more information regarding use restrictions, dose modification, dosing in special populations
(e.g., renal or liver impairment, advanced age, pregnancy), drug-drug interactions, and other warnings and precautions.
Abbreviations: GI: gastrointestinal; hrs: hours; IM: intramuscular; mg: milligram; MI: myocardial infarction; NSAIDs: nonsteroidal anti-
inflammatory drugs; OTC: over-the-counter; SubQ: sub-cutaneous

Table B-4. Prophylactic Migraine Pharmacotherapy*

*Medications are listed in alphabetical order, not by preference
Dosing Recommendations: Prophylactic Migraine Medications**

It may take up to 3 months for patients to receive the full benefit of prophylactic therapies.
Anti-Convulsants
Initial Dose: 100-300 mg at bedtime  Dizziness  Dual benefits of gabapentin
 Somnolence (neuropathic pain, seizure
Titration Dose: 100-300 mg every 5 days disorder, diabetic
Gabapentin  Weight gain
as necessary/tolerated on a TID schedule
neuropathy)
Initial Dose: 25 mg once daily  Paresthesia  May worsen cognitive
 Nausea dysfunction
Titration Dose: Increase weekly by 25 mg
daily  Anorexia  May cause renal stones
Topiramate
 Sedation
 Ataxia
 Dizziness
Extended Release  Weight gain  Association with
Initial Dose: 500 mg once daily  Tremor teratogenicity (neural tube
 Liver toxicity defects); caution in women
Titration Dose: Increase after 7 days to of childbearing potential
1000 mg daily, adjust dose based on  Nausea
 Evaluate for drug
patient response  Asthenia
interactions
Maximum Dose: 1000 mg daily  Dizziness
Divalproex
sodium  Somnolence
products Immediate Release  Diplopia
Initial Dose: 250 mg twice daily
Titration Dose: Increase by 250 mg per
day every week; adjust dose based on
patient response
Beta-Blockers
Immediate Release  Fatigue  May mask signs and
Initial Dose: 80 mg per day divided every  Exercise intolerance symptoms of hypoglycemia
6 to 8 hours  Bradycardia  Avoid withdrawal of agent
abruptly to avoid cardiac
Titration Dose: Increase by 20-40 mg per
related events
dose every 3-4 weeks
Propranolol
Maximum Dose: 160-240 mg per day
given in divided doses
Long-Acting
Initial Dose: 80 mg once daily
Effective Dose Range: 160-240 mg daily

Dosing Recommendations: Prophylactic Migraine Medications**

It may take up to 3 months for patients to receive the full benefit of prophylactic therapies.
Alpha-Blockers
Initial Dose: 1 mg at bedtime  Dizziness  Evaluate for orthostatic
 Palpitations hypotension and syncope
Titration Dose: Increase dose weekly to 4
Prazosin mg, 6 mg, 8 mg, 10 mg  May offer additional benefit
in patients with nightmares
Maximum Dose: 10 mg at bedtime and PTSD
Tricyclic Antidepressants
Initial Dose: 10-25 mg at bedtime  Weight gain  Monitor for suicidality
Titration Dose: Increase at weekly  Xerostomia  Multiple drug interactions
Amitriptyline  Sedation  Caution in patients with a
increments of 10-25 mg daily
 Agitation history of cardiovascular
Maximum Dose: 150 mg daily disease
Initial Dose: 10-25 mg at bedtime  Avoid abrupt discontinuation
Titration Dose: Increase at weekly
Desipramine
Initial Dose: 10 mg at bedtime
Titration Dose: Increase at weekly
Nortriptyline
Maximum Dose: 50-100 mg daily
Vitamins/Supplements
Usual Dose: 600 mg daily  Diarrhea  Administer at least 2 hrs apart
Magnesium from other medications
oxide  Assess for drug interactions
 Take with food
Vitamin B2 Usual Dose: 400 mg daily  Discoloration of  Protect storage bottle from
(Riboflavin) urine light
(e.g., renal or liver impairment, advanced age, pregnancy), drug-drug interactions and adverse events.
Abbreviations: GI: gastrointestinal; hrs: hours; mg: milligram; PTSD: posttraumatic stress disorder; TID: three times daily

E. Dizziness and Disequilibrium

a. Background
Dizziness and disequilibrium is one of the most common symptoms in primary care, and may also result from
mTBI. Dizziness and disequilibrium due to various causes can be broadly organized into the following disorders:
inner ear disorders (peripheral vestibular disorders), central nervous system disorders, psychological disorders,
musculoskeletal disorders, and idiopathic disorders (one of the most common forms of dizziness).
Table B-5. Criteria for Categorization and Referral for Dizziness and Disequilibrium After mTBI
[109,110]
# Possible Diagnosis Symptoms Duration/Provocation Referral
Inner Ear Disorders (Peripheral Vestibular Disorders)
 Vertigo  Spells that last for seconds to  Canalithic
 Lightheadedness minutes and are associated with repositioning
Benign paroxysmal changes in head position maneuver
1 positional vertigo  Nausea
(BPPV)  Nystagmus, often with a  PT
torsional component, usually
observed when symptomatic
 Vertigo with movement  History of event, symptoms  ENT Specialist
 Disequilibrium improved since event but  PT
Labyrinthine  Oscillopsia with head remain problematic
2  Mostly related to fast head
concussion movements
 Nausea and vomiting movements/turns
(acute)
 Vertigo  Spontaneous, episodic spells  ENT
Posttraumatic  Disequilibrium that can last for hours
3 endolymphatic
hydrops  Aural fullness
 Tinnitus
 Loud tinnitus  Onset related to an event  ENT
4 Perilymphatic fistula  Hearing loss  Increase in abdominal pressure
 Vertigo can elicit symptoms
 Disequilibrium  Related to one or more events,  ENT
Bilateral labyrinthine  Vertigo and oscillopsia if induced by head movements,  PT
5
dysfunction lesions asymmetrical difficulty with postural control in
the dark or on uneven surfaces
Central Disorders
 Motion sensitivity  Movement induced spells of  See Appendix B:
 Disequilibrium vertigo that usually last for Headache
Migraine-induced
6  Headache minutes to 1 hour, usually close  PT
vestibulopathy
temporal relationship with
 Vertigo headache
 Dizziness  Difficulties with balance on  Ophthalmology
 Disequilibrium uneven, conforming terrain  Optometry
 Blurred vision  Dizziness with increased  Vision
 Diplopia environmental stimulation Rehabilitation
7 Visual dysfunction  Squinting/closing one eye during
 Impaired visual-spatial
orientation activities
 Eye hand incoordination  Difficulty standing in midline or
noted head tilt

# Possible Diagnosis Symptoms Duration/Provocation Referral

 Reading difficulties
 Sensitivity to light
Psychological Disorders
 Lightheadedness  May be related to event but  Psychiatry
Depression, anxiety,  Floating could report chronic history,  Psychology
8 somatic symptom symptoms can be induced by
disorder  Rocking  PT
eye movements with head still
 Vague/bizarre accounts
Musculoskeletal Disorders
Flexion-extension,  Disequilibrium  Onset with event  Physiatry
9 rotation, cervical  Lightheadedness  Symptoms coincide with  PT
injury (cervicogenic)  Neck pain movement of cervical spine
Uncommon Central Disorders
 Nausea and vomiting  Related to an event  Neurology
 Vertigo  Usually symptoms induced by  Neurosurgery
 Visual hallucinations/loss cervical extension and rotation
Vertebral-basilar  Visual field deficit
insufficiency related to
10  Numbness/weakness
occipitoatlantal
instability  Ataxia
 Drop attacks
 Diplopia
 Headaches
Other
 Conductive hearing loss  Onset with event  ENT
 Vertigo  Will follow the course of  PT
Temporal bone labyrinthine concussion
11  Disequilibrium
fracture
 Nausea and vomiting
 Oscillopsia
 Non-specific dizziness and  One of the most common  Generally best to
many other related symptoms in primary care, and treat in primary
symptoms most common reason for care setting and
12 Idiopathic
dizziness minimize
referrals, unless
clinically indicated
Abbreviations: ENT: ear, nose and throat specialist; PT: physical therapy
b. Assessment
i. Physical Examination
Defining how the patient characterizes dizziness (e.g., vertigo, lightheadedness, syncope, disequilibrium,
confusion), describes the temporal pattern (e.g., seconds, minutes, hours, days), and provokes symptoms (e.g.,
rolling over in bed, bending over, head movement) may provide valuable information in establishing a working
differential diagnosis. Primary care assessment for vestibular disturbance should be done before referring for
further vestibular examination and exercise. Once initial primary care assessment is complete and other causes
are eliminated (e.g., vertebral basilar insufficiency, orthostatic hypotension, polypharmacy), refer to vestibular
rehabilitation specialist for trial intervention sessions.

Observation and patient interview are key elements to the exam and often guide the clinician in determining
the plan of care. Evaluation should include a thorough neurologic examination and the following functions and
structures: orthostatics, vision (acuity, monocular confrontation fields, pupils, eye movements, nystagmus),
auditory (hearing screen, otoscopic exam), sensory (sharp, light touch, proprioception, vibration), motor (power,
coordination), cervical, and vestibular (dynamic acuity, positional testing). Evaluation of functional activities
should include sitting and standing balance (Romberg with eyes open/closed, single leg stance), transfers
(supine↔sit, sit↔stand) and gait (walking, tandem walking, and turning).
ii. Medication Review

A detailed medication history is warranted. Numerous medications include dizziness as a potential side effect.
The following classes of medication can cause or aggravate dizziness: stimulants, benzodiazepines, tricyclics,
monoamine oxidase inhibitors, tetracyclics, neuroleptics, anticonvulsants, selective serotonin agonists, beta
blockers and cholinesterase inhibitors. The temporal relationship to the onset of dizziness and the
initiation/dosing of these medications should be investigated.
c. Treatment
i. Pharmacologic Treatment
Initiating vestibular suppressants for dizziness may delay central compensation or promote counterproductive
compensation.[111,112] Vestibular suppressants might be helpful during the acute period of several vestibular
disorders but have not been shown to be effective in chronic dizziness after concussion.[113] Medications
should only be considered if symptoms are severe enough to significantly limit functional activities. Trials
should be brief and optimally less than a week. It is important to be particularly careful regarding dosing and
titration due to the effects on arousal and memory as well as the potential addictive qualities of these
medications.[114] First-line medication choice would be meclizine, followed by scopolamine and
dimenhydrinate, depending upon symptom presentation. Pharmacotherapy with clonazepam, diazepam or
lorazepam is discouraged due to the sedating and addictive qualities of those agents.
ii. Non-Pharmacologic Treatment

Non-pharmacologic interventions for posttraumatic dizziness may be useful as an alternative to
pharmacotherapies, although the effectiveness of such interventions is not fully established with
concussion/mTBI.[115] Efficacy of vestibular and balance rehabilitation has been shown in different
populations with vestibular disorders.[61-63] Patients with vestibular disorders who received customized
programs showed greater improvement than those who received generic exercises.[62] Studies utilizing
vestibular exercises have shown up to an 85% success rate in reducing symptoms and improving function in the
population with peripheral vestibular disorders.[62,116]
With mTBI, recovery of vestibular lesions is often limited or protracted due to the coexistence of central or
psychological disorders.[56] Evidence is limited regarding the benefits patients with a history of mTBI
participating in specific vestibular exercises.
Knowledge of the canalith repositioning procedures for the treatment of benign paroxysmal positional vertigo
(BPPV) would be beneficial for primary care physicians.[117] In addition, patients with history and clinical
examination consistent with BPPV may also be sent to a vestibular rehabilitation therapist for further specialized

BPPV assessment and treatment with guided follow-up, should symptoms not fully resolve after one trial of
canalithic repositioning maneuver.
In cases of persistent dizziness and disequilibrium, a qualified vestibular rehabilitation therapist may also be
utilized to execute a more comprehensive vestibular/balance evaluation and treatment program. The types of
specialized assessment tools, maneuvers and exercises to treat dizziness and disequilibrium are beyond the
scope of this guideline. Patients with central and psychological disorders need a coordinated team effort to
address the underlying impairments in order to maximize the outcome of vestibular rehabilitation.
If an individual appears to be at fall risk due to symptoms of dizziness and disequilibrium, referral for home
evaluation for adaptive equipment should also be considered as a compensatory strategy to limit further injury.
The OTSG Army Toolkit as well as DVBIC may also provide guidance regarding symptoms of dizziness and
vestibular rehabilitation. These additional resources are mentioned to provide assistance to primary care
providers; however, it should be noted that information contained in these documents was not reviewed. (See
Additional Educational Materials and Resources.)
F. Visual Symptoms
a. Background
Vision difficulties, including sensitivity to light, eye fatigue, difficulty focusing and/or blurry vision occur acutely
in some individuals who sustain an mTBI. The vast majority of vision difficulties resolve within minutes or hours,
with some individuals experiencing symptoms for longer. Therefore, targeted treatments aimed at symptom
management during the early period when these symptoms are occurring are usually effective. If, over time,
visual problems persist and impact daily function, a referral to optometry, ophthalmology, neuro-
ophthalmology, neurology, and/or vision rehabilitation team is indicated.
Primary care providers need to be keenly aware of potential reasons for an urgent referral to an eye care
provider in cases of vision loss or decline, diplopia, abnormal pupils, abnormal external eye exam, abnormal
visual behavior (e.g., unexpectedly bumping into things), abnormal eye movements (e.g., nystagmus) or acute
ocular symptoms (e.g., evidence of trauma, severe eye pain, flashes and/or floaters, severe photophobia).
b. Assessment and Treatment

In response to persistent vision problems the primary care provider should inquire about how the vision
impairment has been impacting the patient’s daily functioning, by asking questions such as “how have your
vision problems impacted school or work such as reading and/or using a computer?” If functional impairments
are evident, proceed with a basic eye/vision exam which should include visual acuity (distant and near),
monocular confrontational fields, pupils (size/equality/response), eye movements, external exam (direct
illumination of anterior segment) and a check for nystagmus (primary position and gaze evoked). A slit lamp
exam can be helpful, if available.
All current medications should be evaluated as they may be the cause of the visual dysfunction. Drugs to be
aware of that may be associated with vision problems include antihistamines, anticholinergics, digitalis
derivatives, antimalarial drugs, corticosteroids, erectile dysfunction drugs, phenothiazines, chlorpromazine,
indomethacin and others. Other comorbidities may also be contributing factors or the source of the vision
dysfunction, such as migraines, sleep disturbances, chronic pain, mood disorders and PTSD.

If the vision problem is impacting function over time, consider a referral to a specialist trained in oculomotor
rehabilitation care (e.g., a polytrauma blind rehabilitation outpatient specialist, low vision therapist,
occupational therapist) to complete a vision screen and functional assessment. If indicated, an eye care provider
can complete a comprehensive vision assessment and together with the rehabilitation team can develop a
treatment intervention to address the individual’s visual complaints and functional deficits.
The types of specialized vision rehabilitation assessment tools and interventions (e.g., vision exercises) to
address visual dysfunction related to mTBI are beyond the scope of this guideline. Patients will need a
coordinated team effort to address the underlying impairments in order to maximize the outcome of vision
rehabilitation.
Refer to DCoE Clinical Recommendations for clinical algorithm, functional vision questions, yellow and red flags
for referral to a specialist and additional guidance on how to manage vision deficits following mTBI.
G. Fatigue
a. Background
Fatigue is the third most common symptom reported after mTBI, and is also one of the most common symptoms
in other primary care populations. It can be due to a primary effect related to central nervous system
dysfunction or a secondary effect of common coexisting disorders in mTBI such as depression or sleep
disturbances, or any number of other reasons. Medications, substance use and lifestyle may also contribute to
fatigue.[118,119]
b. Assessment and Treatment

A detailed history of pre/post-injury level of physical activity, cognitive function and mental health is important
to determine the effects of fatigue in temporal relation to the injury. The ability to maintain a job is often a
good measure of the impact of this symptom. Several outcome measures exist for fatigue, and many have been
studied in other populations. Common measures in TBI include the Multidimensional Assessment of Fatigue
(MAF), Fatigue Impact Scale (FIS) or Fatigue Assessment Instrument (FAI). However, there is no specific scale
recommended for mTBI. Laboratory tests to rule out other medical conditions affecting fatigue may be
considered. Current pharmacotherapy and supplement use must be reviewed to eliminate the contribution of
these agents to fatigue.
Education is important in the treatment of fatigue. Educational efforts should be focused on factors contributing
to fatigue, importance of well-balanced meals, promotion of sleep hygiene and encouragement of regular
exercise. Exercise routines should be individualized to maximize benefit and promote a proper ratio of activity
and rest. Scheduling of exercise may need to be addressed depending upon when the patient is at his or her
best. CBT and PT can be tried to decrease fatigue level and improve functional performance in patients with a
history of mTBI.
H. Sleep Disturbance
Pharmacologic treatment of sleep disturbance following mTBI may be complex. For all pharmacologic
interventions, providers should weigh the risk-benefit profiles, including toxicity and abuse potential.

Table B-6. Dosing Recommendations for Sleep Agents*

*Medications listed in alphabetical order, not by preference
Dosing Recommendations: Sleep Agents**

Alpha-Blockers
Initial Dose: 1 mg at bedtime  Dizziness  For patients with nightmares
 Palpitations associated with PTSD
 Orthostasis  Evaluate for orthostatic
Titration Dose: Increase dose hypotension and syncope
Prazosin
weekly to 4 mg, 6 mg, 8 mg, 10 mg
Maximum Dose: 10 mg at bedtime

Hypnotics
Initial Dose: 1 mg before bedtime  Headache  Not indicated for long-term
 Drowsiness use
Eszopiclone
Maximum Dose: 3 mg before  Abnormal dreams  Sleep walking effects
bedtime  Memory impairment  Short-term amnesia
Initial Dose: 10 mg immediately at  Disorientation  Abnormal behavior
bedtime  Unpleasant taste  Recommend taking
Low body weight: 5 mg (specifically with immediately before bedtime
Zaleplon eszopiclone)  Zaleplon has a very short half-
Titration Dose: Less than 65 years: life of about 1 hr; as a result, it
20 mg may be more effective for
patients who have difficulty
with sleep onset and sleep
Immediate Release latency
Initial Dose: Females: 5 mg before  Patients using eszopiclone or
bedtime; Males: 5-10 mg before zolpidem should be advised to
bedtime refrain from driving or other
activities that require mental
Maximum Dose: 10 mg before alertness the day after taking
bedtime the drug
Zolpidem
Extended Release
Initial Dose: Females: 6.25 mg
before bedtime; Males: 6.25-12.5
mg before bedtime
Maximum Dose: 12.5 mg before

bedtime

Dosing Recommendations: Sleep Agents**

SSRIs/Antidepressants
Usual Dose: 50-100 mg at bedtime Sedation  Risk of serotonin syndrome
 Headache when used concomitantly with
Trazodone
 Xerostomia other serotonergic drugs
Maximum Dose: 200 mg at bedtime  Dizziness  Monitor for suicidality
Initial Dose: 25 mg at bedtime  Priapism (specifically  May lower seizure threshold
with trazodone)  May use for patients with
Amitriptyline comorbid conditions such as
Maximum Dose: 150 mg depression,*** pain or
headaches
Initial Dose: 3 mg taken within 30  Somnolence  Monitor for suicidality
minutes of bedtime  May lower seizure threshold
Doxepin  May use for patients with
comorbid conditions such as
Maximum Dose: 6 mg depression,*** pain or
headaches
Initial Dose: 15 mg at bedtime  Somnolence  Degree of sedation is
 Nausea moderate to high relative to
Mirtazapine  Dizziness other antidepressants
Maximum Dose: 45 mg at bedtime  Monitor for suicidality
 Increased appetite
 Weight gain  May lower seizure threshold
Melatonin receptor agonists

Initial Dose: 8 mg taken within 30  Somnolence  Do not use in combination
minutes of bedtime  Dizziness with fluvoxamine
 Nausea  Use caution in patients taking
 Fatigue other CYP1A2-inhibiting drugs
Ramelteon Maximum Dose: 8 mg per day
 Headache
 Hallucinations have
been reported in
some patients
Orexin receptor antagonists
Initial Dose: 10 mg taken within 30  Somnolence  CNS depression impairing
minutes of bedtime  Headache physical and mental
 Dizziness capabilities
 Significant drug interactions
Suvorexant Maximum Dose: 20 mg exist, requiring dose or
frequency adjustment,
additional monitoring, and/or
selection of alternative
therapy
(e.g., renal or liver impairment, advanced age, pregnancy), drug-drug interactions and adverse events.
Abbreviations: CNS: central nervous system; hr: hour; mg: milligram; PTSD: posttraumatic stress disorder; SSRIs: selective serotonin re-
uptake inhibitors
***Doses used for depression are higher than those recommended for sleep. Additionally, if a patient has comorbid depression and
cannot sleep, then a wider range of antidepressants can be considered (SSRIs/serotonin–norepinephrine reuptake inhibitors [SNRIs]) as
treating depression often improves sleep.

I. Cognitive Symptoms
a. Clinical Guidance
• Cognitive complaints (e.g., forgetting appointments or medication schedules, losing items more than
expected or usual) should be followed up with a comprehensive patient history and, if they persist after
30 to 90 days, a functional cognitive assessment.
• A comprehensive evaluation that includes reliable and valid tools, self-report and ecologically-relevant
measures requiring higher levels of sustained effort or similar to the everyday environments of the
individual may help determine clinical indications for treatment, need for referral to other rehabilitation
specialists and/or a treatment plan based on functional needs.[120]
• Education should be an integral part of the management process. Clinicians should use principles of risk
communication to provide reassurance, promote normalization and minimize the perception of disability.
Cautious risk communication also will help reduce the perception of neurologically-based deficits and
guide treatment based on symptoms and functional needs. Education should include information about
the potential effects of coexisting conditions and medication side effects on cognition.
• Motivational interviewing techniques may help with identifying activity limitations and setting
meaningful goals, as well as promoting active patient engagement in the treatment process.[121]
• Goal attainment scaling (GAS) for rehabilitation may facilitate setting measurable and term-limited goals
that are individualized to the unique situation and needs of the patient.[122,123] GAS may help
clinicians develop goals that are based on gradual improvements in activity participation, thus setting
positive and realistic expectations of treatment.
• Referrals for clinician-directed interventions, whether in individual or group settings, are suggested over
self-directed computer-based programs and exercises. Computer-based interventions and the selective
use of mobile applications (e.g., Concussion Coach) may be considered when used by clinicians in support
of a comprehensive treatment approach focused on symptom management and real-world benefit.
 Compensatory strategy training can involve adaptive strategies such as environmental
modifications to facilitate attention, as well as establishing and practicing new techniques to
support daily functioning, work and school activities.
 Cognitive AT may range from a wrist watch with an alarm function, to a multi-function device
(e.g., smartphone, tablet). Familiar and readily available devices are preferred over customized
devices.
 Successful long-term utilization of strategies and devices requires specialized evaluation to
select the appropriate technique or device (for the person and the situation) and sufficient
practice in real-life contexts.
 Techniques that promote self-reflection and self-regulation during therapeutic treatment trials
are suggested to support generalization of treatment gains to community-based activities
leading to functional independence.
• Cognitive rehabilitation requires patient and family engagement and often collaboration with other
rehabilitation team members (e.g., OT, PT, vocational rehabilitation, recreational therapy, speech-
language pathology). Collaboration with mental health professionals, particularly for patients with

associated or comorbid mental health issues, may help reduce distress, improve emotional functioning
and facilitate improvement in functional outcomes.[85]
J. Persistent Pain
(See also discussion of Headache)
a. Background
Approximately 40-50% of patients with a history of mTBI may experience chronic pain.[48] Pain management is
similar to patients without a history of mTBI. However, in a patient with a history of mTBI, the complaint of
chronic pain is sometimes interwoven with comorbid conditions such as sleep disorders, anxiety, MDD, or PTSD.
b. Assessment
Assessing patients for pain and its underlying causes is an essential component of the clinical work-up. It is
important to attribute symptoms correctly and to identify and treat any comorbid conditions. If medication is
being considered, it is essential to establish the underlying cause prior to prescribing and to clearly define the
goals of therapy.
c. Treatment
Pain management is a priority and all patients presenting with a history of mTBI and complaints of pain should
be assessed. The underlying cause of the pain should be determined and treated. The use of non-pharmacologic
therapies should be considered. Rehabilitation therapies may be beneficial for the management of pain in
patients with a history of or who have sustained mTBI. The use of opioid agents in chronic pain conditions
should be avoided until other avenues of pain control have been given appropriate treatment trials.
Providers may also consult the VA/DoD CPG for the Management of CMI 27 or the VA/DoD CPG for Opioid
Therapy for Chronic Pain 28 for additional strategies to manage persistent pain.
K. Hearing Difficulties
a. Background
Hearing difficulties, including altered acuity and sensitivity to noise, occur acutely in the majority of individuals
who sustain a blast-related mTBI.[66] Symptoms are either decreased auditory acuity or sensitivity to noise. The
vast majority of symptoms resolve within a month, unless there is significant or permanent injury to the ear
drum. Aggressive, targeted treatments aimed at symptom management (e.g., reassurance, pain management,
controlling environmental noise, white noise generators) in the early treatment period are usually effective.
True abnormalities in central auditory acuity or processing are extremely rare with mTBI. Other causes of
problems are also extremely rare and often not related directly to the concussion injury. Pre-injury hearing
deficits are common and need to be ruled out.
28 See the VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. Available at:
http://www.healthquality.va.gov/guidelines/pain/cot/index.asp

b. Assessment and treatment

1. Perform an otologic examination.
2. Review medications for ototoxicity.
3. Refer to audiology for hearing assessment if no other apparent cause is found.
L. Smell (Olfactory Deficits)

a. Background
Posttraumatic olfactory deficits (anosmia) are not common in individuals who sustain an mTBI.[124] The vast
majority of cases resolve within a six month period. Treatments have limited effect and are usually aimed at
flavoring/spicing food to enhance taste and providing specific safety education (e.g., particular attention to
working smoke detectors for patients who may not smell smoke). Other causes are also extremely rare and
often not related directly to the concussion injury. Depression, common among those with persistent symptoms
following mTBI, has been associated with perceptual biases in olfaction that may drive patient complaints of
changes in smell and taste.[125] Pre-injury causes of anosmia need to be ruled out.[52]

1. Perform a nasal and oropharyngeal examination. Screen for depression.
2. Refer to ear, nose and throat specialist (ENT) for further evaluation, if needed.
3. If neurologic status is stable and there are no objective findings, reassurance and monitoring are
appropriate.
4. For depressed patients, treatment with psychotherapy may improve olfaction.[126]
5. Increase spicing of foods (+/- dietary referral). Monitor weight. Provide specific safety education.
M. Nausea
a. Background
Occasionally, posttraumatic nausea occurs acutely after mTBI, most often in combination with dizziness, as a
secondary effect of medications (pain), or due to an exacerbation of underlying gastroesophageal reflux disease
(GERD)/gastrointestinal (GI) dysfunction. This symptom may also be associated with psychological stressors.

1. Define triggers and patterns of nausea. Refer to Table B-5 as appropriate.
2. Assess medication lists for agents that may cause or worsen GI symptoms.
3. The initial focus should be on the rapid management of dizziness and return to activity. Formal
assessment should be limited.
N. Changes in Appetite
While changes in appetite can occur, these are not a primary effect from mTBI but rather are the result of
secondary issues. When a change in appetite is noted, it may be related to mood, medications, smell, or other
factors and will likely resolve as these factors are addressed.

O. Numbness
Numbness following mTBI in the absence of peripheral nerve injury is atypical and may be associated with
psychological stressors. A sensory examination may be performed to assess the symptom.

Appendix C: Mechanism of Injury

Figure C-1. DoD TBI Diagnoses from 2002-2009 [127] Figure C-2. Leading Causes of mTBI [127]
In both blast and non-blast etiologies, primary injury can involve neurons, neuroglia, and vascular
structures.[128] A multitude of diffuse and dynamic processes also can contribute to secondary injury to include
hypoxia and hypotension. The result of this secondary process is the release of inflammatory cytokines,
initiation of an excitotoxic cascade, development of cerebral edema, and apoptotic signaling. The effects of free
radical oxygen species, excitatory amino acids, and fluctuations in ion gradients such as calcium, alterations in
neurotransmitters such as glutamate, receptor activation, lipid peroxidation, and mitochondrial uncoupling all
result in increased neurologic injury. While the extent of such processes may be limited within the mTBI
spectrum, the disturbances in brain metabolism and network connectivity associated with mTBI are related
more to the complex cascade of ionic, metabolic and physiologic events rather than to structural injury or
damage. The unique molecular activation and intracellular processes associated with individual mTBI etiologies
require continued investigation. In addition, the effect of these physiologic responses needs to be studied over a
variety of acute, sub-acute, and chronic time points in order to identify the underlying pathophysiology
associated with mTBI and its association with the development of chronic neurodegenerative changes in a
subpopulation of at-risk individuals.
An individual blast produces a complex mechanical profile consisting of a primary shock wave, followed
immediately by a period of negative pressure, generation of a supersonic blast wind, and a delayed period of
dissipating elevated pressure. However, depending on multiple blast and environmental variables this profile is
quickly modified. Primary blast injury originates from early time point interactions between the blast-induced
shock wave and the regional parenchyma and extra parenchymal tissues. This may result in a diffuse traumatic
injury which precedes the onset of any linear or rotational acceleration injury. Passage of the shock wave
through the tissues generates a combination of mechanical stresses which engage the neurons, glial cells,
extracellular matrix, vascular structures, and cerebrospinal fluid-containing structures. These forces include
spalling, shearing, mean and deviatoric stress, pressure, and volumetric tension. Secondary blast injury is related
to objects which are displaced by the blast overpressure and blast wind. Secondary injuries may include a
combination of both penetrating and blunt trauma. Tertiary blast injury occurs when an individual is thrown by
the blast, sustaining blunt trauma such as a closed brain injury. Quaternary blast injuries, such as burns,
chemical exposure, and asphyxia are directly related to the blast, but cannot be classified as a primary,
secondary, or tertiary injury. Physical effects of the primary blast on an individual depend not only on blast

characteristics but also on the physical relationship to the blast, such as the distance from the blast and
exposure in an open environment versus an enclosed structure.
While isolated head trauma does occur, often mTBI blast-related mechanisms of TBI are associated with multi-
system polytrauma and complicated by factors known to exacerbate secondary injury such as hypotension,
hypoxia, and hypothermia, and primary blast effects on an individual likely do not often occur in the absence of
secondary or tertiary blast effects, due to the narrower radius of primary blast dispersion compared with more
widespread dispersion of blast fragment. The neurometabolic cascade following TBI is diverse and dynamic. The
contribution of any particular physiologic response varies based on the magnitude of the forces involved,
environmental features, and an individual's unique characteristics at the time of the event. Potential modifiers
include, but are not limited to, genetic profile and epigenetic response to blast or non-blast stimulus, a history of
previous TBI, general medical conditions, sleep deprivation, increased levels of stress hormone, and nutritional
and hydration status.
Non-blast injuries are associated with focal, multifocal, and diffuse injury. Coup/contracoup injury is the result of
a mismatch in brain and skull movement. When the skull moves faster than the brain, the brain will strike the
inner table of the calvarium causing a focal contusion, then, after the skull and brain have stopped their initial
direction of movement, the brain may rebound in the opposite direction and impact the calvarium a second
time. The orbitofrontal and anterior temporal lobes are most often affected as these are the most common sites
of impact from motor vehicle accidents and sports-related injuries. The secondary effects of an
acceleration/deceleration injury include edema and hemorrhage. Depending on the individual forces
transmitted during an event, white matter injury through axonal stretch may play a prominent role in the
pathology and clinical sequelae associated with both blast and non-blast mechanisms of TBI. With increased
energy transfer, acceleration/deceleration is the primary etiology associated with diffuse axonal injury (DAI) and
can occur as a primary mechanism of injury in closed brain injury or as a secondary force associated with blast
exposure. A complex interrelationship exists between impact location, linear and rotational acceleration and
concussion as a primary or secondary effect of acceleration/deceleration forces. To what extent the addition of
shock wave propagation plays in modulation of biomechanical properties and what, if any, distinct physiologic
effects are generated from the cumulative effects of blast plus acceleration, rather than either primary
mechanism of injury in isolation, is currently unknown.
In the systematic evidence review for the current mTBI CPG, six prognostic cohort studies were reviewed
specifically as they related to either the treatment or outcome prognostication of mTBI. Four of the studies
evaluated blast versus non-blast cohorts; however, none of the studies were specifically designed to evaluate
mechanisms of injury or effectiveness of treatment. Treatment was not controlled for, nor was it reported in any
of the included studies. Cooper et al. included blast versus non-blast mechanism of injury as part of a
multivariable analysis in an attempt to identify prognostic variables of outcome.[129] The study was limited in
that it did not control for treatment, diagnosis was based on a retrospective self-report, it included a
significantly heterogeneous population and the time from injury was delayed with an average time from injury
of 354 (+/-457) days. However, even with this heterogeneous population, the mechanism of injury, blast versus
non-blast and time from injury combined accounted for only 1.4% of variance and was not a statistically
significant predictor of neurocognitive outcome. MacDonald et al. evaluated outcomes between combat-
associated blast and non-blast mTBI using the Glasgow Outcome Scale (GOS) at six and 12 months from injury
and found no significant difference between the two cohorts.[36] This study is severely limited in that the blast-

exposed cohort has no objective validation of overpressure exposure, and environmental data such as mounted
versus dismounted exposure, direct versus shielded exposure, explosive device, and distance from exposure are
not provided. MacDonald et al. did report that the non-blast TBI group had significantly more olfactory deficits
which would be consistent with a primary axonal stretch injury such as acceleration/deceleration etiology.[36]
Belanger et al. evaluated the reported symptoms between patients who had sustained blast and non-blast
mechanism of mTBI using a Neurobehavioral Symptom Inventory (NSI).[33] While there were limitations in
retrospective data collection, subjective event reporting, and a significant variance in time from injury between
the two groups (mean blast exposure time since injury was 11.9 months and mean time from injury for non-
blast TBI was 25.9 months), the study found no significant effect regarding mechanism of injury on the NSI score.
The study did note that hearing difficulties were the only significant symptoms difference between the groups
with more severe hearing difficulty in the blast group. Cooper et al. examined the relationship between combat
stress and post-concussive symptoms and found that there was no association between the mechanism of
injury, blast versus non-blast, and the observed differences in post-concussive symptoms.[34] Belanger et al.
found no difference in neurocognitive testing in patients with blast versus non-blast mechanisms at a mean time
of 1021 days from injury.[32] Finally, Lingsma et al. evaluated the performance of existing mTBI prognostic
models in a prospective, unselected population of patients with non-blast, closed head-associated mechanisms
of mTBI injury, to include assaults, motor vehicle accidents, and falls.[35] In a 21 variable univariate and
multivariable proportional odds regression model with three and six month Glasgow Outcome Score, Extended
(GOS-E) as ordinal outcomes, the study found that, in univariate analyses, assault was more predictive of a
worse outcome and in multivariable analyses assault was also associated with a worse outcome where falls and
motor vehicle accident did not vary.
Given the limited evidence base and lack of evidence to suggest a difference in mTBI symptoms, therapy and
outcomes should not be modified based on mechanism of injury at this time.

Appendix D: Evidence Table

2009 Strength of Recommendation
Recommendation Grade 29 Evidence30 Recommendation31 Category 32
1. We suggest using the terms “history of mild traumatic brain injury (mTBI)” Additional
References: Not Reviewed,
or “concussion” and to refrain from using the terms “brain damage” or None Weak for
Amended
“patients with mTBI” in communication with patients and the public. [10]
2. We recommend evaluating individuals who present with symptoms or Additional Not Reviewed,
Strong for
complaints potentially related to brain injury at initial presentation. None References: Amended
[12,14,15]
3. Excluding patients with indicators for immediate referral, for patients
identified by post-deployment screening or who present to care with
symptoms or complaints potentially related to brain injury, we suggest
against using the following tests to establish the diagnosis of mTBI or
direct the care of patients with a history of mTBI: [16-20]
a. Neuroimaging Reviewed, New-
None, I Weak against
Additional replaced
b. Serum biomarkers, including S100 calcium-binding protein B (S100-B),
glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal References:
esterase L1 (UCH-L1), neuron specific enolase (NSE), and α-amino-3- [130]
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) peptide
4. We recommend against performing comprehensive neuropsychological/ Additional
Strong against Not Reviewed,
cognitive testing during the first 30 days following mTBI. For patients with D References:
symptoms persisting after 30 days, see Recommendation 17. Amended
[21-24]
29 The 2009 VA/DoD mTBI CPG used the U.S. Preventive Services Task Force (USPSTF) evidence grading system (http://www.uspreventiveservicestaskforce.org). Inclusion of
more than one 2009 Grade indicates that more than one 2009 CPG recommendation is covered under the 2016 recommendation.
30 The evidence column indicates studies that support each recommendation. For new recommendations, developed by the 2016 guideline Work Group, the literature cited
corresponds directly to the 2015 evidence review. For recommendations that have been carried over from the 2009 VA/DoD mTBI CPG, slight modifications were made to
the language in order to better reflect the current evidence and/or the change in grading system used for assigning the strength of each recommendation (USPSTF to
GRADE). For these “modified” recommendations, the evidence column indicates “additional evidence,” which can refer to either 1) studies that support the
recommendation and which were identified through the 2015 evidence review, or 2) relevant studies that support the recommendation, but which were not systematically
identified through a literature review.
31 Refer to the Grading Recommendations section for more information on how the strength of the recommendation was determined using GRADE methodology.
32 Refer to the Recommendation Categorization section for more information on the description of the categorization process and the definition of each category.


5. For patients identified by post-deployment screening or who present to
care with symptoms or complaints potentially related to brain injury, we
recommend against using the following tests in routine diagnosis and care
of patients with symptoms attributed to mTBI: [25-30] Reviewed, New-
None Strong against
a. Comprehensive and focused neuropsychological testing, including replaced
Automated Neuropsychological Assessment Metrics (ANAM), Neuro-
Cognitive Assessment Tool (NCAT), or Immediate Post-Concussion
Assessment and Cognitive Testing (ImPACT)
6. For patients with new symptoms that develop more than 30 days after Additional
mTBI, we suggest a focused diagnostic work-up specific to those symptoms References: Not Reviewed,
None Weak for
only. Amended
[31]
7. We recommend assessing patients with symptoms attributed to mTBI for
psychiatric symptoms and comorbid psychiatric disorders including major Additional
Strong for Not Reviewed,
depressive disorder (MDD), posttraumatic stress disorder (PTSD), None References:
Amended
substance use disorders (SUD) and suicidality. Consult appropriate VA/DoD [15,32-39]
clinical practice guidelines.
8. We suggest considering, and offering as appropriate, a primary care, Additional
symptom-driven approach in the evaluation and management of patients References: Not Reviewed,
None, C Weak for
with a history of mTBI and persistent symptoms. Amended
[43,44]
9. We recommend not adjusting treatment strategy based on mechanism of
-- [45,46] Strong against Reviewed, New-added
injury.
10. We recommend not adjusting outcome prognosis based on mechanism of
-- [45,46] Strong against Reviewed, New-added
injury.
11. We suggest that the treatment of headaches should be individualized and
tailored to the clinical features and patient preferences. The treatment
may include:
a. Headache education including topics such as stimulus control, use of
caffeine/tobacco/alcohol and other stimulants
Reviewed, New-
b. Non-pharmacologic interventions such as sleep hygiene education, None [47,49,50] Weak for
replaced
dietary modification, physical therapy (PT), relaxation and modification
of the environment (for specific components for each symptom, see
Appendix B: Clinical Symptom Management)
c. Pharmacologic interventions as appropriate both for acute pain and
prevention of headache attacks


12. In individuals with a history of mTBI who present with functional
impairments due to dizziness, disequilibrium, and spatial disorientation
symptoms, we suggest that clinicians offer a short-term trial of specific
vestibular, visual, and proprioceptive therapeutic exercise to assess the Weak for Reviewed, Amended
None [53-64]
individual’s responsiveness to treatment. Refer to occupational therapy
(OT), physical therapy (PT) or other vestibular trained care provider as
appropriate. A prolonged course of therapy in the absence of patient
13. There is no evidence to suggest for or against the use of any particular
-- [68] N/A Reviewed, New-added
modality for the treatment of tinnitus after mTBI.
14. There is no evidence to suggest for or against the use of any particular [72-74]
modality for the treatment of visual symptoms such as diplopia,
accommodation or convergence disorder, visual tracking deficits and/or -- Additional N/A Reviewed, New-added
photophobia after mTBI. References:
[69-71]
15. We suggest that treatment of sleep disturbance be individualized and
tailored to the clinical features and patient preferences, including the
assessment of sleep patterns, sleep hygiene, diet, physical activities and
sleep environment. The treatment may include, in order of preference:
a. Sleep education including education about sleep hygiene, stimulus [76]
control, use of caffeine/tobacco/alcohol and other stimulants
b. Non-pharmacologic interventions such as cognitive behavioral therapy None Additional Weak for Reviewed, Amended
specific for insomnia (CBTi), dietary modification, physical activity, References:
relaxation and modification of the sleep environment (for specific [77,78]
components for each symptoms see Appendix B: Clinical Symptom
Management)
c. Pharmacologic interventions as appropriate to aid in sleep initiation
and sleep maintenance
16. We recommend that the presence of psychological or behavioral
symptoms following mTBI should be evaluated and managed according to
A, I [83-87] Strong for Reviewed, Amended
existing evidence-based clinical practice guidelines, and based upon
individual factors and the nature and severity of symptoms.


17. We suggest that patients with a history of mTBI who report cognitive
symptoms that do not resolve within 30-90 days and have been refractory to Additional
treatment for associated symptoms (e.g., sleep disturbance, headache) be References: Not Reviewed,
B Weak for
referred as appropriate for a structured cognitive assessment or Amended
neuropsychological assessment to determine functional limitations and guide [22,88]
treatment.
18. We suggest that individuals with a history of mTBI who present with
symptoms related to memory, attention or executive function problems
that do not resolve within 30-90 days and have been refractory to [92-95]
treatment for associated symptoms should be referred as appropriate to
cognitive rehabilitation therapists with expertise in TBI rehabilitation. We Reviewed, New-
C Additional Weak for
suggest considering a short-term trial of cognitive rehabilitation treatment replaced
to assess the individual patient responsiveness to strategy training, References:
including instruction and practice on use of memory aids, such as cognitive [22,88-91]
assistive technologies (AT). A prolonged course of therapy in the absence
of patient improvement is strongly discouraged.
19. We suggest against offering medications, supplements, nutraceuticals or Additional
References: Not Reviewed,
herbal medicines for ameliorating the neurocognitive effects attributed to None Weak against
Amended
mTBI. [97-103]
20. We suggest against routine referral to specialty care in the majority of
None [46,92,104] Weak against Reviewed, Amended
patients with a history of mTBI.
21. If the patient’s symptoms do not resolve within 30-90 days and are
refractory to initial treatment in primary care and significantly impact
None [104] Weak for Reviewed, Amended
activities of daily living (ADLs), we suggest consultation and collaboration
with a locally designated TBI or other applicable specialist.
22. For patients with persistent symptoms that have been refractory to initial
psychoeducation and treatment, we suggest referral to case managers
None [104] Weak for Reviewed, Amended
within the primary care setting to provide additional psychoeducation,
case coordination and support.
23. There is insufficient evidence to recommend for or against the use of
Reviewed, New-
interdisciplinary/multidisciplinary teams in the management of patients None [37,92] N/A
replaced
with chronic symptoms attributed to mTBI.

Appendix E: 2009 Recommendation Categorization

2009
CPG 2009 2016
Section 2009 CPG Recommendation Text 33 Grade 34 Category 35 Recommendation36
The following physical findings, signs and symptoms (“Red Flags”) may indicate an acute
neurologic condition that requires urgent specialty consultation (neurology, neuro-
surgical):
a. Altered consciousness
b. Progressively declining neurological examination
c. Pupillary asymmetry
d. Seizures
e. Repeated vomiting Not Reviewed,
A-2 - -
Deleted
f. Double vision
g. Worsening headache
h. Cannot recognize people or is disoriented to place
i. Behaves unusually or seems confused and irritable
j. Slurred speech
k. Unsteady on feet
l. Weakness or numbness in arms/legs
A diagnosis of mTBI should be made when there is an injury to the head as a result of
blunt trauma, acceleration or deceleration forces or exposure to blast that result in one or
more of the following conditions:
a. Any period of observed or self-reported:
i. Transient confusion, disorientation, or impaired consciousness Not Reviewed,
A-3 - -
ii. Dysfunction of memory immediately before or after the time of injury Deleted
iii. Loss of consciousness (LOC) lasting less than 30 minutes.
b. Observed signs of neurological or neuropsychological dysfunction, such as:
i. Headache, dizziness, irritability, fatigue or poor concentration, when identified soon
after injury, can be used to support the diagnosis of mild TBI, but cannot be used to
33 The 2009 Recommendation Text column contains the wording of each recommendation from the 2009 mTBI CPG.
34 The 2009 VA/DoD mTBI CPG used the U.S. Preventive Services Task Force (USPSTF) evidence grading system (http://www.uspreventiveservicestaskforce.org). The strength of
recommendations were rated as follows: A- a strong recommendation that the clinicians provide the intervention to eligible patients; B- a recommendation that clinicians
provide (the service) to eligible patients; C- no recommendation for or against the routine provision of the intervention is made; D- recommendation is made against
routinely providing the intervention; I- the conclusion is that the evidence is insufficient to recommend for or against routinely providing the intervention.
35 The Category column indicates the way in which each 2009 mTBI CPG recommendation was updated. See Recommendation Categorization for more information.
36 For recommendations that were carried forward to the 2016 mTBI CPG, this column indicates the new recommendation(s) to which they correspond.

2009
CPG 2009 2016
make the diagnosis in the absence of loss of consciousness or altered
consciousness.
The severity of TBI must be defined by the acute injury characteristics and not by the Not Reviewed,
A-3 - -
severity of symptoms at random points after trauma. Deleted
Management of Service Members presenting for care immediately after a brain injury
(within 7 days) during military combat or ongoing operation should follow guidelines for
Not Reviewed,
A-5 acute management published by DoD. (See: Recommendations for acute management of - -
Deleted
concussion/mTBI in the deployed setting, Defense and Veterans Brain Injury Center
Consensus August, 2008) (This guidance is not included in this evidence-based guideline.)
Management of non-deployed Service Members, Veterans, or civilian patients presenting
for care immediately after a brain injury (within 7 days) should follow guidelines for acute
management. (See Recommendations for acute management in guideline published by Not Reviewed,
A-6 - -
the American College of Emergency Medicine and the Center for Disease Control and Deleted
Prevention (ACEP/CDC, 2008) (These protocols and guidance are not included in this
evidence-based guideline.)
Service Members or Veterans identified by post deployment screening or who present
with symptoms should be assessed and diagnosed according to Algorithm A – Initial Reviewed, New-
A-6 - Recommendation 5
Presentation. The initial evaluation and management will then follow the replaced
recommendations in Algorithm B – Management of Symptoms.
Patients who continue to complain of concussion/mTBI-related symptoms beyond 4 to 6
weeks after treatment has been initiated, should have the assessment for these chronic Not Reviewed,
A-6 - -
symptoms repeated and should be managed using Algorithm C – Follow-up Persistent Deleted
Symptoms.
Patients who continue to have persistent symptoms despite treatment for persistent
symptoms (Algorithm C) beyond 2 years post-injury do not require repeated assessment Not Reviewed,
for these chronic symptoms and should be conservatively managed using a simple Amended
symptom-based approach.
Patients with symptoms that develop more than 30 days after a concussion should have a
focused diagnostic work-up specific to those symptoms only. These symptoms are highly Not Reviewed,
unlikely to be the result of the concussion and therefore the work-up and management Amended
should not focus on the initial concussion.
Persons who complain about somatic, cognitive or behavioral difficulties after
Not Reviewed,
A-7 concussion/mTBI should be assessed and treated symptomatically regardless of the - -
Deleted
elapsed time from injury.
The assessment of an individual with persistent concussion /mTBI related symptoms Not Reviewed,
A-7 - -
should be directed to the specific nature of the symptoms regardless of their etiology. Deleted

2009
CPG 2009 2016
The management of an individual who has sustained a documented concussion/mTBI and
has persistent physical, cognitive and behavioral symptoms after one month should not Not Reviewed,
A-7 - -
differ based on the specific underlying etiology of their symptoms (i.e., concussion vs. Deleted
pain, concussion vs. stress disorder).
In communication with patients and the public, this guideline recommends using the term Not Reviewed,
concussion or history of mild-TBI and to refrain from using the term ‘brain damage.’ Amended
Individuals who sustain a concussion/mTBI and are asymptomatic should be reassured Not Reviewed,
A-8 - -
about recovery and advised about precautionary measures to prevent future brain injury. Deleted
Patients should be provided with written contact information and be advised to contact
Not Reviewed,
A-8 their healthcare provider for follow-up if their condition deteriorates or they develop - -
Deleted
symptoms.
Individuals who sustain a concussion/mTBI and are asymptomatic should be screened for Not Reviewed,
comorbid mental health disorders (MDD, PTSD, and SUD) and dangerousness. Amended
Individuals who are presumed to have symptoms related to concussion/mTBI or who are
Not Reviewed,
B-2 identified as positive for mTBI on the initial screening should receive specific assessment - Recommendation 6
Amended
of their symptoms.
Medical history should include the following:
a. Obtaining detailed information on the patient's symptoms and health concerns.
b. Obtaining detailed information of the injury event including mechanism of injury,
duration and severity of alteration of consciousness, immediate symptoms, symptom
course and prior treatment
c. Screening for pre-morbid conditions, potential co-occurring conditions or other Not Reviewed,
B-2 - -
psychosocial risk factors, such as substance use disorders that may exacerbate or Deleted
maintain current symptom presentation (using standardized screening tools such as,
PHQ-2, Audit-C, PTSD screen)
d. Evaluating signs and symptoms indicating potential for neurosurgical emergencies that
require immediate referrals
e. Assessing of danger to self or others.
Patient’s experiences should be validated by allowing adequate time for building a Not Reviewed,
B-2 - -
provider-patient alliance and applying a risk communication approach. Deleted

2009
CPG 2009 2016
The physical examination of the person sustaining a concussion/mTBI should focus on the
following:
a. A focused neurologic examination, including a Mental Status Examination (MSE),
cranial nerve testing, extremity tone testing, deep tendon reflexes, strength, sensation,
and postural stability (Romberg’s Test, dynamic standing) Not Reviewed,
B-2 - -
Deleted
b. A focused vision examination including gross acuity, eye movement, binocular function
and visual fields/attention testing
c. A focused musculoskeletal examination of the head and neck, including range of
motion of the neck and jaw, and focal tenderness and referred pain.
The following physical findings, signs and symptoms (“Red Flags”) may indicate an acute
neurologic condition that requires urgent specialty consultation (neurology, neuro-surgical):
a. Altered consciousness
b. Progressively declining neurological examination
c. Pupillary asymmetry
d. Seizures
e. Repeated vomiting Not Reviewed,
B-2 - -
f. Double vision Deleted
g. Worsening headache
h. Cannot recognize people or is disoriented to place
i. Behaves unusually or seems confused and irritable
j. Slurred speech
k. Unsteady on feet
l. Weakness or numbness in arms/legs.
Laboratory testing is not necessary to confirm or manage symptoms associated with Reviewed, New-
B-2 - Recommendation 3
concussion/mTBI. replaced
Laboratory testing may be considered for evaluating other non-TBI causes of the Reviewed, New-
symptoms presented. replaced
There is insufficient evidence to support the use of serum biomarkers for Reviewed, New-
B-2 I Recommendation 3
concussion/mTBI in clinical practice. replaced
A patient who presents with any signs or symptoms that may indicate an acute neurologic
Not Reviewed,
B-2 condition that requires urgent intervention should be referred for evaluation that may - -
Deleted
include neuroimaging studies.

2009
CPG 2009 2016
Neuroimaging is not recommended in patients who sustained a concussion/mTBI beyond
Reviewed,
B-2 the emergency phase (72 hours post-injury) except if the condition deteriorates or red - Recommendation 3
Amended
flags are noted.
The management of a patient who has sustained multiple concussions should be similar Not Reviewed,
B-2 I -
to the management for a single concussion/mTBI. Deleted
The patient with multiple concussions and his/her family should be educated to create a Not Reviewed,
B-2 I -
positive expectation of recovery. Deleted
Self-reported symptomatology is an appropriate assessment of the patient’s condition in
Not Reviewed,
B-3 concussion/mTBI when the history is consistent with having sustained an injury event and [SR = C] Recommendation 8
Amended
having a subsequent alteration in consciousness.
Assessment of the patient with concussion/mTBI should include detailed questioning
Not Reviewed,
B-3 about the frequency, intensity and nature of symptoms the patient experiences, and their - -
Deleted
impact on the patient’s social and occupational functioning.
Assessment should include a review of all prescribed medications and over-the-counter
Not Reviewed,
B-3 supplements for possible causative or exacerbating influences. These should include - -
Deleted
caffeine, tobacco and other stimulants, such as energy drinks.
The patient who sustained a concussion/mTBI should be assessed for sleep patterns and Reviewed,
sleep hygiene. Amended
If the patient’s symptoms significantly impact daily activities (such as child care, safe
Reviewed,
B-3 driving), a referral to rehabilitation specialists for a functional evaluation and treatment - Recommendation 21
Amended
should be considered.
Not Reviewed,
B-5 Develop and document a summary of the patient’s problems. - -
Deleted
Develop a potential treatment plan that includes severity and urgency for treatment Not Reviewed,
B-5 - -
interventions. Deleted
Discuss with the patient the general concept of concussion sequelae, treatment options
Not Reviewed,
B-5 and associated risk/benefits and prognosis of illness to determine the patient’s - -
Deleted
preferences.
Not Reviewed,
B-5 Emphasizing good prognosis and empowering the patient for self-management. - -
Deleted
Not Reviewed,
B-5 Implement the treatment plan and follow up. - -
Deleted
Referral to specialty care is not required in the majority of patients with concussion/mTBI, Reviewed,
if their symptoms resolve in the early post-acute recovery period as expected. Amended

2009
CPG 2009 2016
Treatment should be coordinated and may include consultation with rehabilitation Reviewed, New-
therapists, pharmacy, collaborative mental health, and social support. replaced
Patients who sustain a concussion/mTBI should be provided with information and
education about concussion/mTBI symptoms and recovery patterns as soon as possible
after the injury. Education should be provided in printed material combined with verbal
review and consist of: a.[SR = A]
a. Symptoms and expected outcome b.[SR = A] Not Reviewed,
B-6 -
b. Normalizing symptoms (education that current symptoms are expected and common c.[SR = A] Deleted
after injury event) d.[SR = B]
c. Reassurance about expected positive recovery
d. Techniques to manage stress (e.g., sleep education, relaxation techniques; minimize
consumption of alcohol, caffeine and other stimulants).
Information and education should also be offered to the patient’s family, friends, Not Reviewed,
B-6 - -
employers, and/or significant others. Deleted
Symptomatic management should include tailored education about the specific signs and Not Reviewed,
B-6 - -
symptoms that the patient presents and the recommended treatment. Deleted
Patients should be provided with written contact information and be advised to contact
Not Reviewed,
B-6 their healthcare provider for follow-up if their condition deteriorates or if symptoms [SR = B] -
Deleted
persist for more than 4-6 weeks.
Provide early intervention maximizing the use of non-pharmacological therapies:
a. Review sleep patterns and hygiene and provide sleep education including education Reviewed,
about excess use of caffeine/tobacco/alcohol and other stimulants Amended
b. Recommend graded aerobic exercise with close monitoring.
Immediately following any concussion/mTBI, individuals who present with post-injury
Not Reviewed,
B-7 symptoms should have a period of rest to avoid sustaining another concussion and to - -
Deleted
facilitate a prompt recovery.
Individuals with concussion/mTBI should be encouraged to expediently return to normal Not Reviewed,
B-7 - -
activity (work, school, duty, leisure) at their maximal capacity. Deleted
In individuals who report symptoms of fatigue, consideration should be given to a graded Not Reviewed,
B-7 - -
return to work/activity. Deleted
In instances where there is high risk for injury and/or the possibility of duty-specific tasks
that cannot be safely or competently completed, an assessment of the symptoms and Not Reviewed,
B-7 - -
necessary needs for accommodations should be conducted through a focused interview Deleted
and examination of the patient.

2009
CPG 2009 2016
If a person's normal activity involves significant physical activity, exertional testing can be Not Reviewed,
B-7 - -
conducted that includes stressing the body. Deleted
If exertional testing results in a return of symptoms, a monitored progressive return to Not Reviewed,
B-7 - -
normal activity as tolerated should be recommended. Deleted
Individually based work duty restriction should apply if:
a. There is a duty specific task that cannot be safely or competently completed based on
symptoms
Not Reviewed,
B-7 b. The work/duty environment cannot be adapted to the patient’s symptom-based - -
Deleted
limitation
c. The deficits cannot be accommodated
d. Symptoms reoccur
Initial treatment of physical complaints of a patient with concussion/mTBI should be Not Reviewed,
B-8 - -
based upon a thorough evaluation, individual factors and symptom presentation. Deleted
The evaluation should include:
a. Establishing a thorough medical history, completing a physical examination, and review
of the medical record (for specific components for each symptoms see Table B-2
Physical Symptoms-Assessment) Not Reviewed,
B-8 - -
Deleted
b. Minimizing low yield diagnostic testing
c. Identifying treatable causes (conditions) for patient’s symptoms
d. Referring for further evaluation as appropriate
The treatment should include:
a. Non-pharmacological interventions such as sleep hygiene education, physical therapy, Reviewed,
relaxation and modification of the environment Amended
b. Use of medications to relieve pain, enable sleep, relaxation and stress reduction
A consultation or referral to specialists for further assessment should occur when:
a. Symptoms cannot be linked to a concussion event (suspicion of another diagnosis) Recommendation 20
b. An atypical symptom pattern or course is present Reviewed, New-
B-8 -
c. Findings indicate an acute neurologic condition that requires urgent neurologic/neuro- replaced
surgical intervention Recommendation 21
d. There are other major co-morbid conditions requiring special evaluation
All individuals who sustain a concussion/mTBI should be provided with information and
Not Reviewed,
B-8 education about concussion/mTBI symptoms and recovery patterns as soon as possible [SR = A] -
Deleted
after the injury.

2009
CPG 2009 2016
A patient sustaining a concussion/mTBI should be evaluated for cognitive difficulties using Not Reviewed,
B-8 [SR = C] -
a focused clinical interview. Deleted
Comprehensive neuropsychological/cognitive testing is not recommended during the first Not Reviewed,
B-8 [SR = D] Recommendation 4
30 days post injury. Amended
If a pre-injury neurocognitive baseline was established in an individual case, then a post
Reviewed,
B-8 injury comparison may be completed by a psychologist but should be determined using [SR = B] -
Deleted
reliable tools and test-retest stability should be ensured.
Patients with concussion/mTBI should be screened for psychiatric symptoms and co- Not Reviewed,
morbid psychiatric disorders (Depression, Post Traumatic Stress, and Substance Use). Amended
Treatment of psychiatric/behavioral symptoms following concussion/mTBI should be psycho-
based upon individual factors and nature and severity of symptom presentation, and therapeutic
include both psychotherapeutic and pharmacological treatment modalities. [SR = A] Reviewed,
B-8 Recommendation 16
pharma- Amended
cological
[SR = I]
Individuals who sustain a concussion/mTBI and present with anxiety symptoms and/or
Not Reviewed,
B-8 irritability should be provided reassurance regarding recovery and offered a several week [SR = I] -
Deleted
trial of pharmacologic agents.
Medication for ameliorating the neurocognitive effects attributed to concussion/mTBI is Not Reviewed,
not recommended. Amended
Not Reviewed,
B-8 Treatment of concussion/mTBI should be symptom-specific. - Recommendation 8
Amended
Recommendation 11
Medications may be considered for headaches, musculoskeletal pain, depression/anxiety, Reviewed, New-
B-8 -
sleep disturbances, chronic fatigue or poor emotional control or lability. replaced
Recommendation 15
Reviewed,
B-8 Appropriate and aggressive pain management strategies should be employed. -
Deleted

2009
CPG 2009 2016
When prescribing any medication for patients who have sustained a concussion/mTBI, the
following should be considered:
a. Review and minimize all medication and over-the-counter supplements that may
exacerbate or maintain symptoms
b. Use caution when initiating new pharmacologic interventions to avoid the sedating
properties that may have an impact upon a person's attention, cognition, and motor
performance. Not Reviewed,
B-8 -
Deleted
c. Recognize the risk of overdose with therapy of many medication classes (e.g.,
tricyclics). Initial quantities dispensed should reflect this concern.
d. Initiate therapy with the lowest effective dose, allow adequate time for any drug trials,
and titrate dosage slowly based on tolerability and clinical response.
e. Document and inform all those who are treating the person of current medications and
any medication changes
There is no contraindication for return to aerobic, fitness and therapeutic activities after
concussion/mTBI. Non-contact, aerobic and recreational activities should be encouraged Not Reviewed,
B-8 [SR = B]
within the limits of the patient’s symptoms to improve physical, cognitive and behavioral Deleted
complaints and symptoms after concussion/mTBI.
Specific vestibular, visual, and proprioceptive therapeutic exercise is recommended for Reviewed,
dizziness, disequilibrium, and spatial disorientation impairments after concussion/mTBI. Amended
Specific therapeutic exercise is recommended for acute focal musculoskeletal Not Reviewed,
B-8 -
impairments after concussion/mTBI. Deleted
Complementary-alternative medicine treatments may be considered as adjunctive Not Reviewed,
B-8 [SR = I]
treatments or when requested by individuals with concussion/mTBI. Deleted
All patients should be followed up in 4 – 6 weeks to confirm resolution of symptoms and Not Reviewed,
B-9 -
address any concerns the patient may have. Deleted
Follow-up after the initial interventions is recommended in all patients to determine
patient status. The assessment will determine the following course of treatment:
a. Patient recovers from acute symptoms – provide contact information with instructions
for available follow-up if needed.
b. Patient demonstrates partial improvement (e.g., less frequent headaches, resolution of Not Reviewed,
B-9 -
physical symptoms, but no improvement in sleep) – consider augmentation or Deleted
adjustment of the current intervention and follow-up within 4-6 weeks.
c. Patient does not improve or status worsens – Focus should be given to other factors
including psychiatric, psychosocial support, and compensatory/litigation. Referral to a
specialty provider should be considered

2009
CPG 2009 2016
Follow-up after the initial interventions is recommended in all patients with Not Reviewed,
C-2 -
concussion/mTBI to determine patient status and the course of treatment Deleted
Evaluation of patients with persistent symptoms following concussion/mTBI should Not Reviewed,
C-2 - Recommendation 7
include assessment for dangerousness to self or others. Amended
In assessment of patients with persistent symptoms, focus should be given to other
factors including psychiatric, psychosocial support, and compensation/litigation issues
and a comprehensive psychosocial evaluation should be obtained, to include:
a. Support systems (e.g., family, vocational)
b. Mental health history for pre-morbid conditions which may impact current care
c. Co-occurring conditions (e.g., chronic pain, mood disorders, stress disorder, personality Not Reviewed,
disorder) Amended
d. Substance use disorder (e.g., alcohol, prescription misuse, illicit drugs, caffeine)
e. Secondary gain issues (e.g., compensation, litigation)
f. Unemployment or/change in job status
g. Other issues (e.g., financial/housing/legal)
Assessment of the patient with concussion/mTBI should include a detailed history
regarding potential pre-injury, peri-injury, or post-injury risk factors for poorer outcomes.
These risk factors include:
a. Pre-injury: older age, female gender, low socio-economic status, low education or
lower levels of intellectual functioning, poorer coping abilities or less resiliency, pre- Not Reviewed,
C-3 existing mental health conditions (e.g., depression, anxiety, PTSD, substance use -
Deleted
disorders).
b. Peri-injury: lower levels of or less available social support.
c. Post-injury: injury-related litigation or compensation, comorbid mental health
conditions or chronic pain, lower levels of or less available social support
Not Reviewed,
C-3 Any substance abuse and/or intoxication at the time of injury should be documented. - Recommendation 7
Amended
Establish and document if the patient with concussion/mTBI experienced headaches, Not Reviewed,
C-3 -
dizziness, or nausea in the hours immediately following the injury. Deleted
Symptom exaggeration or compensation seeking should not influence the clinical care
Not Reviewed,
C-3 rendered, and doing so can be counter-therapeutic and negatively impact the quality of -
Deleted
care.
Focus of the provider-patient interaction should be on the development of a therapeutic Not Reviewed,
C-3 [SR=C]
alliance. Deleted

2009
CPG 2009 2016
For clinical treatment purposes the use of post-concussion syndrome, post-concussive
syndrome (PCS) or post-concussion disorder (PCD) as a diagnosis is not recommended. Not Reviewed,
C-3 -
The unique individual pattern of symptoms should be documented and be the focus of Deleted
treatment.
Patients with persistent symptoms following concussion/mTBI should be re-evaluated for Not Reviewed,
psychiatric symptoms and co-morbid psychiatric disorders. Amended
psycho-
therapeutic
Treatment of psychiatric symptoms following concussion/mTBI beyond the acute phase [SR = A] Reviewed,
C-4 should still be based on individual factors and nature and severity of symptom pharma- Recommendation 16
Amended
presentation, including psychotherapeutic and pharmacologic treatment modalities. cologic
[SR = I]
In patients with persistent post-concussive symptoms, which have been refractory to
Not Reviewed,
C-4 treatment, consideration should be given to other factors including psychiatric disorders, - Recommendation 7
Amended
lack of psychosocial support, and compensation/litigation.
A consultation or referral to specialists should occur in a patient with concussion/mTBI
who complains of persistent or chronic symptoms when:
a. An atypical pattern or course (worsening or variable symptom presentation) is
demonstrated Reviewed,
Amended
b. The patient is experiencing difficulties in return to pre-injury activity
(work/duty/school)
c. Problems emerge in the role of the patient in family or social life
Patients with multiple problems may benefit from an inter-disciplinary approach to
include occupational therapy, recreation therapy, social work, psychology and/or Reviewed, New-
psychiatry, neurology, ENT, ophthalmology or audiology, based on individual symptoms. replaced
The patient’s provider should remain involved in the patient’s care.
Referral to mental health specialty of patients with persistent behavioral symptoms Reviewed,
should be considered. Amended
Patients who are refractory to treatment of physical symptoms in the initial care setting Reviewed,
should be referred to specialty care for further evaluation and management. Amended
Patients who have cognitive symptoms that do not resolve or have been refractory to
treatment should be considered for referral for neuropsychological assessment. The Not Reviewed,
C-6 [SR = B] Recommendation 17
evaluation may assist in clarifying appropriate treatment options based on individual Amended
patient characteristics and conditions.

2009
CPG 2009 2016
Neuropsychological testing should only be conducted with reliable and standardized tools
Not Reviewed,
C-6 by trained evaluators, under controlled conditions, and findings interpreted by trained [SR = C]
Deleted
clinicians.
Individuals who present with memory, attention, and/or executive function problems
which did not respond to initial treatment (e.g., reassurance, sleep education, or pain
management) may be considered for referral to cognitive rehabilitation therapists with Reviewed, New-
C-6 [SR = C] Recommendation 18
expertise in TBI rehabilitation (e.g., speech-language pathology, neuropsychology, or replaced
occupational therapy) for compensatory training; and/or instruction and practice on use
of external memory aids such as a PDA.
Patients with persistent symptoms following concussion/mTBI may be considered for case Reviewed,
management. Amended
Case managers should complete a comprehensive psychosocial assessment of the patient
and the patient's family. It may be necessary or beneficial to meet with other members of Not Reviewed,
C-7 -
the patient’s support system (family, care giver) and/or invite the patient to ask them to Deleted
come to an appointment together with the patient.
Case managers should collaborate with the treatment team, the patient, and the patient's
Not Reviewed,
C-7 family in developing a treatment plan that emphasizes the psychosocial needs of the -
Deleted
patient.
Case managers (in collaboration with the treatment team) should prepare and document
Not Reviewed,
C-7 a detailed treatment plan in the medical record describing follow-up care and services -
Deleted
required.
Case managers who provide care in the clinical setting should communicate and
coordinate with other potential care coordinators that provide care for the patient (such Not Reviewed,
C-7 -
as a VHA social worker liaison or military social worker at the referring Military Treatment Deleted
Facility, Patient Treatment Advocate [PTA]).
Case managers may provide assistance to the patient and family who are transferred to Not Reviewed,
C-7 -
another facility (e.g., a polytrauma rehabilitation center). Deleted

2009
CPG 2009 2016
Case management may serve as the main point of contact for the patient and family. This
may include the following:
a. Provide the patient with contact information including after-hours calls
b. Maintain frequent contact by phone to remind about or facilitate an appointment
Not Reviewed,
C-7 c. Facilitate access to supportive services to the patient and family -
Deleted
d. Serve as a liaison for the patient's family and as an advocate for the patient and the
patient's family
e. Provide easy-to-understand information in writing for the patient and the patient's
family
All members of the treatment team should be involved in patient education as part of Not Reviewed,
C-7 -
their interaction with the patient experiencing persistent symptoms. Deleted
Educational interventions should generally include information and a description of the
Not Reviewed,
C-7 specific procedures and events the patient will experience at the various phases of -
Deleted
treatment and continue throughout the continuum of care.
General supportive counseling (e.g., eliciting and validating the patient’s anxieties, fears,
and concerns) may also be helpful. Open-ended questioning, active listening techniques,
eliciting anticipation of future stressors, encouraging the patient to ask questions, and Not Reviewed,
C-7 -
eliciting and encouraging utilization of the patient’s social support resources are Deleted
important strategies regardless of whether information-giving or coping skills training
interventions are being used.
Educational interventions may also include coping techniques for symptom management, Not Reviewed,
C-7 -
such as patient education handouts and helpful tips. Deleted
As with other chronic conditions, the focus of the management of patients with persistent
Not Reviewed,
C-7 symptoms following concussion/mTBI should shift to the psychological and social impacts -
Deleted
on the patient.
The clinician should consider having the spouse or partner accompany the patient with
Not Reviewed,
C-7 concussion/mTBI to a consultation, to help them better understand the condition and -
Deleted
provide an opportunity to discuss any coping difficulties.
Family members should be encouraged to consider joining a support group to provide
education, advice and opportunities to exchange coping strategies for dealing with the Not Reviewed,
C-7 -
day-to-day difficulties of living with an individual with persistent symptoms following Deleted
concussion/mTBI.

2009
CPG 2009 2016
Vocational interventions for the patient with persistent symptoms following concussion/
mTBI may include modifications such as:
a. Modification of the length of the work day
b. Gradual work re-entry (e.g., starting at 2 days/week and expanding to 3 days/week) Not Reviewed,
C-7 -
c. Additional time for task completion Deleted
d. Change of job
e. Environmental modifications (e.g., quieter work environment; enhanced level of
supervision)
Patients who have not successfully resumed pre-injury work duties following injury should
Not Reviewed,
C-7 be referred for a vocational evaluation by clinical specialists with expertise in assessing -
Deleted
and treating concussion/mTBI.
For patients with persistent symptoms following concussion/mTBI, return to full
work/duty in the jobs they have previously performed may not be possible. Patients may Not Reviewed,
C-7 -
need to proceed through medical or disability evaluation processes. This process should Deleted
follow national and local regulations and is beyond the scope of the guideline.
A referral to a structured program that promotes community integration may be
Not Reviewed,
C-7 considered for individuals with residual persistent post-concussive symptoms that impede -
Deleted
return to pre-injury participation in customary roles.
Scheduled follow-up visits are recommended. The amount of time between visits will vary
depending on a number of factors, including the following:
a. Quality of the provider/patient relationship
i. Distress of the patient
ii. Need for refinement of the treatment plan or additional support
iii. Presence or absence of psychosocial stressors.
b. Severity of the symptoms Not Reviewed,
C-8 -
i. Initially, a follow-up at two to three weeks would be appropriate Deleted
ii. As soon as the patient is doing well, then follow-up every 3 to 4 months would be
recommended
iii. Telephone follow-up may be sufficient to evaluate resolution of symptoms and
reinforce education
c. For concussion/mTBI patients with complicated histories, comorbidities, and lack of
social support consider case management
Continually re-evaluate the patient for worsening of chronic symptoms or presence of Not Reviewed,
new symptoms suggestive of other diagnoses. Amended

Appendix F: Participants List

Amy O. Bowles, MD Jennifer Burton, DPT
Chief, Brain Injury Rehabilitation Service Physical Therapy Clinician
San Antonio Military Medical Center George E. Whalen Veterans Affairs Medical Center Salt
Fort Sam Houston, TX Lake City, UT
Megan Chilson, PharmD David X. Cifu, MD (Co-Chair)
Clinical Pharmacist Senior TBI Specialist,
Department of Pharmacy National Director of PM&R Program Office
William Beaumont AMC Cabinet-appointed member, Senior Executive Staff
El Paso, TX Department of Veterans Affairs
Chairman and Herman J. Flax, M.D. Professor,
Department of PM&R
Founding Director, Center for Rehabilitation Sciences
and Engineering, Virginia Commonwealth University
Richmond, VA
Mary Dameron, MSN, RN, CRRN, CCM, CBIS Thomas J. DeGraba, MD
RN Case Manager Deputy Director, Chief of Medical Operations National
McGuire VA Medical Center Intrepid Center of Excellence (NICoE)
Richmond, VA Walter Reed National Military Medical Center
Bethesda, MD
Ernest Degenhardt, COL USA (Ret.), MSN, RN, ANP, Corinne K.B. Devlin MSN, RN, FNP-BC
FNP Chief, Office of Evidence Based Practice
Former Chief, Office of Evidence Based Practice Clinical Performance Directorate
Clinical Performance Directorate U.S. Army Medical Command
U.S. Army Medical Command Fort Sam Houston, TX
Fort Sam Houston, TX
CDR Josh L. Duckworth, MD Blessen C. Eapen, MD
Assistant Professor, Department of Neurology Section Chief, Polytrauma Rehabilitation Center
F. Edward Hébert School of Medicine Brain Injury Medicine/Polytrauma Fellowship Program
Uniformed Services University of the Health Sciences Director
Bethesda, MD South Texas Veterans Health Care System
San Antonio, TX
CDR Jeffrey Feinberg, MD, MPH, FAAFP Louis M. French, PsyD
Staff Family Physician Deputy Director for Operations
Department Head Family Medicine National Intrepid Center of Excellence (NICoE), Walter
Naval Hospital Camp Pendleton Reed National Military Medical Center
Oceanside, CA Bethesda, MD
COL Geoffrey G. Grammer, MD (Co-Chair) COL Sidney R. Hinds II, MD
Chief, Department of Research National Director, Defense and Veterans Brain Injury
National Intrepid Center of Excellence (NICoE) Center (DVBIC)
Walter Reed National Military Medical Center Defense Centers of Excellence for Psychological Health
Bethesda, MD and Traumatic Brain Injury (DCoE)
Silver Spring, MD
Charles W. Hoge, MD Robin A. Hurley, MD, FANPA
Senior Scientist, Walter Reed Army Institute of Associate Chief of Staff, Research and Academic Affairs
Research Salisbury VAMC
Neuropsychiatry Consultant, Office of the Army Professor, Wake Forest School of Medicine
Surgeon General Departments of Psychiatry and Radiology

Attending Psychiatrist, Walter Reed National Military Richmond, VA

Medical Center
Bethesda, MD
Timothy Lacy, MD Scott D. McDonald, PhD
Tri-Service Work Flow Team BH Lead Co-Director, VA VISN-6 MIRECC Advanced Fellowship
Contract Support (EHRTS) Program (Richmond)
Defense Health Headquarters Research Neuropsychologist
Office of the Chief Information Officer Affiliate Assistant Professor, Virginia Commonwealth
Silver Spring, MD University,
Departments of PM&R and Psychology
Hunter Holmes McGuire VA Medical Center
Richmond, VA
Linda M. Picon, MCD, CCC-SLP Ronald G. Riechers, II, MD
Speech-Language Pathologist Chief, Department of Neurology
VA Senior Consultant/TBI Liaison, Defense Centers of Medical Director, Polytrauma Team
Excellence Louis Stokes Cleveland VA Medical Center
Rehabilitation and Prosthetic Services, VA Central Assistant Professor, Department of Neurology
Office Case Western Reserve University
Washington, DC Cleveland, OH
M. Eric Rodgers, PhD, FNP, BC James Sall, PhD, FNP-BC
Director, VA/DoD Evidence-Based CPG Program Primary Care
Office of Quality, Safety & Value (10A4B) Chronic Disease Clinical Practice Guideline Coordinator,
Department of Veterans Affairs U.S. Army Medical Command Quality Management
Veterans Health Administration - Virtual Division, Office of Evidence Based Practice
Glendale, CO JBSA Fort Sam Houston, TX
Rene M. Sutton, BS, HCA COL Lisa Teegarden, PsyD (Co-Chair)
Educational Program Specialist, VA/DoD Evidence- Chief, Department of Psychology
Based CPG Program Walter Reed National Military Medical Center
Office of Quality, Safety and Value Bethesda, MD
Washington, DC
Kathryn Tortorice, PharmD, BCPS Linda Van Horn, MSN, BSN, CFNP
National PBM Clinical Pharmacy Program Manager, Polytrauma Coordinator
Neurology and Solid Organ Transplant New Mexico VA Health Care System
Chair, National Drug File Support Group Farmington, NM
National Pharmacy Benefits Management Services,
Hines, IL
Major Derrick F. Varner, PhD, DFAAPA Deborah Voydetich, OTR/L, SCLV
Clinical Coordinator, Interservice PA Program Occupational Therapy Discipline Lead
Graduate School, Academy of Health Sciences Blind Rehabilitation Planning Specialist
JBSA Fort Sam Houston, TX Minneapolis VA Health Care System
Minneapolis, MN

Appendix G: Acronym List

Abbreviation Definition
ACEM American College of Emergency Medicine
ADHD Attention deficit hyperactivity disorder
ADLs Activities of daily living
AOC Alteration of consciousness
AHRQ Agency for Healthcare Research and Quality
AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor peptide
ANAM Automated Neuropsychological Assessment Metrics
AT Assistive technologies
BPPV Benign paroxysmal positional vertigo
CBT Cognitive behavioral therapy
CBTi Cognitive behavioral therapy specific for insomnia
CCBT Computer-based cognitive behavioral therapy
CDC Centers for Disease Control and Prevention
CMI Chronic multisymptom illness
COR Contracting Officer’s Representative
CPG Clinical practice guideline
CT Computerized tomography
DAI Diffuse axonal injury
DCoE Defense Centers of Excellence
DoD Department of Defense
DTI Diffusion tensor imaging
DVBIC Defense and Veterans Brain Injury Center
EBPWG Evidence-Based Practice Working Group
EEG Electroencephalogram
ENT Ear, nose and throat
FA Fractional anisotropy
FAI Fatigue Assessment Instrument
FDA Food and Drug Administration
FIS Fatigue Impact Scale
GCS Glasgow Coma Scale
GAD-2 or GAD-7 Generalized Anxiety Disorder Scale
GFAP Glial fibrillary acidic protein
GI Gastrointestinal
GOS-E Glasgow Outcome Score, Extended
HTA Health technology assessment
IADLs Instrumental ADLs
IM Intramuscular
ImPACT Immediate Post-Concussion Assessment and Cognitive Testing

KQ Key question
LOC Loss of consciousness
MACE Military Acute Concussion Evaluation
MAF Multidimensional Assessment of Fatigue
MDD Major depressive disorder
MI Myocardial infarction
mTBI Mild traumatic brain injury
MRI Magnetic resonance imaging
MSE Mental Status Examination
NCAT Neuro-Cognitive Assessment Tool
NFL National Football League
NICE National Institute for Health and Care Excellence
NSAIDs Nonsteroidal anti-inflammatory drugs
NSE Neuron specific enolase
NSI Neurobehavioral Symptom Inventory
OEF Operation Enduring Freedom
OIF Operation Iraqi Freedom
OND Operation New Dawn
OT Occupational therapy
OTC Over-the-counter
OTSG Office of the Surgeon General
PACT Providers/patient aligned care team
PCD Post-concussion disorder
PCL PTSD Checklist
PCS Post-concussive syndrome
PDHA Post-Deployment Health Assessment
PHQ-2 or PHQ-9 Patient Health Questionnaire
PICOTS Population, Intervention, Comparison, Outcome, Timing and Setting
PT Physical therapy
PTA Posttraumatic amnesia
PTSD Posttraumatic stress disorder
RCT Randomized controlled trial
RSS Recovery Support Specialist Program (DVBIC)
rTMS Repetitive transcranial magnetic stimulation
S100-B S100 calcium-binding protein B
SNRI Serotonin-norepinephrine reuptake inhibitor
SPECT Single photon emission computed tomography
SSRI Selective serotonin reuptake inhibitor
SUD Substance use disorder
TBI Traumatic brain injury

TMS Transcranial magnetic stimulation
UCH-L1 Ubiquitin carboxyl-terminal esterase L1
USPSTF U.S. Preventive Services Task Force
VA Department of Veterans Affairs
VHA Veterans Health Administration

References
1. U.S. Department of Veteran Affairs, Department of Defense. Guideline for guidelines. Veterans Health
Administration, Office of Quality & Performance, Evidence Review Subgroup; Revised April 10, 2013.
2. Centers for Disease Control Prevention; National Center for Injury Prevention and Control; Division of
Unintentional Injury Prevention. Report to congress on traumatic brain injury in the United States:
Epidemiology and rehabilitation. Atlanta, GA: Centers for Disease Control Prevention; 2014.
3. Assistant Secretary of Defense. Traumatic brain injury: Updated definition and reporting. Washington,
DC: Department of Defense; 2015.
4. Defense and Veterans Brain Injury Center. About traumatic brain injury. Silver Spring, MD: 2015.
https://dvbic.dcoe.mil/about-tbi/about-traumatic-brain-injury?audience[0]=1. Updated February 2,
2016. Accessed February 2, 2016.
5. Guirguis-Blake J, Calonge N, Miller T, Siu A, Teutsch S, Whitlock E. Current processes of the U.S.
Preventive Services Task Force: Refining evidence-based recommendation development. Ann Intern
Med. Jul 17 2007;147(2):117-122.
6. The guidelines manual. London: National Institute for Health and Care Excellence;2012.
http://www.nice.org.uk/article/pmg6/resources/non-guidance-the-guidelines-manual-pdf.
7. Martinez Garcia L, McFarlane E, Barnes S, Sanabria AJ, Alonso-Coello P, Alderson P. Updated
recommendations: An assessment of NICE clinical guidelines. Implement Sci. 2014;9:72.
8. White CM, Ip S, McPheeters M, et al. AHRQ methods for effective health care using existing systematic
reviews to replace de novo processes in conducting comparative effectiveness reviews. Methods guide
for effectiveness and comparative effectiveness reviews. Rockville (MD): Agency for Healthcare Research
and Quality (US); 2008.
9. Society for Medical Decision Making Committee on Standardization of Clinical Algorithms. Proposal for
clinical algorithm standards. Med Decis Making. Apr-Jun 1992;12(2):149-154.
10. Wood RL. Understanding the 'miserable minority': A diasthesis-stress paradigm for post-concussional
syndrome. Brain Inj. Nov 2004;18(11):1135-1153.
11. Department of Defense Instruction. DoD policy guidance for management of mild traumatic brain
injury/concussion in the deployed setting. 6490.11: Department of Defense; September 18, 2012.
12. McCrea M, Guskiewicz K, Doncevic S, et al. Day of injury cognitive performance on the military acute
concussion evaluation (MACE) by U.S. Military service members in OEF/OIF. Mil Med. Sep
2014;179(9):990-997.
13. Coldren RL, Kelly MP, Parish RV, Dretsch M, Russell ML. Evaluation of the military acute concussion
evaluation for use in combat operations more than 12 hours after injury. Mil Med. Jul 2010;175(7):477-
481.
14. Vanderploeg RD, Belanger HG. Screening for a remote history of mild traumatic brain injury: When a
good idea is bad. J Head Trauma Rehabil. May-Jun 2013;28(3):211-218.
15. Hoge CW, Goldberg HM, Castro CA. Care of war veterans with mild traumatic brain injury--flawed
perspectives. N Engl J Med. Apr 16 2009;360(16):1588-1591.
16. Kim du S, Kong MH, Jang SY, Kim JH, Kang DS, Song KY. The usefulness of brain magnetic resonance
imaging with mild head injury and the negative findings of brain computed tomography. J Korean
Neurosurg Soc. Aug 2013;54(2):100-106.
17. Harnan SE, Pickering A, Pandor A, Goodacre SW. Clinical decision rules for adults with minor head injury:
A systematic review. J Trauma. Jul 2011;71(1):245-251.
18. Aoki Y, Inokuchi R, Gunshin M, Yahagi N, Suwa H. Diffusion tensor imaging studies of mild traumatic
brain injury: A meta-analysis. J Neurol Neurosurg Psychiatry. Sep 2012;83(9):870-876.
19. Mac Donald CL, Johnson AM, Cooper D, et al. Detection of blast-related traumatic brain injury in U.S.
Military personnel. N Engl J Med. Jun 2 2011;364(22):2091-2100.

20. Dambinova SA, Shikuev AV, Weissman JD, Mullins JD. AMPAR peptide values in blood of nonathletes and
club sport athletes with concussions. Mil Med. Mar 2013;178(3):285-290.
21. Comper P, Bisschop SM, Carnide N, Tricco A. A systematic review of treatments for mild traumatic brain
injury. Brain Inj. Oct 2005;19(11):863-880.
22. Belanger HG, Curtiss G, Demery JA, Lebowitz BK, Vanderploeg RD. Factors moderating
neuropsychological outcomes following mild traumatic brain injury: A meta-analysis. J Int Neuropsychol
Soc. May 2005;11(3):215-227.
23. Belanger HG, Vanderploeg RD. The neuropsychological impact of sports-related concussion: A meta-
analysis. J Int Neuropsychol Soc. Jul 2005;11(4):345-357.
24. Schretlen DJ, Shapiro AM. A quantitative review of the effects of traumatic brain injury on cognitive
functioning. Int Rev Psychiatry. Nov 2003;15(4):341-349.
25. Carroll LJ, Cassidy JD, Cancelliere C, et al. Systematic review of the prognosis after mild traumatic brain
injury in adults: Cognitive, psychiatric, and mortality outcomes: Results of the international collaboration
on mild traumatic brain injury prognosis. Arch Phys Med Rehabil. Mar 2014;95(3 Suppl):S152-173.
26. Pape TL, High WM, Jr., St Andre J, et al. Diagnostic accuracy studies in mild traumatic brain injury: A
systematic review and descriptive analysis of published evidence. Pm r. Oct 2013;5(10):856-881.
27. Iverson GL, Schatz P. Advanced topics in neuropsychological assessment following sport-related
concussion. Brain Inj. 2015;29(2):263-275.
28. Bayley MT, Tate R, Douglas JM, et al. INCOG guidelines for cognitive rehabilitation following traumatic
brain injury: Methods and overview. J Head Trauma Rehabil. Jul-Aug 2014;29(4):290-306.
29. Lange RT, Pancholi S, Bhagwat A, Anderson-Barnes V, French LM. Influence of poor effort on
neuropsychological test performance in U.S. Military personnel following mild traumatic brain injury. J
Clin Exp Neuropsychol. 2012;34(5):453-466.
30. Stulemeijer M, Vos PE, Bleijenberg G, van der Werf SP. Cognitive complaints after mild traumatic brain
injury: Things are not always what they seem. J Psychosom Res. Dec 2007;63(6):637-645.
31. Mooney G, Speed J, Sheppard S. Factors related to recovery after mild traumatic brain injury. Brain Inj.
Nov 2005;19(12):975-987.
32. Belanger HG, Kretzmer T, Yoash-Gantz R, Pickett T, Tupler LA. Cognitive sequelae of blast-related versus
other mechanisms of brain trauma. J Int Neuropsychol Soc. Jan 2009;15(1):1-8.
33. Belanger HG, Proctor-Weber Z, Kretzmer T, Kim M, French LM, Vanderploeg RD. Symptom complaints
following reports of blast versus non-blast mild TBI: Does mechanism of injury matter? Clin
Neuropsychol. Jul 2011;25(5):702-715.
34. Cooper DB, Kennedy JE, Cullen MA, Critchfield E, Amador RR, Bowles AO. Association between combat
stress and post-concussive symptom reporting in OEF/OIF service members with mild traumatic brain
injuries. Brain Inj. 2011;25(1):1-7.
35. Lingsma HF, Yue JK, Maas AI, et al. Outcome prediction after mild and complicated mild traumatic brain
injury: External validation of existing models and identification of new predictors using the track-TBI
pilot study. J Neurotrauma. Jan 15 2015;32(2):83-94.
36. Mac Donald CL, Johnson AM, Wierzechowski L, et al. Prospectively assessed clinical outcomes in
concussive blast vs nonblast traumatic brain injury among evacuated US military personnel. JAMA
Neurol. Aug 2014;71(8):994-1002.
37. Browne AL, Appleton S, Fong K, et al. A pilot randomized controlled trial of an early multidisciplinary
model to prevent disability following traumatic injury. Disabil Rehabil. Jul 2013;35(14):1149-1163.
38. Hoge CW, Castro CA. Treatment of generalized war-related health concerns: Placing TBI and PTSD in
context. Jama. Oct 22-29 2014;312(16):1685-1686.
39. Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA. Mild traumatic brain injury in U.S. Soldiers
returning from iraq. N Engl J Med. Jan 31 2008;358(5):453-463.

40. Centers for Disease Control and Prevention; National Center for Injury Prevention and Control. Report to
congress on mild traumatic brain injury in the United States: Steps to prevent a serious public health
problem. Atlanta, GA: Centers for Disease Control and Prevention; 2003.
41. Owens BD, Kragh JF, Jr., Wenke JC, Macaitis J, Wade CE, Holcomb JB. Combat wounds in operation Iraqi
Freedom and operation Enduring Freedom. J Trauma. Feb 2008;64(2):295-299.
42. Sayer NA, Chiros CE, Sigford B, et al. Characteristics and rehabilitation outcomes among patients with
blast and other injuries sustained during the global war on terror. Arch Phys Med Rehabil. Jan
2008;89(1):163-170.
43. Belanger HG, Uomoto JM, Vanderploeg RD. The Veterans Health Administration's (VHA's) polytrauma
system of care for mild traumatic brain injury: Costs, benefits, and controversies. J Head Trauma
Rehabil. Jan-Feb 2009;24(1):4-13.
44. Brenner LA, Vanderploeg RD, Terrio H. Assessment and diagnosis of mild traumatic brain injury,
posttraumatic stress disorder, and other polytrauma conditions: Burden of adversity hypothesis. Rehabil
Psychol. Aug 2009;54(3):239-246.
45. Bauman RA, Ling G, Tong L, et al. An introductory characterization of a combat-casualty-care relevant
swine model of closed head injury resulting from exposure to explosive blast. J Neurotrauma. Jun
2009;26(6):841-860.
46. Bell RS, Vo AH, Neal CJ, et al. Military traumatic brain and spinal column injury: A 5-year study of the
impact blast and other military grade weaponry on the central nervous system. J Trauma. Apr 2009;66(4
Suppl):S104-111.
47. Uomoto JM, Esselman PC. Traumatic brain injury and chronic pain: Differential types and rates by head
injury severity. Arch Phys Med Rehabil. Jan 1993;74(1):61-64.
48. Nampiaparampil DE. Prevalence of chronic pain after traumatic brain injury: A systematic review. Jama.
Aug 13 2008;300(6):711-719.
49. Silberstein SD, Olesen J, Bousser MG, et al. The international classification of headache disorders, 2nd
edition (ICHD-II)--revision of criteria for 8.2 medication-overuse headache. Cephalalgia. Jun
2005;25(6):460-465.
50. Lew HL, Lin PH, Fuh JL, Wang SJ, Clark DJ, Walker WC. Characteristics and treatment of headache after
traumatic brain injury: A focused review. Am J Phys Med Rehabil. Jul 2006;85(7):619-627.
51. Cicerone KD, Kalmar K. Persistent postconcussion syndrome: The structure of subjective complaints
after mild traumatic brain injury. The Journal of Head Trauma Rehabilitation. 1995;10(3):1-17.
52. Terrio H, Brenner LA, Ivins BJ, et al. Traumatic brain injury screening: Preliminary findings in a US army
brigade combat team. J Head Trauma Rehabil. Jan-Feb 2009;24(1):14-23.
53. Ernst A, Basta D, Seidl RO, Todt I, Scherer H, Clarke A. Management of posttraumatic vertigo.
Otolaryngol Head Neck Surg. Apr 2005;132(4):554-558.
54. Hoffer ME, Gottshall KR, Moore R, Balough BJ, Wester D. Characterizing and treating dizziness after mild
head trauma. Otol Neurotol. Mar 2004;25(2):135-138.
55. Staab JP, Ruckenstein MJ. Expanding the differential diagnosis of chronic dizziness. Arch Otolaryngol
Head Neck Surg. Feb 2007;133(2):170-176.
56. Gottshall KR, Gray NL, Drake AI, Tejidor R, Hoffer ME, McDonald EC. To investigate the influence of acute
vestibular impairment following mild traumatic brain injury on subsequent ability to remain on activity
duty 12 months later. Mil Med. Aug 2007;172(8):852-857.
57. Catena RD, van Donkelaar P, Chou LS. Altered balance control following concussion is better detected
with an attention test during gait. Gait Posture. Mar 2007;25(3):406-411.
58. Heitger MH, Jones RD, Dalrymple-Alford JC, Frampton CM, Ardagh MW, Anderson TJ. Motor deficits and
recovery during the first year following mild closed head injury. Brain Inj. Jul 2006;20(8):807-824.
59. Parker TM, Osternig LR, P VAND, Chou LS. Gait stability following concussion. Med Sci Sports Exerc. Jun
2006;38(6):1032-1040.

60. Savola O, Hillbom M. Early predictors of post-concussion symptoms in patients with mild head injury.
Eur J Neurol. Mar 2003;10(2):175-181.
61. Herdman SJ, Clendaniel RA, Mattox DE, Holliday MJ, Niparko JK. Vestibular adaptation exercises and
recovery: Acute stage after acoustic neuroma resection. Otolaryngol Head Neck Surg. Jul
1995;113(1):77-87.
62. Shepard NT, Telian SA. Programmatic vestibular rehabilitation. Otolaryngol Head Neck Surg. Jan
1995;112(1):173-182.
63. Yardley L, Beech S, Zander L, Evans T, Weinman J. A randomized controlled trial of exercise therapy for
dizziness and vertigo in primary care. Br J Gen Pract. Apr 1998;48(429):1136-1140.
64. Naguib MB, Madian YT. Betahistine dihydrochloride with and without early vestibular rehabilitation for
the management of patients with balance disorders following head trauma: A preliminary randomized
clinical trial. J Chiropr Med. Mar 2014;13(1):14-20.
65. Theodoroff SM, Lewis MS, Folmer RL, Henry JA, Carlson KF. Hearing impairment and tinnitus:
Prevalence, risk factors, and outcomes in US service members and veterans deployed to the iraq and
afghanistan wars. Epidemiol Rev. 2015;37:71-85.
66. Oleksiak M, Smith BM, St Andre JR, Caughlan CM, Steiner M. Audiological issues and hearing loss among
veterans with mild traumatic brain injury. J Rehabil Res Dev. 2012;49(7):995-1004.
67. Lew HL, Jerger JF, Guillory SB, Henry JA. Auditory dysfunction in traumatic brain injury. J Rehabil Res Dev.
2007;44(7):921-928.
68. Henry JA, Zaugg TL, Myers PJ, et al. Pilot study to develop telehealth tinnitus management for persons
with and without traumatic brain injury. J Rehabil Res Dev. 2012;49(7):1025-1042.
69. Brahm KD, Wilgenburg HM, Kirby J, Ingalla S, Chang CY, Goodrich GL. Visual impairment and dysfunction
in combat-injured service members with traumatic brain injury. Optom Vis Sci. Jul 2009;86(7):817-825.
70. Magone MT, Kwon E, Shin SY. Chronic visual dysfunction after blast-induced mild traumatic brain injury.
J Rehabil Res Dev. 2014;51(1):71-80.
71. Goodrich GL, Flyg HM, Kirby JE, Chang CY, Martinsen GL. Mechanisms of TBI and visual consequences in
military and veteran populations. Optom Vis Sci. Feb 2013;90(2):105-112.
72. Thiagarajan P, Ciuffreda KJ. Effect of oculomotor rehabilitation on vergence responsivity in mild
traumatic brain injury. J Rehabil Res Dev. 2013;50(9):1223-1240.
73. Thiagarajan P, Ciuffreda KJ. Effect of oculomotor rehabilitation on accommodative responsivity in mild
traumatic brain injury. J Rehabil Res Dev. 2014;51(2):175-191.
74. Thiagarajan P, Ciuffreda KJ, Capo-Aponte JE, Ludlam DP, Kapoor N. Oculomotor neurorehabilitation for
reading in mild traumatic brain injury (mTBI): An integrative approach. NeuroRehabilitation.
2014;34(1):129-146.
75. Ouellet MC, Beaulieu-Bonneau S, Morin CM. Insomnia in patients with traumatic brain injury:
Frequency, characteristics, and risk factors. J Head Trauma Rehabil. May-Jun 2006;21(3):199-212.
76. Zollman FS, Larson EB, Wasek-Throm LK, Cyborski CM, Bode RK. Acupuncture for treatment of insomnia
in patients with traumatic brain injury: A pilot intervention study. J Head Trauma Rehabil. Mar-Apr
2012;27(2):135-142.
77. National Institutes of Health state of the science conference statement on manifestations and
management of chronic insomnia in adults, June 13-15, 2005. Sleep. Sep 2005;28(9):1049-1057.
78. McCurry SM, Logsdon RG, Teri L, Vitiello MV. Evidence-based psychological treatments for insomnia in
older adults. Psychol Aging. Mar 2007;22(1):18-27.
79. Vaishnavi S, Rao V, Fann JR. Neuropsychiatric problems after traumatic brain injury: Unraveling the
silent epidemic. Psychosomatics. May-Jun 2009;50(3):198-205.
80. Whelan-Goodinson R, Ponsford J, Johnston L, Grant F. Psychiatric disorders following traumatic brain
injury: Their nature and frequency. J Head Trauma Rehabil. Sep-Oct 2009;24(5):324-332.

81. Bryant RA, O'Donnell ML, Creamer M, McFarlane AC, Clark CR, Silove D. The psychiatric sequelae of
traumatic injury. Am J Psychiatry. Mar 2010;167(3):312-320.
82. Ponsford J, Cameron P, Fitzgerald M, Grant M, Mikocka-Walus A. Long-term outcomes after
uncomplicated mild traumatic brain injury: A comparison with trauma controls. J Neurotrauma. Jun
2011;28(6):937-946.
83. Bryant RA, Moulds M, Guthrie R, Nixon RD. Treating acute stress disorder following mild traumatic brain
injury. Am J Psychiatry. Mar 2003;160(3):585-587.
84. Soo C, Tate R. Psychological treatment for anxiety in people with traumatic brain injury. Cochrane
Database Syst Rev. 2007(3):Cd005239.
85. Tiersky LA, Anselmi V, Johnston MV, et al. A trial of neuropsychologic rehabilitation in mild-spectrum
traumatic brain injury. Arch Phys Med Rehabil. Aug 2005;86(8):1565-1574.
86. Hammond FM, Bickett AK, Norton JH, Pershad R. Effectiveness of amantadine hydrochloride in the
reduction of chronic traumatic brain injury irritability and aggression. J Head Trauma Rehabil. Sep-Oct
2014;29(5):391-399.
87. Hammond FM, Sherer M, Malec JF, et al. Amantadine effect on perceptions of irritability after traumatic
brain injury: Results of the amantadine irritability multisite study. J Neurotrauma. Mar 31 2015.
88. Vanderploeg RD, Curtiss G, Belanger HG. Long-term neuropsychological outcomes following mild
traumatic brain injury. J Int Neuropsychol Soc. May 2005;11(3):228-236.
89. Lange RT, Brickell TA, Ivins B, Vanderploeg RD, French LM. Variable, not always persistent,
postconcussion symptoms after mild TBI in U.S. Military service members: A five-year cross-sectional
outcome study. J Neurotrauma. Jun 1 2013;30(11):958-969.
90. Binder LM, Rohling ML, Larrabee GJ. A review of mild head trauma. Part i: Meta-analytic review of
neuropsychological studies. J Clin Exp Neuropsychol. Jun 1997;19(3):421-431.
91. Cicerone KD, Dahlberg C, Malec JF, et al. Evidence-based cognitive rehabilitation: Updated review of the
literature from 1998 through 2002. Arch Phys Med Rehabil. Aug 2005;86(8):1681-1692.
92. Snell DL, Surgenor LJ, Hay-Smith EJ, Siegert RJ. A systematic review of psychological treatments for mild
traumatic brain injury: An update on the evidence. J Clin Exp Neuropsychol. Jan 2009;31(1):20-38.
93. Nelson LA, Macdonald M, Stall C, Pazdan R. Effects of interactive metronome therapy on cognitive
functioning after blast-related brain injury: A randomized controlled pilot trial. Neuropsychology. Nov
2013;27(6):666-679.
94. Twamley EW, Jak AJ, Delis DC, Bondi MW, Lohr JB. Cognitive symptom management and rehabilitation
therapy (CogSMART) for veterans with traumatic brain injury: Pilot randomized controlled trial. J Rehabil
Res Dev. 2014;51(1):59-70.
95. Twamley EW, Thomas KR, Gregory AM, et al. CogSMART compensatory cognitive training for traumatic
brain injury: Effects over 1 year. J Head Trauma Rehabil. Jul 16 2014.
96. Montgomery E, Turkstra L. Evidence-based practice: Let's be reasonable. Journal of Medical Speech-
Language Pathology. 2003;11(2):IX-XII.
97. Ripley DL, Morey CE, Gerber D, et al. Atomoxetine for attention deficits following traumatic brain injury:
Results from a randomized controlled trial. Brain Inj. 2014;28(12):1514-1522.
98. Whyte J, Vaccaro M, Grieb-Neff P, Hart T, Polansky M, Coslett HB. The effects of bromocriptine on
attention deficits after traumatic brain injury: A placebo-controlled pilot study. Am J Phys Med Rehabil.
Feb 2008;87(2):85-99.
99. Silver JM, Koumaras B, Meng X, et al. Long-term effects of rivastigmine capsules in patients with
traumatic brain injury. Brain Inj. Feb 2009;23(2):123-132.
100. Kim YW, Kim DY, Shin JC, Park CI, Lee JD. The changes of cortical metabolism associated with the clinical
response to donepezil therapy in traumatic brain injury. Clin Neuropharmacol. Mar-Apr 2009;32(2):63-
68.

101. Zhang L, Plotkin RC, Wang G, Sandel ME, Lee S. Cholinergic augmentation with donepezil enhances
recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med
Rehabil. Jul 2004;85(7):1050-1055.
102. Tramontana MG, Cowan RL, Zald D, Prokop JW, Guillamondegui O. Traumatic brain injury-related
attention deficits: Treatment outcomes with lisdexamfetamine dimesylate (vyvanse). Brain Inj.
2014;28(11):1461-1472.
103. Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: A review. Postgrad
Med. Sep 2014;126(5):64-81.
104. Bell KR, Hoffman JM, Temkin NR, et al. The effect of telephone counselling on reducing post-traumatic
symptoms after mild traumatic brain injury: A randomised trial. J Neurol Neurosurg Psychiatry. Nov
2008;79(11):1275-1281.
105. Agency for Health Research and Quality. The Effective Health Care Program stakeholder guide Appendix
D: Research questions & PICO(TS) 2011. http://www.ahrq.gov/research/findings/evidence-based-
reports/stakeholderguide/index.html.
106. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations:
The significance and presentation of recommendations. J Clin Epidemiol. Jul 2013;66(7):719-725.
107. Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to
recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol. Jul
2013;66(7):726-735.
108. Scholten JD, Sayer NA, Vanderploeg RD, Bidelspach DE, Cifu DX. Analysis of US Veterans Health
Administration comprehensive evaluations for traumatic brain injury in operation Enduring Freedom
and operation Iraqi Freedom veterans. Brain Inj. 2012;26(10):1177-1184.
109. Shumway-Cook A. Assessment and management of the patient with traumatic brain injury and
vestibular dysfunction. Vestibular Rehabilitation. 3rd ed. Philadelphia, PA: FA Davis Company. 2007:444-
457.
110. Shepard N, Clendaniel R, Ruckenstein M. Balance and dizziness. Brain Injury Medicine Principles and
Practice. 2007;1:491-510.
111. Hain TC, Yacovino D. Pharmacologic treatment of persons with dizziness. Neurol Clin. Aug
2005;23(3):831-853, vii.
112. Pyykko I, Magnusson M, Schalen L, Enbom H. Pharmacological treatment of vertigo. Acta Otolaryngol
Suppl. 1988;455:77-81.
113. Zee DS. Perspectives on the pharmacotherapy of vertigo. Arch Otolaryngol. Sep 1985;111(9):609-612.
114. Arciniegas DB, Anderson CA, Topkoff J, McAllister TW. Mild traumatic brain injury: A neuropsychiatric
approach to diagnosis, evaluation, and treatment. Neuropsychiatr Dis Treat. Dec 2005;1(4):311-327.
115. de Kruijk JR, Leffers P, Meerhoff S, Rutten J, Twijnstra A. Effectiveness of bed rest after mild traumatic
brain injury: A randomised trial of no versus six days of bed rest. J Neurol Neurosurg Psychiatry. Aug
2002;73(2):167-172.
116. Krebs DE, Gill-Body KM, Parker SW, Ramirez JV, Wernick-Robinson M. Vestibular rehabilitation: Useful
but not universally so. Otolaryngol Head Neck Surg. Feb 2003;128(2):240-250.
117. Fife TD, Iverson DJ, Lempert T, et al. Practice parameter: Therapies for benign paroxysmal positional
vertigo (an evidence-based review): Report of the quality standards subcommittee of the American
Academy of Neurology. Neurology. May 27 2008;70(22):2067-2074.
118. Cantor JB, Ashman T, Gordon W, et al. Fatigue after traumatic brain injury and its impact on
participation and quality of life. J Head Trauma Rehabil. Jan-Feb 2008;23(1):41-51.
119. Juengst S, Skidmore E, Arenth PM, Niyonkuru C, Raina KD. Unique contribution of fatigue to disability in
community-dwelling adults with traumatic brain injury. Arch Phys Med Rehabil. Jan 2013;94(1):74-79.
120. Coelho C, Ylvisaker M, Turkstra LS. Nonstandardized assessment approaches for individuals with
traumatic brain injuries. Semin Speech Lang. Nov 2005;26(4):223-241.

121. Medley AR, Powell T. Motivational interviewing to promote self-awareness and engagement in
rehabilitation following acquired brain injury: A conceptual review. Neuropsychol Rehabil. Aug
2010;20(4):481-508.
122. Malec JF. Goal attainment scaling in rehabilitation. Neuropsychological Rehabilitation. 1999;9(3-4):253-
275.
123. Grant M, Ponsford J. Goal attainment scaling in brain injury rehabilitation: Strengths, limitations and
recommendations for future applications. Neuropsychol Rehabil. Oct 2014;24(5):661-677.
124. Vanderploeg RD, Cooper DB, Belanger HG, et al. Screening for postdeployment conditions: Development
and cross-validation of an embedded validity scale in the neurobehavioral symptom inventory. J Head
Trauma Rehabil. Jan-Feb 2014;29(1):1-10.
125. Naudin M, Carl T, Surguladze S, et al. Perceptive biases in major depressive episode. PLoS One.
2014;9(2):e86832.
126. Croy I, Symmank A, Schellong J, et al. Olfaction as a marker for depression in humans. J Affect Disord.
May 2014;160:80-86.
127. Defense and Veterans Brain Injury Center. TBI awareness and prevention. Silver Spring, MD: 2015.
https://dvbic.dcoe.mil/about-tbi/about-traumatic-brain-injury?audience[0]=3. Updated September 8,
2015. Accessed September 9, 2015.
128. Casey KF, Mclntosh T. The role of novel pharmacotherapy in brain injury. The Journal of Head Trauma
Rehabilitation. 1994;9(1):82-90.
129. Cooper DB, Vanderploeg RD, Armistead-Jehle P, Lewis JD, Bowles AO. Factors associated with
neurocognitive performance in OIF/OEF servicemembers with postconcussive complaints in
postdeployment clinical settings. J Rehabil Res Dev. 2014;51(7):1023-1034.
130. Hoge CW, Castro CA. Blast-related traumatic brain injury in U.S. Military personnel. N Engl J Med. Sep 1
2011;365(9):860; author reply 860-861.

mTBICPGFullCPG50821816 PDF

Uploaded by

Document Informationclick to expand document information

Copyright:

Available Formats

mTBICPGFullCPG50821816 PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

mTBICPGFullCPG50821816 PDF

Uploaded by

Copyright:

Available Formats

VA/DoD CLINICAL PRACTICE GUIDELINE FOR

THE MANAGEMENT OF CONCUSSION-MILD

Department of Veterans Affairs

Version 2.0 – 2016

The Management of Concussion-mild Traumatic Brain Injury

With support from:

The Office of Quality, Safety and Value, VA, Washington, DC

Version 2.0 – 2016

Based on evidence reviewed through March 2015

February 2016 Page 2 of 133

II. Background ..............................................................................................................................6

III. About this Clinical Practice Guideline ........................................................................................9

IV. Guideline Working Group ....................................................................................................... 15

VI. Recommendations ................................................................................................................. 19

VII. Knowledge Gaps and Recommended Research ....................................................................... 43

Appendix A: Guideline Development Methodology........................................................................... 44

February 2016 Page 3 of 133

E. Recommendation Categorization ............................................................................................. 75

Appendix B: Clinical Symptom Management ..................................................................................... 79

Appendix C: Mechanism of Injury ................................................................................................... 101

Appendix D: Evidence Table ........................................................................................................... 104

Appendix E: 2009 Recommendation Categorization ........................................................................ 108

Appendix F: Participants List .......................................................................................................... 122

Appendix G: Acronym List .............................................................................................................. 124

February 2016 Page 4 of 133

February 2016 Page 5 of 133

February 2016 Page 6 of 133

Table 1. Classification of TBI Severity [3]

A. Terminology Conventions within this CPG

B. Additional Educational Materials and Resources

1 See the OTSG Army Toolkit here: http://www.cs.amedd.army.mil/borden/Portlet.aspx?ID=065de2f7-81c4-4f9d-9c85-

February 2016 Page 7 of 133

February 2016 Page 8 of 133

III. About this Clinical Practice Guideline

February 2016 Page 9 of 133

a. Reconciling 2009 CPG Recommendations

February 2016 Page 10 of 133

b. Peer Review Process

• Defense and Veterans Brain Injury Center

February 2016 Page 11 of 133

Noted conflict of interest disclosures:

C. Scope of this CPG

D. Highlighted Features of this CPG

February 2016 Page 12 of 133

February 2016 Page 13 of 133

February 2016 Page 14 of 133

IV. Guideline Working Group

February 2016 Page 15 of 133

Rounded rectangles represent a clinical state or condition.

Hexagons represent a decision point in the guideline, formulated as a question

Rectangles represent an action in the process of care.

February 2016 Page 16 of 133

A. Module A: Initial Presentation (>7 Days Post-injury)

February 2016 Page 17 of 133

B. Module B: Management of Symptoms Persisting >7 days

February 2016 Page 18 of 133

February 2016 Page 19 of 133

Recommendation Strength* Category†